КОСМЕТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ВОЛОС, СПОСОБ ИХ КОСМЕТИЧЕСКОЙ ОБРАБОТКИ

Изобретение касается косметических композиций для волос, содержащих в косметически приемлемой водной среде один катионный полимер и тройной акриловый полимер, а также способ их обработки. Тройной акриловый полимер содержит 20 - 70 мас.% α,β -моноэтиленненасыщенной карбоновой кислоты; 20 - 80 мас. % моноэтиленненасыщенного мономера, не обладающего поверхностно-активными свойствами, и 0,5 - 60 мас.% неионного уретанового мономера, который является продуктом реакции неионного поверхностно-активного вещества, содержащего один подвижный атом водорода, с моноэтиленненасыщенным моноизоцианатом. Изобретение касается, в частности, средств для волос, содержащих, когда они находятся в несмываемой форме, кватернизованные или некватернизованные сополимеры винилпирролидона и диалкиламиноалкилакрилата или диалкиламиноалкилметакрилата или кватернизованные полимеры винилпирролидона и винилимидазола. Изобретение придает волосам мягкость, естественность на ощупь, обладая фиксирующими свойствами. 2 с. и 17 ...

КОНДИЦИОНИРУЮЩАЯ И МОЮЩАЯ КОМПОЗИЦИЯ И ЕЕ ПРИМЕНЕНИЕ

Изобретение относится к кондиционирующей и моющей косметической композиции для кератиновых материалов, содержащей в водной среде: (А) по меньшей мере одно нелетучее растительное масло, (Б) по меньшей мере одно анионное поверхностно-активное вещество сульфатного типа, (В) по меньшей мере одно неионное поверхностно-активное вещество типа алкилполигликозида, причем отношения (Б)/(В) меньше или равно 2, а также к способу мытья и кондиционирования кератиновых материалов, в частности волос, с использованием названной композиции. Технический результат: композиция обладает достаточным пенообразованием и хорошими кондиционирующими свойствами, придавая волосам мягкость и блеск и не делая их жирными. 2 с. и 19 з.п.ф-лы, 5 табл.

ПРИМЕНЕНИЕ ЭКСТРАКТА IRIDACEAE, КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЕГО И СПОСОБ КОСМЕТИЧЕСКОГО ЛЕЧЕНИЯ

Применение экстракта клеток по меньшей мере одного растения из семейства Iridaceae в фармацевтической композиции в качестве антагониста CGRP и/или вещества Р. Косметические или фармацевтические композиции, содержащие экстракт клеток по меньшей мере одного растения из семейства Iridaceae и продукт с раздражающим действием или соединение, снижающее синтез или активность медиатора воспаления. Способ косметологического лечения, включающий использование одной из композиций. Изобретение позволяет получать и применять стандартизированный материал для терапевтического и косметологического лечения кожи, волос и слизистых оболочек. 7 с. и 46 з.п. ф-лы.

МОЮЩАЯ И КОНДИЦИОНИРУЮЩАЯ КОМПОЗИЦИЯ НА ОСНОВЕ СИЛИКОНА И ДИАЛКИЛОВОГО ЭФИРА И СПОСОБ МЫТЬЯ И КОНДИЦИОНИРОВАНИЯ КЕРАТИНОВЫХ МАТЕРИАЛОВ

Изобретение относится к вспенивающей моющей и кондиционирующей композиции для кератиновых материалов, содержащей, по меньшей мере, один силикон, по меньшей мере, одно поверхностно-активное вещество с моющими свойствами и, по меньшей мере, один диалкиловый эфир, находящийся в твердом состоянии при температуре ниже или равной 30oС и имеющий формулу R-O-R', где R и R', одинаковые или различные, означают насыщенный или ненасыщенный, линейный или разветвленный алкильный радикал C12 - C30, причем содержание поверхностно-активного вещества составляет 5 - 50% от общей массы композиции. Изобретение относится также к способу мытья и кондиционирования кератиновых материалов с помощью названной композиции. 2 с. и 29 з.п. ф-лы.

КОСМЕТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ СОПОЛИМЕР ВИНИЛДИМЕТИКОНА И ДИМЕТИКОНА И КАТИОННЫЙ ПОЛИМЕР, И ИХ ПРИМЕНЕНИЕ

Изобретение относится к косметическим композициям для мытья и ухода за кератиновыми материалами, такими как волосы, кожа, ресницы, брови, ногти, губы, включающим в косметически приемлемой среде по крайней мере один сополимер диметикона с двойной связью и диметикона с вязкостью 106-100•106 сП и по крайней мере один катионный полимер, а также к способу обработки кератиновых материалов, таких как волосы. Технический результат: это сочетание придает такие косметические свойства кератиновым материалам, как способность к разглаживанию, легкость, мягкость, без явления повышения их жирности. 2 с. и 11 з.п. ф-лы.

СРЕДСТВО ДЛЯ ОБРАБОТКИ ВОЛОС

Изобретение относится к косметике касается средств для окраски волос. Средство для обработки волос выполнено на основе субстантивных красителей и/или предшественников окисляемых красителей, в состав которых входят целевые в косметике добавки и, как минимум, один кондиционер. Средство для обработки волос позволяет улучшить состояние волос уже на стадии окрашивания, улучшается структура волос. 2 с. и 27 з.п. ф-лы, 5 табл. 3 ил.

ВОССТАНАВЛИВАЮЩАЯ КОМПОЗИЦИЯ ДЛЯ ОБРАБОТКИ КЕРАТИНОВЫХ ВОЛОКОН, ВКЛЮЧАЮЩАЯ ОСОБЫЙ АМИНИРОВАННЫЙ СИЛИКОН

Изобретение относится к косметической композиции, предназначенной для обесцвечивания или необратимой деформации кератиновых волокон человека, и, в частности волос, включающий, в косметически приемлемой среде (i) по меньшей мере один восстановитель и (ii) по меньшей мере один аминированный силикон с аминоэтилимино-(С4-С8 )-алкильными группами; а также к способу получения композиции, способу обесцвечивания и способу необратимой деформации кератиновых волокон человека и, в частности волос, и к набору. Технический результат: достижение кондиционирующих и устойчивых эффектов, превосходящих эффекты ранее известных систем, без ухудшения интенсивности и однородности обесцвечиваний или необратимых деформаций, а также достижение улучшения состояния волокна, которое сохраняет свою мягкость на ощупь, легкость расчесывания и свой блеск после нескольких обработок шампунем. 5 н. и 15 з.п.ф-лы.

СПОСОБ ПОЛУЧЕНИЯ КОСМЕТИЧЕСКОГО СЫРЬЯ НА ОСНОВЕ МОЛОЧНОЙ СЫВОРОТКИ

Изобретение относится к области биотехнологии, а именно к переработке молока, и может быть использовано при получении сырья для производства косметических средств, регулирующих обменные процессы кожи. Способ получения косметического сырья на основе молочной сыворотки включает добавление глюкозы в концентрации 0,50-0,75% в обезжиренное молоко, охлажденное до комнатной температуры, внесение Lactobacillus siccum и Bifidobacterium siccum, культивирование при температуре 36-38°С в течение 48-52 ч с последующим доведением температуры до 80-90°С. Сыворотку выделяют при комнатной температуре фильтрацией или центрифугированием, после чего последовательно производят дополнительное прогревание при температуре 70-80°С и давлении 0,8-0,9 атм, охлаждение до минус 10°С и мембранную стерильную фильтрацию. Использование изобретения обеспечивает получение косметического сырья на основе молочной сыворотки, которое соответствует необходимым требованиям, предъявляемым к косметическим средствам по показателям ...

МАСШТАБИРУЕМОЕ ПОЛУЧЕНИЕ ТРЕХМЕРНЫХ ЭЛАСТИЧНЫХ КОНСТРУКЦИЙ

Группа изобретений относится к медицине, конкретно к тропоэластину и восстановлению тканей с применением эластичных материалов. Описан способ получения эластичного материала из тропоэластина, предусматривающий нагревание раствора тропоэластина для образования эластичного материала из тропоэластина в растворе. Также описаны эластичные материалы, полученные согласно способу. Описан эластичный гидрогель для восстановления ткани, который обладает биосовместимостью, прочностью, упругой деформацией. 2 н. и 16 з.п. ф-лы, 10 ил., 9 пр.

БЕЛКИ, ВЫЗЫВАЮЩИЕ ИЗМЕНЕННУЮ ИММУНОГЕННУЮ РЕАКЦИЮ, И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ

Изобретение относится к биотехнологии и касается варианта белка субтилизина Bacillus amyloliguefaciens с заменой Y217L, содержащий Т-клеточный эпитоп, при этом указанный Т-клеточный эпитоп указанного варианта включает одну или несколько аминокислотных замен, выбранных из группы, состоящей из остатков, соответствующих положениям 76, 79 и 122, где указанный вариант субтилизина необязательно имеет замену в одном или нескольких из положений 3, 31, 40, 41, 46, 47, 48, 50, 76, 101, 104, 107, 111, 128, 147, 154, 181, 182, 183, 185, 206, 215, 216, 218, 238, 247, 248, 250, 254, 258, 262. Изобретение относится также к молекулам ДНК, которые кодируют варианты субтилизина, клеткам-хозяевам, содержащим данную ДНК, а также к композициям для ухода за кожей, содержащим указанный вариант субтилизина. Изобретение позволяет получить варианты субтилизина, которые проявляют уменьшенную иммуногенную реакцию у человека по сравнению с исходным субтилизином. 8 н. и 23 з.п. ф-лы, 16 ил., 3 табл.

ДЕРМАТОЛОГИЧЕСКИЕ КОМПОЗИЦИИ

Изобретение относится к косметологии и касается дерматологических и/или косметических композиций, позволяющих избежать появления симптомов гиперчувствительности и кожной непереносимости, которые включают эффективную комбинацию ингибиторов размножения микробов, содержащую первый ингибитор размножения микробов, который состоит из водной смеси полиакрилата натрия, по меньшей мере, одного полиола и, по меньшей мере, одного гликольного соединения формулы (I) R1-O-(R2-O)nR3, в которой R1 и R3 независимо представляют собой Н или С1-С5 алкильную группу с прямой или разветвленной цепью, R2 представляет собой С1-С5 алкиленовую группу с прямой или разветвленной цепью и n равно числу между 1 и 400000, и второй ингибитор размножения микробов, который состоит, по меньшей мере, из одного моноалкильного простого эфира глицерина или его сложного эфира формулы (II) R4OCH2CH(OH)CH2OR5, в которой R4 представляет собой алкильную группу с прямой или разветвленной цепью, содержащей от 6 до 24 атомов углерода, ...

АНТИПЕРСПИРАНТНЫЕ КОМПОЗИЦИИ

Изобретение относится к антиперспирантным композициям для применения на коже человека и к приготовлению и применению таких композиций. Прозрачные безводные твердые композиции антиперспиранта содержат от 1 до 30% по массе сыпучей соли-антиперспиранта, суспендированной в несмешиваемом с водой жидком носителе, который отверждается эффективным количеством структурирующего вещества. Заявленные композиции обладают улучшенной прозрачностью. 4 н. и 28 з.п. ф-лы, 5 табл.

ПРОДУКТЫ И СПОСОБЫ ДЛЯ УХОДА ЗА ПОЛОСТЬЮ РТА, СОДЕРЖАЩИЕ HLP

Группа изобретений относится к биотехнологии и стоматологии. Способ восстановления или ингибирования зубной эрозии, промотирования зубной реминерализации и/или усиления противокариозных эффектов фторида, включающий нанесение на зуб композиции для ухода за полостью рта, содержащей гидрофобин-подобный белок (HLP), имеющий полипептидную последовательность, выбранную из SEQ ID NO: 20 или SEQ ID NO: 22, и перорально приемлемый носитель. HLP присутствует в композиции в количестве от 0,01 до 3 мас. % от общей массы композиции. Композиция для ухода за полостью рта содержит HLP, имеющий полипептидную последовательность, выбранную из SEQ ID NO: 20 или SEQ ID NO: 22, при необходимости эффективное количество фторида и перорально приемлемый носитель. HLP присутствует в композиции в количестве от 0,01 до 3 мас. % от общей массы композиции. Группа изобретений эффективна для восстановления или смягчения эффектов зубной эрозии, способствуя зубной реминерализации и усиливая противокариозные эффекты фторида ...

Пептиды и их применение в уходе за кожей

Группа изобретений относится к косметологии и предназначена для уменьшения появления дерматологических признаков старения и вырабатывания кожного сала и/или уменьшения нежелательного липогенеза или увеличения липолиза. Описана композиция и способы, включающие наружное нанесение на кожу композиции, содержащей, в пригодном для наружного применения средстве доставки, пептид, имеющий в своем составе: (a) последовательность QILSKLRL (SEQ ID NO: 5), LRLК (SEQ ID NO: 6) или MVV (SEQ ID NO: 7), или его соль, сложный эфир или пролекарство; (b) последовательность TAKDGAP (SEQ ID NO: 8), IFGGTVYRS (SEQ ID NO: 9) или RTPKISKPIKFELSG (SEQ ID NO: 10), или его соль, сложный эфир или пролекарство; или (c) последовательность AECK (SEQ ID NO: 11), или его соль, сложный эфир или пролекарство; где указанные пролекарства представляют собой N-ацетильное производное, N-ацетильное производное боковой цепи, N-гидроксиметилированное или N-фталированное производное его N-конца и/или боковой цепи. Группа изобретений ...

ЖЕВАТЕЛЬНАЯ КОНДИТЕРСКАЯ КОМПОЗИЦИЯ ДЛЯ ЗУБОВ ПРОТИВ ОБРАЗОВАНИЯ ЗУБНОГО НАЛЕТА

Изобретение относится к кондитерской промышленности. Жевательная кондитерская композиция содержит от 0,1 до 3 мас.% фермента, твердый материал основы, не вызывающий кариес подсластитель, вещество, стабилизирующее ферменты, и менее 5 мас.% воды. Фермент выбран из протеаз, которые экстрагируют из фруктовых продуктов и вводят в твердый материал основы композиции при температуре 80°С, причем ферментативная активность протеаз сохраняется в композиции в течение периода по меньшей мере 4 недель при 23°С. Введение фермента в композицию способствует разрушению зубного налета и препятствует его образованию и адгезии на зубной поверхности при потреблении продукта. 12 з.п. ф-лы, 7 табл.

КОМПОЗИЦИЯ ДЛЯ ОКИСЛИТЕЛЬНОЙ ОКРАСКИ КЕРАТИНОВЫХ ВОЛОКОН, СПОСОБ ИХ ОКРАСКИ

Заявка относится к косметической композиции для окислительной окраски кератиновых волокон, включающей в соответствующем для окраски кератиновых волокон носителе (а) фермент типа лакказы; (б) подщелачивающий компонент; (в) фиксирующийся при окислении краситель, а также к способу окраски, при которых используют эту композицию. Изобретение обеспечивает однородное, хроматичное и интенсивное окрашивание волос. 2 с. и 19 з.п. ф-лы.

КОСМЕТИЧЕСКАЯ МАСКА ДЛЯ ЛИЦА ЭНЕРГЕТИЧЕСКАЯ

Изобретение относится к области косметики и касается средств для гигиены и очистки кожи. Косметическая маска энергетическая содержит нипагин, нипазол, метил-, пропиларабены, глицерин, воду, дополнительно содержит воск пчелиный, масло минеральное - гидролизат белковый, изопропилмиристат, диоксид титана, глину белую, витамины А, D, Е, комплексный СО2-экстракт из семян горчицы, моркови и рисовой мучки, коэнзим Q10, парфюмерную композицию. Компоненты берут в определенном количественном содержании. Маска повышает внутреннюю энергию клеток, оказывает витаминизирующее, регенерирующее, питающее и гидрантное действие. 6 табл.

ЗАГУЩЕННАЯ КОМПОЗИЦИЯ ДЛЯ ОБРАБОТКИ ВОЛОС, СОДЕРЖАЩАЯ ФИКСИРУЮЩИЙ ПОЛИМЕР И ПОРОШКООБРАЗНОЕ СОЕДИНЕНИЕ

Изобретение относится к косметической композиции в форме геля для фиксации и/или поддержания прически, содержащей в косметически приемлемой среде по меньшей мере один загущающий полимер (а), один фиксирующий полимер (b) и одно нерастворимое порошкообразное соединение (с), где загущающий агент (а) выбирают из природных полимеров или модифицированных природных соединений (i), сшитых сополимеров акриловой и/или метакриловой кислоты (ii), загущающих сшитых полиакриламидов (iii) и ассоциативных полимеров, содержащих по крайней мере одно гидрофильное звено и по крайней мере одну жирную цепь (iv); фиксирующий полимер (b) представляет собой несшитый полимер, выбранный из анионных, катионных, амфотерных и неионных фиксирующих полимеров и их смесей, и порошкообразное соединение (с) образовано нерастворимым и неслоистым материалом, а также к способу для косметической обработки волос, при котором используют вышеописанную композицию. Технический результат: композиция в форме геля оставляет руки чистыми ...

КОСМЕТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АМФОТЕРНЫЙ КРАХМАЛ И КАТИОННЫЙ КОНДИЦИОНЕР, И ИХ ПРИМЕНЕНИЯ

Изобретение касается косметических композиций для мытья и ухода за кератиновыми материалами, такими как волосы, кожа, ресницы, брови, ногти, губы и кожа волосистой части головы, содержащее в косметически приемлемой среде по меньшей мере один особый амфотерный крахмал и по меньшей мере один катионный кондиционер, выбираемый среди поверхностно-активных веществ четвертичных солей аммония, циклополимеров алкилдиаллиламина или диалкилдиаллиламмония, катионных полимеров, содержащих четвертичные группы аммония в основной цепи, и катионных силиконов, а также способа обработки кератиновых волокон, таких как волосы с использованием названных косметических композиций. Технический результат: изобретение позволяет устранить проблемы, связанные с применением композиций для волос на основе кондиционеров, а именно таких, как утяжеление, недостаточная гладкость и мягкость волос, при сохранении других положительных косметических свойств, которые связаны с композициями на основе кондиционеров. 2 с. и 17 з.п.ф-лы ...

ПРИМЕНЕНИЕ НОВОГО НАТУРАЛЬНОГО АГЕНТА В КОСМЕТИЧЕСКИХ КОМПОЗИЦИЯХ

Предложена группа изобретений, включающая способ косметической обработки, предназначенный для увлажнения эпидермиса, повышения упругости дермы, борьбы со старением кожи, регуляции секреции кожного сала, восстановления волос и/или улучшения роста волос, включающий стадию приведения в контакт с кожей и/или придатками кожи композиции, содержащей маннопротеины, экстрагированные из клеточной стенки Saccharomyces, при этом указанная композиция не содержит полифенолов, а также косметическая композиция для топического нанесения, содержащая маннопротеины и применение маннопротеинов, экстрагированных из клеточной стенки Saccharomyces, в качестве текстурирующего агента в косметических композициях для топического нанесения. Изобретения обеспечивают эффективную косметическую обработку с использованием композиции с определенными маннопротеинами, полученных из конкретных клеточных стенок грибов. 3 н. и 10 з.п. ф-лы, 3 табл., 2 пр.

ПЕННАЯ КОМПОЗИЦИЯ ДЛЯ УХОДА ЗА ВОЛОСАМИ

Изобретение относится к пенной композиции для мытья и обработки волос и/или кожи головы, отличающейся тем, что она содержит в водной среде по меньшей мере одно активное начало, выбранное из кортикоидов и ретиноидов, по меньшей мере одно анионное ПАВ, по меньшей мере одно амфотерное ПАВ, по меньшей мере один пропиточный агент. Технический результат: композиция позволяет улучшить проникновение активного начала, сохраняя при этом легкость применения и обладая хорошими косметическими свойствами. 29 з.п. ф-лы.

КОСМЕТИЧЕСКАЯ МАСКА И СПОСОБ ЕЕ ИСПОЛЬЗОВАНИЯ

Изобретение относится к косметологии и касается косметической маски. Маска содержит водно-спиртовую основу, биологически активные вещества, пенообразующий агент, при этом в качестве биологически активных веществ используют масло примулы вечерней, протеины шелка, аллантоин, токоферол ацетат, а в качестве пенообразующего агента - ПЭГ-глицерил кокоат, ПЭГ-глицериды пальмового ядра, дополнительно содержит сорбитан лаурат, феноксиэтанол или пропилпарабен, гели метилпарабен, или этилпарабен, или бутилпарабен, цетилстеариловый спирт, воду, компоненты берут в определенном количественном содержании. Способ использования маски заключается в нанесении ее на поверхность кожи. Маска позволяет достичь на поверхности кожи устойчивый слой пены. 2 с.п.ф-лы.

УВЛАЖНЯЮЩАЯ КОМПОЗИЦИЯ И СПОСОБ УВЛАЖНЕНИЯ КОЖИ

Изобретение относится к косметологии и касается увлажняющей композиции и способа увлажнения кожи. Сущность изобретения заключается в создании увлажняющей композиции, содержащей две дисперсии везикул, из которых первая дисперсия способна проникать в глубокие слои кожи и содержит по меньшей мере одно активное вещество, и второй дисперсии, способной проникать в поверхностные слои кожи и содержащей по меньшей мере одно поверхностно-активное вещество для обработки этих поверхностных слоев. Технический результат заключается в создании композиции, в которой один и тот же агент может действовать как в глубоких, так и поверхностных слоях кожи, обеспечивая, таким образом, более полное и эффективное воздействие на кожу. 2 с. и 12 з.п.ф-лы, 1 табл.

ВОССТАНАВЛИВАЮЩАЯ КОМПОЗИЦИЯ И СПОСОБ ОБРАБОТКИ КЕРАТИНОВЫХ МАТЕРИАЛОВ

Изобретение относится к косметической композиции, предназначенной для необратимой деформации (завивки или распрямления) кератиновых материалов, предпочтительно волос, и способу их обработки композицией. Композиция предназначена для первой стадии необратимой деформации кератиновых материалов. Она содержит не менее одного активного агента для восстановления дисульфидных связей кератина, один подщелачивающий агент и не менее одного катионного полимера. Подщелачивающий агент выбран из группы, включающей орнитин, лизин и аргинин, катионный полимер содержит первичные, вторичные или третичные аминогруппы или четвертичные аммониевые группы в основной цепи. Композиция выполнена в форме лосьона, густого или жидкого крема или геля. Для обработки кератиновых материалов наносят на них восстанавливающую композицию до, во время или после их механического натяжения на соответствующие средства. Затем кератиновый материал ополаскивают и наносят на него окисляющую композицию до или после отделения его от ...

НОВЫЕ ДИОРГАНОСИЛОКСАНЫ ИЛИ ТРИОРГАНОСИЛАНЫ, СВЕТОЗАЩИТНАЯ КОСМЕТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЗАЩИТЫ КОЖИ И/ИЛИ ВОЛОС ОТ УЛЬТРАФИОЛЕТОВОГО ИЗЛУЧЕНИЯ

Ди- или триорганосилоксаны с короткими, линейными или циклическими цепями содержат по крайней мере одно фильтрующее звено, происходящее от оксанилида с алкиленовой или алкиленоксифункцией, причем эти соединения преимущественно используют в качестве органических солнечных фильтров в косметических композициях, предназначенных для защиты кожи и волос от ультрафиолетового излучения. Органосилоксаны обладают хорошей растворимостью в жировых веществах и превосходной фотостабильностью. 3 с. и 20 з.п.ф-лы.

ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ ПОКРАСНЕНИЙ КОЖИ НЕЙРОГЕННОГО ПРОИСХОЖДЕНИЯ НА ОСНОВЕ АНТАГОНИСТА ВЕЩЕСТВА Р

Изобретение относится к медицине. Предложено применение антагониста вещества Р для получения фармацевтической композиции для местного применения с целью лечения покраснений кожи неврогенного происхождения, и особенно красных угрей и "стыдливой" эритемы. Антагонист вещества Р может представлять собой пептидное соединение или азотсодержащее соединение или азот-, серо- или кислородсодержащее гетероциклическое соединение. 10 з.п.ф-лы.

ЛЕЧЕБНО-КОСМЕТИЧЕСКОЕ ПРОТИВОГЕРПЕСНОЕ СРЕДСТВО "АНТИГЕРПЕС"

Изобретение относится к косметологии и может быть применено при изготовлении лечебно-профилактических гигиенических противогерпесных средств. Средство содержит тринатриевую соль фосфонмуравьиной кислоты в качестве антигерпесного ингредиента в количестве 0,1-3 мас.% и дополнительно, по крайней мере, одну косметически приемлемую насыщенную дикарбоновую кислоту в количестве 0,05-0,2 мас.%, на примере глутаровой и адипиновой кислот, а также любую косметически приемлемую основу, предпочтительно содержащую в эффективных количествах в качестве консервантов метиловый и пропиловый эфиры параоксибензойной кислоты, в качестве эмульгатора - диполигидроксистеарат и/или лаурилметикон кополиол, в качестве эмолента каприловые триглицериды, и/или изогексадекан, и/или диметикон, в качестве липидного носителя - растительные масла. Средство также может содержать биологически-активные, лекарственные, ароматизирующие, красящие добавки, например пчелиный воск, бетаин, Трилон-Б, лимонную кислоту. Средство обладает ...

ЛИФТИНГ-КРЕМ "Д" ДЛЯ СУХОЙ И ЧУВСТВИТЕЛЬНОЙ КОЖИ

Изобретение относится к косметологии и касается средств для ухода за кожей. Лифтинг-крем для сухой и чувствительной кожи содержит структурообразующие эмульгаторы, эмоленты, циклометикон, увлажняющие добавки - глицерин или пропиленгликоль, масляную фазу, биологически активные добавки, пигменты, эфиры метиловый и пропиловый параоксибензойной кислоты или Катон CG, или Гермабен II, или бронитрол или бронопол, парфюмерную композицию и воду, отличается тем, что дополнительно содержит желирующие агенты - карбомеры или карбопол и нейтрализующие агенты - триэтаноламин или натрия гидроокись, или натр едкий технический, УФ-фильтры - смесь октилметоксициннамата, бутилметоксидибензоил-метана, октилсалицилата в соотношении 1:1:1 или смесь октилметоксициннамата и бутилметоксидибензоилметана в соотношении 1:1, трилон Б, в качестве структурообразующих эмульгаторов содержит смесь ПЭГ-100 стеарат и моностеарата глицерина в соотношении 1:1, спирты высокомолекулярные синтетические С16-С18, или спирты синтетические ...

КРЕМ ДЛЯ РУК "МОЛОКО И МЕД"

Изобретение относится к медицине, а именно косметическим средствам, предназначенным для ухода за кожей рук. Крем для рук содержит масляную фазу, структурообразующие эмульгаторы, карбопол или карбомеры, или САКАП, нейтрализующий агент, увлажняющие добавки - глицерин или пропиленгликоль, биологически активные добавки - гидролизованный молочный протеин и экстракт меда, консерванты, витамин F. Крем обладает противовоспалительным действием, способствует заживлению мелких ран и трещин на коже, стимулирует естественные защитные механизмы кожи и регенерацию клеток, увлажняет и смягчает кожу, питает клетки кожи, придает коже нежность и мягкость. 1 ил., 2 табл.

КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ КОЖНЫХ НАРУШЕНИЙ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Изобретение относится к дерматологии и касается композиций для лечения кожных заболеваний. Композиция для лечения кожных нарушений содержит способный всасываться кожей антимикробный, антибиотический, антибактериальный или противогрибковый агент, альфа- или бета-гидроксикислоту и соединения цинка, в дерматологически приемлемом носителе. Предложенная композиция и способ лечения кожных нарушений с помощью этой композиции позволяет устранить патологические изменения кожи, как камедоны, узелки и кисты угрей, отчетливо видимые вросшие волосы или пустулоподобные воспаленные папулы. 4 с. и 29 з.п.ф-лы, 5 табл.

БИЦИКЛИЧЕСКОЕ АРОМАТИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ И КОСМЕТИЧЕСКАЯ КОМПОЗИЦИИ

Изобретение относится к новым биоароматическим соединениям общей формулы I, где значения R1, R2, R3, X и Ar указаны в п.1 формулы. Они обладают активностью в областях дифференциации и пролиферации клеток. Описывается также фармацевтическая композиция, предназначенная для лечения дерматологических, ревматических, респираторных, сердечно-сосудистых и офтальмологических заболеваний, а также и косметическая композиция для гигиены тела и для ухода за волосами. 3 с. и 13 з.п.ф-лы, 4 ил.

КОСМЕТИЧЕСКАЯ ИЛИ ДЕРМАТОЛОГИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ОБРАБОТКИ КЕРАТИНОВОГО МАТЕРИАЛА И СПОСОБ КОСМЕТИЧЕСКОЙ ОБРАБОТКИ КЕРАТИНОВЫХ МАТЕРИАЛОВ

Изобретение относится к косметике и касается композиции для обработки кератиновых материалов. Композиция для обработки волос содержит в косметически или дерматологически приемлемой среде по меньшей мере один привитой кремнийорганический полимер с полисилоксановым скелетом, на который привиты органические мономеры, не содержание силиконовых групп и по меньшей мере один силикон, выбираемый среди силиконов, содержащих по меньшей мере одну квартернизованную или некватернизованную аминогруппу силиконовых смол и силиконовых каучуков. Композиция обеспечивает кондиционирование волос, сохраняя прическу, придавая ей необходимую форму. 2 с. и 25 з.п. ф-лы.

СПОСОБ ИЗОМЕРИЗАЦИИ ЛИНЕЙНЫХ ОЛЕФИНОВ В ИЗООЛЕФИНЫ, КАТАЛИТИЧЕСКИЙ СОСТАВ

Описывается способ структурной изомеризации линейного олефина, имеющего по меньшей мере 4 атома углерода, в соответствующий ему разветвленный метилизоолефин, включающий стадию (а) контактирование при температуре подаваемого потока углеводородов, содержащего по меньшей мере указанный олефин с изомеризующим катализатором, содержащим по меньшей мере один цеолит с одномерной или более чем одномерная пористой структурой, имеющей размер пор более 0,42 нм и менее 0,7 нм, связующего, отличающийся тем, что на стадии (а) контактирование проводят при 200 - 650°С с катализатором, дополнительно содержащим до 15 вес. % металла, способствующего окислению коксовых отложений, способ включает дополнительно стадии: б) прекращение контактирования подаваемого потока с катализатором после образования коксовых отложений на поверхности катализатора; в) контактирование катализатора с коксовыми отложениями с потоком кислородсодержащего газа при температуре менее 565°С, давлении системы более 1 атм и парциальном ...

СПОСОБ УХОДА ЗА УВЯДАЮЩЕЙ КОЖЕЙ

Изобретение относится к области косметологии и касается средств и методов ухода за увядающей кожей с пониженным тургором. Способ ухода за увядающей кожей заключается в том, что на глубоко очищенную кожу лица и шеи последовательно воздействуют стимулирующим гелем, осуществляют массаж с использованием массажного крема и наносят стимулирующую маску, причем стимулирующий гель, массажный крем и стимулирующая косметическая маска содержат в качестве основного активного начала гидролизат белков пшеницы и экстракт морских водорослей, а перед воздействием стимулирующего геля, до и после нанесения стимулирующей косметической маски на поверхность кожи наносят активатор, обладающий способностью переносить молекулярный кислород. Способ позволяет улучшить цвет лица, состояние кожи, обеспечивает исчезновение мелких морщин.

КОМПОЗИЦИЯ ДЛЯ ОБРАБОТКИ КЕРАТИНОВЫХ ВОЛОКОН И СПОСОБ ОБРАБОТКИ КЕРАТИНОВЫХ ВОЛОКОН

Изобретение относится к косметической промышленности и касается композиции для обработки кепатиновых волокон, в частности человеческих волос. Композиция содержит по меньшей мере один анионогенный, неионогенный, амфотерный или цвиттерионогенный фиксирующий полимер и по меньшей мере одно соединение керамидного типа, а также к способу обработки с использованием этой композиции. Композиция позволяет достигнуть хороший защитный эффект против ломкости волос, а именно во время сушки феном. 2 с. и 19 з.п.ф-лы, 1 табл.

КОСМЕТИЧЕСКОЕ СРЕДСТВО ДЛЯ ГУБ

Изобретение относится к косметике и медицине и может быть использовано при профилактике и декоративном уходе за губами. Оно обладает более высоким противогерпетическим эффектом, чем известные аналоги. Средство для губ содержит основу, α-интерферон с активностью 106 МЕ/г и комплекс природных биологически активных веществ, включающий воск и растительные масла. В качестве основы используют гель полиэтиленоксида, в качестве α-интерферона - рекомбинантный α-2 интерферон человека, а комплекс природных биологически активных веществ дополнительно содержит экстракт прополиса, глицерин, мед пчелиный, масло шиповника, масло оливковое и грушевую эссенцию при соотношении компонентов, мас.%: экстракт прополиса 3,9-8,2, глицерин 5,9 - 12,4, мед пчелиный 5,9-12,3, масло шиповника 0,11-0,93, масло оливковое 10,86-22,7, воск 2,36-6,2, грушевая эссенция 0,1-0,22, альфа-2 интерферон с активностью 106 МЕ/г 0,011-0,012, гель полиэтиленоксида - остальное до 100%.

КРЕМ ДЛЯ КОЖИ ЛИЦА

Изобретение относится к косметологии. Предлагаемый биологически активный косметический крем обладает высокой всасывающей и регенерирующей способностью за счет введения в состав натриевой соли дезоксирибонуклеиновой кислоты. 1 табл.

КОСМЕТИЧЕСКАЯ МАСКА

Изобретение относится к косметической промышленности и представляет косметическую маску, содержащую криопорошок лекарственного растительного сырья, молоко сухое витаминизированное и криопорошок овса при следующем соотношении компонентов на 2,5 г маски: криопорошок лекарственного растительного сырья- 0,2-0,8 г; молоко сухое витаминизированное - 0,5-1,5 г; криопорошок овса - остальное. 4 з. п. ф-лы.

НОЧНОЙ АНТИСТРЕССОВЫЙ КРЕМ

Изобретение относится к медицине и касается косметических средств, предназначенных для ухода за кожей. Крем содержит масляную фазу, структурообразующие эмульгаторы, пленкообразующие, желирующие агенты, триэтаноламин, или натрия гидроокись, или натр едкий, стабилизаторы влажности - глицерин дистиллированный или пропиленгликоль, витамины А, Е, С, биологически активные добавки, консерванты, трилон Б, дополнительно к растительным маслам авокадо, абрикосовому, персиковому и ши введены жировые компоненты: ланолин и изопропилпальмитат, структурообразующие эмульгаторы - цетеариловый спирт и цетеарет-20, ПЭГ-20 метил глюкоза сесквистеарат, моностеарат глицерина или моноглицериды дистиллированные, спирты фракции С17-С18 разогнанные (синтетические первичные), или спирты высокомолекулярные синтетические С16-С18 (импортные), или спирты синтетические первичные жирные фракции С16-С20 и микроэлемент - магний сернокислый 7-водный. При использовании крема, содержащего антистрессовый комплекс-1, повышается ...

ГЕЛЬ ДЛЯ УХОДА ЗА КОЖЕЙ ВОКРУГ ГЛАЗ

Изобретение относится к области косметологии и касается косметических средств, предназначенных для ухода за кожей вокруг глаз. Гель для ухода за кожей вокруг глаз содержит желирующие, увлажняющие вещества, витамин С, БАД, парфюмерную композицию, воду, дополнительно содержит диметикон и/или циклометикон, трилон Б, триэтаноламин или натрия гидроокись, или натр едкий, бронопол или бронитрол, или КАТОН CG, гермабен II, в качестве увлажняющих веществ дополнительно содержит пропиленгликоль, аллантоин, в качестве БАД содержит гидролизованный молочный протеин или молочно-пептидный комплекс, экстракт цветков василька синего водно-спиртовый или водно-спирто-глицериновый, экстракт зеленого чая в пропиленгликоле или водно-спирто-глицериновый экстракт мелиссы, в качестве витамина С используют стабилизированную форму в виде натрия аскорбилфосфата или магния аскорбилфосфата, в качестве желирующих - карбопол или карбомеры, или САКАП, или САКАП-Р, компоненты берут в определенном количественном содержании ...

БАЛЬЗАМ ДЛЯ УХОДА ЗА ВОЛОСАМИ

Изобретение относится к области косметологии. Бальзам для ухода за волосами содержит динатриевую соль ЭДТК, воду, дополнительно содержит керопептид, растительные экстракты, многоосновные спирты, ПАВ, эфирные масла, нипагин и нипазол. Компоненты берут в определенном количественном содержании. Бальзам способствует равномерному росту волос, придает блеск и эластичность. 3 з.п.ф-лы, 2 табл.

КОСМЕТИЧЕСКОЕ СРЕДСТВО ДЛЯ УХОДА ЗА КОЖЕЙ "ГАРМОНИЯ-N" ИЛИ "ГАРМОНИЯ-R"

Изобретение относится к косметической промышленности и может быть использовано в качестве средства для ухода за кожей в виде вечерних кремов, а также косметических масок. Технический результат: препарат позволяет использовать высокоактивный белок альфа-фетопротеин, что расширяет спектр используемых в косметике биологически активных веществ. Средство содержит основу в виде геля и биологически активные вещества и добавки. В качестве биологически активного вещества используют природный или рекомбинантный белок альфа-фетопротеин, а в качестве биологически активных добавок используют компоненты природного и химического происхождения, причем соотношение основы и БАВ составляет (0,8 - 5,8):1,0, при их количественном соотношении, мас.%: белок альфа-фетопротеин природный или рекомбинантный 10-5 - 10-4, основа и биологически активные добавки природного и химического происхождения в соотношении (0,8 - 5,8): 1,0 - остальное до 100%. В качестве основы используют гель полиэтиленоксида. 2 з.п. ф-лы.

КОСМЕТИЧЕСКАЯ ИЛИ ДЕРМАТОЛОГИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ МЕСТНОГО ПРИМЕНЕНИЯ В ФОРМЕ ВОДНОЙ И СТАБИЛЬНОЙ ДИСПЕРСИИ ЧАСТИЦ КУБИЧЕСКОГО ГЕЛЯ И ЕЕ ПРИМЕНЕНИЕ

Изобретение относится к области косметологии. Предложена косметическая или дерматологическая композиция в форме водной и стабильной дисперсии частиц кубического геля на основе 3,7,11,15-тетраметил-гексадекан-1,2,3-триола или фитантриола и ее применение для гидратации (увлажнения) кожи. Эта композиция по существу содержит 0,1 - 15 мас.% 3,7,11, 15-тетраметил-гексадекан-1,2,3-триола в расчете на общую массу композиции и 0,1-3 мас.% диспергирующего и стабилизирующего агента в расчете на общую массу композиции, причем вышеуказанный агент выбирают среди водорастворимых при комнатной температуре поверхностно-активных агентов, содержащих насыщенную или нет алифатическую цепь с 8-22 атомами углерода. Эта композиция более стабильна, позволяет включать в нее гидрофильные и/или липофильные действующие начала без проблем совместимости. 2 c. и 29 з.п. ф-лы, 1 табл.

КРЕМ ДЛЯ УВЯДАЮЩЕЙ КОЖИ ЛИЦА "ПЛАЦЕО"

Изобретение относится к косметологии, предназначено для ухода за увядающей кожей лица. Целью изобретения является повышение гериатрического эффекта с устранением побочного действия крема. Поставленная цель достигается тем, что в крем для лица, содержащий масло оливковое, ланолин, воск эмульсионный, консервант, отдушку, воду и биодобавку, дополнительно введены пчелиный воск, масло какао, моноглицериды дистиллированные и бура, а в качестве биологически активного компонента - белковый концентрат плаценты человека при следующем соотношении компонентов, мас.%: масло оливковое 20,0 - 30,0; масло какао 2,0 - 4,0; ланолин 1,0 - 3,0; воск эмульсионный 3,0 - 4,0; воск пчелиный 2,0 - 4,0; моноглицериды дистиллированные 0,5 - 2,0; бура 0,1 - 0,7; белковый концентрат плаценты 0,1 - 0,5; концентрат 0,15 - 0,25; отдушка 0,05 - 0,15; вода дистиллированная остальное. Белковые полипептиды, полученные селективной ультрафильтрацией суммарных белков плаценты, оказывают на кожу лица гериатрическое действие, ...

СПОСОБ ОЗДОРОВЛЕНИЯ КОЖИ, ЧУВСТВИТЕЛЬНОЙ К СТРЕССОВЫМ ФАКТОРАМ

Изобретение относится к области косметологии и касается методов и средств ухода за кожей. Способ оздоровления кожи, чувствительной к стрессовым факторам, заключается в том, что кожу лица, шеи и линии декольте последовательно обрабатывают косметическими средствами, при этом проводят демакияж кожи очищающим молочком, затем наносят жемчужный крем-пилинг и одновременно проводят вапоризацию, далее на кожу лица, шеи и линию декольте наносят фитокомплекс, выдерживают его до впитывания, проводят массаж с использованием крема, повторно наносят фитокомплекс, после впитывания которого наносят жемчужную маску, а затем крем с активным кислородом или бальзам для сухой кожи, при этом после нанесения очищающего молочка, кремов и маски остатки средства смывают теплой водой и кожу протирают тоником. Способ восстанавливает структуру коллагеновых волокон, стимулирует процесс образования новых клеток, укрепляет стенки капилляров, снижает отечность тканей, снимает раздражение, раздражение кожи, разглаживает ...

КРЕМ-ЖЕЛЕ

Изобретение относится к косметическим средствам по уходу за кожей лица и рук. Целью изобретения является получение высокоэффективного крема-желе с использованием в качестве желирующего вещества дешевого материала - отработанной агаризованной питательной среды после выращивания биоженьшеня и повышение биологической активности крема. Для этого в состав крема-желе введена в качестве желирующего вещества отработанная агаризованная питательная среда - отход производства биомассы культуры ткани женьшеня и продукт переработки биоженьшеня при следующем соотношении компонентов, мас.%: отработанная агаризованная питательная среда после выращевания биоженьшеня 30-40, глицерин 10-15, продукт переработки биоженьшеня 1,37%-ный водный раствор формалина 0,27, спирт этиловый 0,01-0,05, вода - до 100.

КРЕМ ДЛЯ КОЖИ ЛИЦА

Изобретение относится к области косметологии и касается средств для ухода за кожей лица. Крем для кожи лица содержит ацетилированный ланолин, масло оливковое, масло какао, спирт этиловый, глицерин, мед, гермабен, триэтаноламин, отдушку, пчелиный воск, цинка стеарат, стеарин, метилцеллюлозу, альбуминовую фракцию сыворотки козъего молока, гидролизат фукоидана, воду дистиллированную. Компоненты берут в определенном количественном содержании. Крем способствует заживлению ранок, улучшает обменные процессы в клетках кожи, предотвращает старение кожи, сухость и шелушение. 1 з.п. ф-лы, 1 табл.

ПРИМЕНЕНИЕ АНТАГОНИСТА CGRP ДЛЯ ОБРАБОТКИ ПОКРАСНЕНИЙ КОЖИ НЕВРОГЕННОГО ПРОИСХОЖДЕНИЯ И КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ

Изобретение относится к дерматологии и косметологии. Предложено новое средство на основе антагониста CGRP в косметической, фармацевтической или дерматологической композиции для местного применения для лечения покраснений кожи неврогенного происхождения, особенно красных угрей и "стыдливой" эритемы, и способ его использования. Изобретение расширяет арсенал средств заявленного назначения. 2 с. и 13 з.п. ф-лы.

МИКРОКАПСУЛА, ВКЛЮЧАЮЩАЯ ПЕПТИД, ОБЛАДАЮЩИЙ АФФИННОСТЬЮ СВЯЗЫВАНИЯ КЛЕТОЧНОГО РЕЦЕПТОРА, И КОСМЕТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЕЕ

Изобретение относится к пептидам, обладающим способностью связываться с клеточными рецепторами, микрокапсуле, включающей пептид, связанный с ней, и косметической композиции, содержащей микрокапсулу. Пептиды демонстрирует высокую аффинность селективного связывания с мишенью, и микрокапсула обладает улучшенной физико-химической стабильностью. Косметическая композиция, содержащая микрокапсулу, с которой связан пептид, демонстрирует высокую эффективность доставки активного ингредиента, включенного в капсулу, к клеткам-мишеням, тем самым демонстрируя лучшие эффекты улучшения состояния кожи. 4 н. и 6 з.п. ф-лы, 11 табл., 7 пр., 10 ил.

Активная против акне добавка к парфюмерно-косметическим продуктам

Изобретение относится к активной добавке к парфюмерно-косметическим продуктам против акне. Описывается активная против акне добавка к парфюмерно-косметическим продуктам, содержащая глицерин, салициловую кислоту, гликолевую кислоту, молочную кислоту, папаин, лимонную кислоту, гиалуроновую кислоту, ретинол, аллантоин, ниацинамид, пантенол, басаболол, обеспечивающая расширение спектра действия известных парфюмерно-косметических продуктов по уходу за кожей лица и улучшенный уход за кожей лица. Технический результат – расширение спектра действий известных парфюмерно-косметических продуктов по уходу за кожей лица, не снижая активности и обеспечивая улучшенный уход за кожей. 14 пр.

КОСМЕЦЕВТИЧЕСКИЙ КОМПЛЕКС ДЛЯ УХОДА ЗА КОЖЕЙ И СПОСОБ ЕГО ПРИМЕНЕНИЯ

Изобретение относится к области косметологии и представляет собой космецевтический комплекс для ухода за кожей, характеризующийся наличием дневной и ночной сывороток, а также дневного и ночного кремов, при этом дневная сыворотка содержит высокоочищенные биологически активные факторы, выработанные собственными клетками кожи пользователя, а ночная сыворотка содержит высокоочищенные биологически активные факторы, выработанные стволовыми клетками пантов марала, где ночная сыворотка содержит Amaze, глицерин, воду очищенную, DC 193, Катон и биологически активные факторы, причем компоненты в ночной сыворотке находятся в определенном соотношении в мас.%, дневная сыворотка содержит Amaze, глицерин, воду очищенную, DC 193, Катон и биологически активные факторы, причем компоненты дневной сыворотки находятся в определенном соотношении в мас.%, дневной крем содержит кремообразующую основу, масло ши, масло авокадо, масло виноградных косточек, Таймкод, Аквафилин, Телосомил, Митоникил и воду, причем компоненты ...

ПРИМЕНЕНИЕ АНТАГОНИСТА CGRP ДЛЯ ОБРАБОТКИ ЛИШАЕВ И ПОЧЕСУХ (ПРУРИГО), КОМПОЗИЦИЯ И СПОСОБ ОБРАБОТКИ

Изобретение относится к применению антагониста CGRP в косметической, фармацевтической или дерматологической композиции, особенно для топического применения, с целью лечения (обработки) лишаев, почесух, пруригинозных токсидермий и тяжелых зудов, а также к новым указанным композициям на его основе. При этом композиции помимо антагониста CGRP содержат по крайней мере один антагонист, выбранный из антагонистов вещества Р и антагонистов медиатора воспаления. Изобретение расширяет арсенал средств указанного назначения. 2 с. и 19 з.п.ф-лы.

ПОЛИЕНОВЫЕ СОЕДИНЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ И КОСМЕТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ

Изобретение относится к новым полиеновым соединениям формулы I, где R1 - COR9; R2, R4, R6 - водород; R3, R5, R10, R11 - водород или низший алкил; R7 - циклоалифатический радикал или низший алкил; R8 - радикал -O-CH2-OCH2-CH2 -O-CH3 или OR11; R4 и R6 взятые вместе могут образовывать с соседним бензольным циклом нафталиновый цикл; R9 - O-R10, а также их солям и их оптическим и геометрическим изомерам. Соединения I обладают значительной активностью в области дифференциации и пролиферации клеток и могут найти применение при местном и системном лечении дерматологических расстройств, связанных с нарушением кератинизации, дерматологических или других заболеваний с воспалительной и/или иммуноаллергической компонентой. 3 c. и 8 з.п. ф-лы, 2 ил., 1 табл.

ПЕНОМОЮЩЕЕ СРЕДСТВО

Использование относится к косметическим средствам по уходу за волосами и тела. Пеномоющее средство содержит натрий лаурилсульфат оксиэтилированный и/или сульфоэтоксилат натрия, композицию лаурилсульфата натрия, дистеарата этиленгликоля и моноэтаноламида кокосового масла, алкиламидопропилбетаин, диэтаноламиды жирных кислот кокосового масла, масло кокосовое, гидроксипропилтримониум хлорид, хлорид натрия, кислоту лимонную или ортофосфорную, формальдегид, отдушку и воду, компоненты взяты в определенных количественных соотношениях. Пеномоющее средство обладает хорошим смягчающим и антистатическим эффектом при одновременном сохранении высоких пенообразующих показателей, укрепляет корни волос и сохраняет структуру, придает гладкость, эластичность и легкость расчесывания. 1 табл.

КОМПОЗИЦИЯ ДЛЯ УСИЛЕНИЯ ВОЗОБНОВЛЕНИЯ РОСТА ВОЛОС И/ИЛИ ДЛЯ УМЕНЬШЕНИЯ ВЫПАДЕНИЯ ВОЛОС

Изобретение относится к косметическим композициям и касается средств для усиления возобновления роста волос. Композиция содержит в водной или водно-спиртовой среде, основой которой является вода и алкиленгликоль или полиалкиленгликоль и являющейся жидкой при комнатной температуре по меньшей мере 0,03 - 0, 3 мас.% фруктозы, 0,002 - 0,05 мас.% глюкозы, 0,03 - 0,2 мас. % одного или нескольких глобулярных белков злаков или их гидролизаторов, а также 0,03 - 1,0 мас.% соли натрия или калия. Композиция позволяет уменьшить выпадение волос, а также лечить десквамативный дерматит, алопецию и облысение. 2 с. и 14 з.п. ф-лы.

КРЕМ ДЛЯ СУХОЙ КОЖИ ЛИЦА

Изобретение относится к косметике и касается крема для сухой кожи. Крем содержит ланолин, масло сои, парафин, масло цитраля, раствор реополигрюкина. Крем легко и быстро впитывается кожей лица, оказывает на нее оздоравливающий, омолаживающий эффект.

СОСТАВ ДЛЯ ЛИЧНОЙ ГИГИЕНЫ С ПОРТАТИВНОЙ УПАКОВКОЙ

... 1. Полутвердая композиция для использования как средство гигиены полости рта, зубов или кожи, отличающаяся тем, что содержит полутвердый гель, в состав которого входит, по меньшей мере, один фармакологически приемлемый активный ингредиент, тщательно смешанный с, по меньшей мере, одним желирующим агентом, который при затвердевании формирует полутвердый гель, имеющий гелевый каркас, образующий средство для эффективного удерживания, по меньшей мере, одного активного ингредиента в период хранения, при этом гелевый каркас способен к распадению, когда композиция с усилием разрушается пользователем, делая доступным для использования в процедуре личной гигиены полости рта, зубов или кожи, по меньшей мере, один активный ингредиент. 2. Композиция по п.1, отличающаяся тем, что указанный, по меньшей мере, один желирующий агент имеет концентрацию, достаточно высокую для того, чтобы поддерживать композицию, после ее затвердевания, в полутвердом состоянии, когда она находится при заданной температуре ...

КОМПОЗИЦИЯ ДЛЯ ОБРАБОТКИ ВОЛОС И СПОСОБ ЕЕ ПРИГОТОВЛЕНИЯ

... 1. Композиция для обработки волос, которая содержит множество агентов, для обработки волос, отличающаяся тем, что агенты композиции, являющиеся обонятельными раздражителями, содержатся в пределах ниже порога восприятия запаха. 2. Композиция для обработки волос по п.1, в которой каждый из указанного множества агентов не содержит отдушек и компонентов с ароматизирующими веществами. 3. Композиция для обработки волос по п.1, в которой агенты, являющиеся обонятельными раздражителями, содержат по меньшей мере аммиак, амины, сероводород и метил меркаптан. 4. Композиция для обработки волос по п.1, в которой указанное множество агентов включает в себя щелочной реагент, разбавитель и восстановитель, причем указанные щелочной реагент, разбавитель и восстановитель перемешивают во время использования, чтобы предотвратить испускание раздражающих неприятных запахов. 5. Композиция для обработки волос по п.4, в которой щелочной реагент включает в себя по меньшей мере один компонент, выбранный из группы, ...

КОМПОЗИЦИИ КОСМЕТИЧЕСКИХ КАРАНДАШЕЙ

... 1. Твердая косметическая композиция в виде эмульсии, содержащая диспергированную фазу полярной жидкости и дисперсионную среду из не смешивающейся с водой жидкости, гелеобразователь, в количестве, достаточном для отверждения не смешивающейся с водой жидкости, эмульгатор и активнодействующее косметическое вещество, отличающаяся тем, что гелеобразователь для не смешивающейся с водой жидкости содержит комбинацию гелеобразователя (i), амида N-ацилзамещенной аминокислоты формулы AX-CO-RX, где AX представляет собой остаток амида аминокислоты, а RX представляет собой разветвленную алкильную группу, содержащую от 4 до 12 атомов углерода, и гелеобразователя (ii), волокнообразующего амидного структурообразователя, отличного от амидов N-ацилзамещенной аминокислоты согласно определению гелеобразователя (i), в эффективном относительном соотношении по массе. 2. Композиция по п.1, отличающаяся тем, что AX представляет собой остаток диамидозамещенной глутаминовой кислоты или аспарагиновая кислоты. 3. Композиция ...

ПРИМЕНЕНИЕ ПЕПТИДОВ XIXVAV В ИЗГОТОВЛЕНИИ КОСМЕТИЧЕСКИХ КОМПОЗИЦИЙ, ПРЕДНАЗНАЧЕННЫХ ДЛЯ ПОВЫШЕНИЯ ПЛОТНОСТИ КОЖИ ЗА СЧЕТ УСИЛЕНИЯ КЛЕТОЧНОЙ АДГЕЗИИ

... 1. Применение пептидов XIXVAV общей формулы I где Х выбран из группы, образованной водородом, аминокислотой или ацильной группой, а Y выбран из группы, образованной амино, гидроксилом или тиолом, отличающееся тем, что они стимулируют биоадгезию кожных клеток путем повышения экспрессии биоадгезивных пептидов. 2. Применение по п.1, отличающееся тем, что Х представляет собой водород или серин. 3. Применение по п.1, отличающееся тем, что Х представляет собой пальмитоил или деканоил. 4. Применение по п.1, отличающееся тем, что Y представляет собой амино. 5. Применение по п.1, отличающееся тем, что Y представляет собой гидроксил. 6. Применение по п.1, отличающееся тем, что Y представляет собой тиол. 7. Применение по п.1, отличающееся тем, что кожные клетки представляют собой кератиноциты. 8. Применение по п.1, отличающееся тем, что биоадгезивные пептиды представляют собой интегрин альфа-6 и ламинин V. 9. Применение пептидов по любому из пп.1-8 в изготовлении косметической композиции. 10. Применение ...

СПОСОБ И КОМПОЗИЦИЯ ДЛЯ РЕСТРУКТУРИРОВАНИЯ КЕРАТИНОВЫХ ВОЛОКОН

... 1. Способ реструктурирования кератиновых волокон, в котором кератиновое волокно одновременно или последовательно приводят в контакт (а) с водным составом, содержащим, по меньшей мере, один полисульфид формулы (I) в которой R3 означает гидрокси или радикал R4 означает водород или радикал А означает связь или двухвалентный насыщенный или однократно либо многократно ненасыщенный алифатический или ароматический углеводородный радикал, содержащий от 1 до 20 атомов углерода, который может быть замещен на один или несколько атомов галогенов, гидроксильных или карбоксильных групп, причем наиболее короткое соединение между обеими соседними с группой А карбонильными группами содержит до 12 атомов углерода, и где R1 и R2 могут быть одинаковыми или различными и выбраны из R5O- и причем R5 означает водород или алкильную группу, содержащую от 1 до 6 атомов углерода, n является целым числом от 1 до 100, и при этом одна или несколько карбоксильных групп может находиться в форме одной или нескольких их ...

СРЕДСТВО ДЛЯ МЫТЬЯ ГОЛОВЫ И ТЕЛА

Изобретение относится к бытовой химии и косметике и может быть использовано в форме пеномоющего средства для принятия ванн или средства для душа, предназначенного для ухода за кожей тела и волосами. Целью изобретения является создание средства, обладающего высокой пеноустойчивостью в условиях применения, повышающего влагоудерживающие свойства кожи, ускоряющего регенерацию ее эпидемальных структур и улучшает расчесываемость волос. Указанная цель достигается тем, что средство дополнительно содержит белковый гидролизат, α лецитин из яичного порошка, настой из биомассы женьшеня или экстракт фиалки, экстракт плодов шиповника и/или ароматическую вытяжку любистка или экстракт цветочной пыльцы, при следующем содержании ингредиентов, мас. % : сульфоэтоксилаты 8, 0 - 13,0; диэтаноламиды жирных кислот 1,0 - 4,0; производные имидазолина или бетаинов 1,5 - 5,0; кислота лимонная или ортофосфорная 0,1 - 0,8; хлористый натрий 0,1 - 2,0; формалин 0,1 - 0,4; краситель 0,0005 - 0,02; отдушка 0,5 - 2,0; белковый ...

КЛОСТРИДИАЛЬНЫЕ НЕЙРОТОКСИНЫ, СОДЕРЖАЩИЕ ЭКЗОГЕННУЮ ПЕТЛЮ АКТИВАЦИИ

ЛЕЧЕБНО-КОСМЕТИЧЕСКОЕ СРЕДСТВО

... 1. Лечебно-косметическое средство в виде эмульсии, содержащее жировую основу, БАВ, компоненты виноградного вина, белковый препарат, вспомогательные добавки и водосодержащий агент, отличающееся тем, что в качестве компонента виноградного вина используют концентрат виноградного вина, получаемый из виноградного вина путем вакуумной перегонки до полного удаления спирта, а в качестве белкового препарата - супероксиддисмутазу, в качестве водосодержащего агента - воду или раствор минеральных солей при следующем соотношении ингредиентов, мас.%: Жировая основа 2-6 Концентрат виноградного вина 1-10 Супероксиддисмутаза 0,01-0,05 Биологически-активные вещества 0,03-6,0 Вспомогательные добавки 6-10 Водосодержащий агент - вода или раствор минеральных солей Остальное. 2. Лечебно-косметическое средство по п.1, отличающееся тем, что в качестве жировой основы использовали - касторовое масло, и/или масло виноградных косточек, и/или оливковое масло, и/или масло ши. 3. Лечебно-косметическое средство по п.1, ...

СПОСОБ, ПРИМЕНЕНИЯ СТАБИЛЬНОГО ФАКТОРА РОСТА РАСТИТЕЛЬНОГО ПРОИСХОЖДЕНИЯ В УХОДЕ ЗА КОЖЕЙ

... 1. Композиция для ухода за кожей/дерматологическая композиция, включающая гиалуроновую кислоту и по меньшей мере один фактор роста, полученный из трансгенных растений, и по меньшей мере одно фармацевтически и/или косметически приемлемое вспомогательное вещество.2. Композиция для ухода за кожей/дерматологическая композиция по п.1, включающая формулу эксципиента, которая стабилизирует белок фактора роста.3. Композиция для ухода за кожей/дерматологическая композиция по п.1, где гиалуроновая кислота содержится в концентрации в диапазоне от около 0,01 до около 2% по массе.4. Композиция для ухода за кожей/дерматологическая композиция по п.1, где фактор роста присутствует в качестве компонента экстракта трансгенного растения, включенного в косметическую композицию.5. Композиция для ухода за кожей/дерматологическая композиция по п.4, где фактор роста присутствует в экстракте трансгенных растений в количестве в диапазоне от около 0,0001% до около 70% общего содержания белка.6. Композиция для ухода ...

СРЕДСТВО ДЛЯ ИЗМЕНЕНИЯ ОКРАСКИ С ЭКСТРАКТОМ МОРИНГИ (MORINGA)

Изобретение относится к косметической промышленности, в частности к средству для изменения окраски кератиновых волокон, содержащему в косметически приемлемом носителе, по меньшей мере, один протеин семян Moringa Pterygosperma и, по меньшей мере, одно изменяющее окраску активное вещество, выбранное из, по меньшей мере, одного компонента-проявителя или краскообразующего компонента или красителя. Вышеописанное средство эффективно изменяет окраску кератиновых волос. 5 з.п. ф-лы, 4 табл.

КОМПОЗИЦИЯ ДЛЯ МЫТЬЯ ДЕТСКИХ ВОЛОС И КУПАНИЯ МЛАДЕНЦЕВ

Изобретение относится к области косметологии и касается средств, предназначенных для мытья детских волос и купания детей. Композиция для мытья детских волос и купания младенцев, содержащая натрия кокоил изотианат, кокоамфоацетат натрия, лаурил глюкозид, кокамидопропил бетаин, полисорбат-20, пропиленгликоль и ПЭГ-55 пропиленгликоль олеат, поликватерниум-10, коко-глюкозид и глицерил олеат, аллантоин, пантенол, экстракт календулы пропиленгликолевый, лаурдимония гидроксипропил гидролизованный протеин пшеницы, лимонную кислоту моногидрат, динатриевую соль ЭДТА 2-водную, метилхлороизотиазолинон, метилизотиазолинон, магния хлорид, магния нитрат, отдушку и воду питьевую, при определенном соотношении компонентов. Композиция для мытья детских волос и купания младенцев является гипоаллергенной, сочетает в своем составе мягкие поверхностно-активные вещества, которые мягко и бережно очищают чувствительную кожу и волосы ребенка и не причиняют беспокойства даже при случайном попадании в глаза.

СОСТАВ ПРЕПАРАТА ДЛЯ КОРРЕКЦИИ ДЕФЕКТОВ КОЖИ

Изобретение относится к области косметологии. Состав для коррекции дефектов кожи, включающий гиалуроновую кислоту и глицерин, согласно изобретению дополнительно содержит пальмитоил дипептид-5 диаминобутироил гидрокситреонин, пальмитоил дипептид-5 диаминогидроксибутират, пальмитоил трипептид-5, рекомбинантный фактор роста фибробластов основной, рекомбинантный эпидермальный фактор роста и питательную среду DMEM F12, причем компоненты в составе находятся в определенном соотношении, масс. %. Изобретение обеспечивает выработку собственных компонентов, а именно гиалуроновой кислоты, коллагена и эластина, при этом обладает сильным антиоксидантным свойством и выраженным длительным эффектом коррекции кожных дефектов кожи. 2 н.п. ф-лы, 4 табл., 4 пр.

СОДЕРЖАЩЕЕ ПОВЕРХНОСТНО-АКТИВНОЕ ВЕЩЕСТВО МОЮЩЕЕ СРЕДСТВО СО СПЕЦИАЛЬНЫМИ БЕЛКАМИ

... 1. Моющее средство, содержащее поверхностно-активное вещество, отличающееся тем, что оно содержит a) по меньшей мере, один йогуртовый белок и b) одно или несколько веществ из группы растительных экстрактов и/или видов молока из растительного сырья и/или витаминов, провитаминов и предшественников витаминов, а также их производных в массовом соотношении а):b) от 10:1 до 1:4. 2. Моющее средство, содержащее поверхностно-активное вещество по п.1, отличающееся тем, что массовое соотношение а):b) составляет от 7:1 до 1:3, предпочтительно от 5:1 до 2:5, весьма предпочтительно от 5:1 до 1:2, особо предпочтительно 4:1 до 2:3 и, в частности, от 3:1 до 1:1. 3. Моющее средство, содержащее поверхностно-активное вещество по п.1, отличающееся тем, что оно содержит один или несколько растительных экстрактов из группы, включающей экстракт алоэ, дынный экстракт, экстракт ванили. 4. Моющее средство, содержащее поверхностно-активное вещество по п.1, отличающееся тем, что оно содержит один или несколько видов ...

ПОЛИЕНОВЫЕ СОЕДИНЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ И КОСМЕТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ

Изобретение относится к новым полиеновым соединениям, фармацевтическим и косметическим композициям на их основе.

ПРОДУКТЫ И СПОСОБЫ ДЛЯ УХОДА ЗА ПОЛОСТЬЮ РТА, СОДЕРЖАЩИЕ ГИДРОКСИАПАТИТ-СВЯЗЫВАЮЩИЕ БЕЛКИ

КОМПОЗИЦИЯ ДЛЯ ПРЕДОТВРАЩЕНИЯ ИЛИ ЛЕЧЕНИЯ ВЫПАДЕНИЯ ВОЛОС, СОДЕРЖАЩАЯ БЕЛОК, ПРЕДСТАВЛЯЮЩИЙ СОБОЙ ЛИГАНД 1 ХЕМОКИНА, СОДЕРЖАЩЕГО С-Х-С МОТИВ (CXCLI)

ЗАЩИТНАЯ, ПИТАТЕЛЬНАЯ И/ИЛИ УКРЕПЛЯЮЩАЯ КОМПОЗИЦИЯ ДЛЯ ОДНОВРЕМЕННОЙ ОБРАБОТКИ ПОВЕРХНОСТНЫХ И БОЛЕЕ ГЛУБОКИХ СЛОЕВ КОЖИ И СПОСОБ ЗАЩИТЫ, ПИТАНИЯ И/ИЛИ УКРЕПЛЕНИЯ КОЖИ

Объектом изобретения является защитная, питательная и/или укрепляющая композиция для одновременной обработки поверхностных и глубоколежащих слоев крови, отличающихся тем, что содержит одну дисперсию липидных пузырьков, которые способны проникать в глубоколежащие слои кожи и содержит по крайней мере один активный агент, выбранный из антиокислительных свободно-радикальных агентов, протеинов, сахаров, ферментов, витаминов, нуклеотидов и их последовательностей, микроэлементов, коферментов, фосфолипидов с большим содержанием ненасыщенных жирных кислот, производных кремния и растительных экстрактов для обработки этих глубоколежащих слоев, и вторую дисперсию липидных пузырьков, которые способны проникать в поверхностные слои кожи и содержат по крайней мере один активный агент, выбранный из экранирующих (screening) агентов, антиокислительных свободно-радикальных агентов, сахаров, аминокислот, витаминов, керамидов (ceramids), неомыляющихся продуктов, полученных из растительных масел, и компонентов ...

КИСЛОРОДПЕРЕНОСЯЩАЯ МНОЖЕСТВЕННАЯ НАНОЭМУЛЬСИЯ И КОСМЕТИЧЕСКОЕ СРЕДСТВО ДЛЯ КУРЯЩИХ НА ЕЕ ОСНОВЕ

... 1. Косметическое средство, защищающее кожу от повреждений, инициируемых активным и пассивным курением, включающее косметически приемлемую основу и кислородпереносящую множественную наноэмульсию, в качестве которой оно содержит кислородпереносящую множественную эмульсию кремнийорганических соединений в концентрации 0,1-20 вес.%. 2. Кислородпереносящая множественная эмульсия кремнийорганических соединений, содержащая органические фосфаты в концентрации 1,0-5,0%, и/или гидрокарбонаты в концентрации 0,2-1%, тканевый ингибитор металлопротеиназы в концентрации 0,1-5,0%, эндогенные антиоксиданты и/или растительные экстракты с антиоксидантной активностью в концентрации 0,01-3,0%. 3. Эмульсия по п.2, отличающаяся тем, что в качестве органических фосфатов используют 2,3-дифосфоглицерат и/или гексаинозитолфосфат. 4. Эмульсия по п.2, отличающаяся тем, что в качестве эндогенных антиоксидантов используют супероксиддисмутазу и/или каталазу. 5. Эмульсия по п.2, отличающаяся тем, что в качестве растительного ...

ПРОДУКТЫ И СПОСОБЫ ДЛЯ УХОДА ЗА ПОЛОСТЬЮ РТА, СОДЕРЖАЩИЕ HLP

Водорастворимые композиции с биологически активными липофильными соединени ми

... 1. Водорастворимая композиция, содержащая биологически активное липофильное соединение и солюбилизирующий агент общей формулы где Х - остаток гидрофобной части молекулы, выбранной из группы, состоящей из стеринов, токоферолов и их производных, Y - остаток гидрофильной части молекулы, выбранной из группы, состоящей из полимерных спиртов, полиэфиров и их производных, р = 1 или 2, m = 0 или 1, и n - целое число в интервале: 0≤n≤18, при условии, что если р и m равны 1, а гидрофобная часть молекулы является α-(+)-токоферолом, то n не равно 2. 2. Композиция по п.1, отличающаяся тем, что биологически активное липофильное соединение выбрано из группы, состоящей из убихинонов, убихинолей, витаминов, провитаминов, полиеновых макролидных антибиотиков и их смесей, при условии, что если биологически активное липофильное соединение - убихинон, а гидрофобная часть молекулы - холестерин, то n не равно 8. 3. Композиция по п.1, отличающаяся тем, что гидрофобная часть молекулы выбрана из группы, состоящей ...

КОСМЕТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ ГИАЛУРОНОВОЙ КИСЛОТЫ, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ЕЕ ПРИМЕНЕНИЕ

КОМПОЗИЦИИ ПО УХОДУ ЗА КОЖЕЙ, СОДЕРЖАЩИЕ САЛИЦИЛОВУЮ КИСЛОТУ

... 1. Композиция для ухода за кожей с pH в диапазоне от 2,5 до 6,0, подходящая для топического нанесения на кожу, содержащая от 0,1 до 5% веса салициловой кислоты или ее соли и гидролизованный молочный белок, в которой отношение веса салициловой кислоты или ее соли к весу гидролизованного молочного белка варьирует от 2:1 до 15:1 весовых частей.2. Композиция по п.1, которая содержит салициловую кислоту.3. Композиция по п.2, в которой концентрация салициловой кислоты составляет по меньшей мере 1% веса.4. Композиция по п.2, в которой концентрация салициловой кислоты составляет менее 3% веса.5. Композиция по п.2, в которой концентрация салициловой кислоты находится в диапазоне от 1 до 3% веса.6. Композиция по п.1, в которой концентрация гидролизованного молочного белка составляет по меньшей мере 0,05% веса, и наиболее предпочтительно по меньшей мере 0,1% веса.7. Композиция по п.1, в которой концентрация гидролизованного молочного белка составляет менее 1% веса.8. Композиция по п.1, в которой концентрация ...

КОМПОЗИЦИЯ ДЛЯ ПРОФИЛАКТИКИ ИЛИ УМЕНЬШЕНИЯ ТРАНСЭПИДЕРМАЛЬНОЙ ПОТЕРИ ВОДЫ И УЛУЧШЕНИЯ ФУНКЦИИ КОЖНОГО БАРЬЕРА

КЕРАТИНСВЯЗЫВАЮЩИЕ ПОЛИПЕПТИДЫ

... 1. Косметическая композиция для обработки кератинсодержащих материалов, содержащая, по меньшей мере, одну кератинсвязывающую полипептидную последовательность (i) в косметически переносимой среде. 2. Косметическая композиция по п.1, отличающаяся тем, что полипептидная последовательность (i) имеет связывающее средство с кератином волос, ногтей или кожи человека. 3. Косметическая композиция по п.1, отличающаяся тем, что полипептидная последовательность (i) включает, по меньшей мере, одну из следующих полипептидных последовательностей: (a) полипептидную последовательность SEQ ID NO:1 положение 2193 до 2481, (b) полипептидную последовательность SEQ ID NO:1 положение 2606 до 2871, (c) полипептидную последовательность, в которой по сравнению с последовательностью (а) изменено до 60% аминокислот, (d) полипептидную последовательность, в которой по сравнению с последовательностью (b) изменено до 50% аминокислот, при условии, что связывание с кератином полипептидной последовательности (с) или (d) ...

ЛЕЧЕНИЕ МОРЩИН ВЕРХНЕЙ ЧАСТИ ЛИЦА

Способ восстановления поврежденных волос

Изобретение относится к способу лечения волос. Способ восстановления поврежденных волос включает этапы: восстанавливают дисульфидные связи посредством нанесения на всю длину волос спрея заявленного состава, выдержки в течение 12 минут, смывки; реконструируют аминокислотные и дипептидные цепи путем нанесения на всю длину волос эмульсии с комплексом аминокислот заявленного состава, выдержки в течение 12 минут, смывки; восстанавливают кортексные липиды путем нанесения на всю длину волос маски заявленного состава, выдержки под вапоризатором при температуре 40°C, смывки; уплотняют и укрепляют волосы путем нанесения на всю длину волос маски заявленного состава, выдержки под шапочкой и вапоризатором при температуре 40°C в течение 15 минут, смывки; увлажняют и придают эластичность волосам путем нанесения на всю длину волос маски заявленного состава, выдержки под шапочкой и вапоризатором при температуре 40°C в течение 10 минут, смывки; восстанавливают кутикулярные липиды путем нанесения на всю длину ...

SHAMPOO FOR HAIR

Шампунь для детей

Изобретение относится к косметике, и именно к средствам для гигиенического ухода за волосами детей. Цель изобретения 2 : снижение аллергических явлений на коже, повышение тонизирующего и противовоспалительного эффекта. Для этого в состав вводят синергетически действующий комплекс ПАВ мягкого моющего действия. Комплекс компонентов содержит магний лаурилсульфат оксиэтилированный, триэта- иоламиновую соль оксиэтилированного ацйламинсульфата, алкиламидопропилен- бетаин, композицию из растительного бырья 15-5, поваренную соль, метиловый эфир параоксибензойной кислоты,- пропи- ло1зый эфир параоксибензойиой кислоты, отдушку и воду. Композиция из растительного сырья 15-5 содержит петрушку, боярышник , трехцветную фиалку, полынь горькую, цидонию. 1 табл.

Средство для мытья волос

Фунгицидное и дезодорирующее средство

Способ получения вещества, обладающего гормональным действием

Способ получения производных аминокислот их солей рацематов или оптически-активных антиподов

Способ получения производных аминокислот или их солей или оптических изомеров

Способ получения производных аминокислот, их солей рацематов или оптически-активных антиподов

Expandiertes festes Produkt auf Basis von natürlichen Stoffe zur Verwendung in Kosmetik

Durch extrudieren erhaltene, in Form einer weichen Paste vorliegende Zusammensetzung und Herstellungsverfahren

Kosmetische Zubereitungen mit Wirkstoffen in Mikrokapseln

Gegenstand der Erfindung sind kosmetische Zubereitungen, welche dadurch gekennzeichnet sind, dass sie Wirkstoffe in einer Mikroverkapselung enthalten, deren Verkapselungsmaterial im pH-Bereich der Haut durchlässig und/oder abgebaut wird.

WAESSRIGE DISPERSIONEN, ENTHALTEND FETTSAEUREMONO-/-DIGLYCERID-GEMISCHE, UND DEREN VERWENDUNG

FLUESSIGE KOERPERREINIGUNGSMITTEL

ORALES VERABREICHUNGSSYSTEM VON DESFERRIOXAMIN

Kosmetische Zusammensetzung für Masken zur Reinigung der Haut, die sphäroidale Polyamid-Partikel vorgegebener Grösse enthält

New phospholipid liposome(s) preserved by alcohol(s) - are sterile and easy to prepare, for use in pharmaceutical and cosmetics

Phospholipid liposomes (I), preserved with alcohols, are new. The starting material for (I) is phospholipid isolated from oil seeds, in particular phosphatidyl choline (PC), acid phospholipids (AP) and other phospholipids (OP). Pref. compsns. contain (wt.%): 60-80 PC, 1-30 AP and 1-30 OP; esp. (a) 80 PC, 1-19 AP and 1-19 OP; or (b) 60 PC, 10-30 AP and 10-30 OP. The alcohol is EtOH or 2-propanol, present in an amt. of 16 wt.%. A claimed liposomal soln. contg. (I) has phospholipid content of 20% (max.), more usually 10%. USE/ADVANTAGE - (I) are important in the pharmaceutical and cosmetics industries. (I) are sterile, easy to prepare requiring no elevated temps. or ultrasound and the alcohol does not lead to destruction of the liposomal system.

Wimper- und/oder Augenbraueschminke und Herstellungsverfahren

Kombinationen von Glycosaminoglycan mit kationischen Polymeren.

Cosmetic and therapeutic use of proteins of dj-1 type for treating skin dryness

The present invention relates to the use, especially the cosmetic and/or therapeutic use, of the protein DJ-1, of polypeptides derived from this protein or of analogues thereof, of a nucleic acid sequence coding for such a polypeptide or of a modulator of the activity, stability or expression of such a polypeptide, especially for preventing and/or treating the signs of skin dryness. The invention also relates to the use of the protein DJ-1, of polypeptides derived from this protein or of analogues thereof or of a nucleic acid sequence coding for such a polypeptide, as a marker for evaluating the state of dryness of an epithelium.

Compositions and improved soft tissue replacement methods

The specification discloses compositions and methods for treating a soft tissue defect of an individual.

High alcohol content foaming compositions

This invention relates to a “high lower alcohol content” (>40% v/v of a C 1-4 alcohol) liquid composition able to be either dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers or as an alcohol gel composition which does not use thickener and gelling agents that leave undesirable deposits or a sticky after-feel and that has a final viscosity less than 4,000 cps. The liquid compositions comprise an alcohol, C 1-4 (>40% v/v), a fluorosurfactant of at least 0.001% by weight to prepare a foamable composition or from 0-2.0% to prepare a gel-like composition of a final viscosity less than 4,000 cps, 0-10% w/w of additional minor components added to obtain the desired performance (a foamable composition or a gel-like composition with a viscosity less than 4,000 cps), and the balance being purified water. The compositions may include emulsifier-emollients and moisturizers, secondary surfactants, foam stabilizers, fragrances, antimicrobial agents, other type of medicinal ingredients, and the like ingredients or additives or combinations thereof commonly added to alcohol gels or foams, aerosol compositions or to toiletries, cosmetics, pharmaceuticals and the like.

Pharmaceutical composition for treating or preventing burn injuries

The present invention relates to a pharmaceutical composition and the method of use for treating or preventing burn injury in patients or subjects in need, including the compound represented by the specific chemical formula as an active ingredient or its pharmaceutically acceptable salts or solvates.

Method for the extraction and hydrolysis of any protein substance, natural auxins and polyphenols from sources of plant origin and their derivatives

Method for the extraction and hydrolysis of any protein substance, natural auxins and polyphenols from sources of plant origin and their derivatives, which from a any vegetable matter (roots, stems including bark, leaves, fruits, seeds and derivatives) and by an hydrolysis in acid alcohol which is added alcohols and mineral acids, the resulting mass is subjected to a thermodynamic treatment, with subsequent utilization of physical systems of separate solid/liquid plant extract is obtained a hydro alcoholic.

Gastroretentive Dosage Forms Of GABA Analogs

The present invention relates to gastroretentive dosage forms of gamma aminobutyric acid (“GABA”) analogs, and to processes for preparation of the same. The present invention provides gastroretentive dosage forms comprising GABA analog, at least one swelling agent and at least one non-swelling release retardant.

MALLEABLE HYDROGEL HYBRIDS MADE OF SELF-ASSEMBLED PEPTIDES AND BIOCOMPATIBLE POLYMERS AND USES THEREOF

Hybrid hydrogels formed of a plurality of peptides that are capable of self-assembling into a hydrogel in an aqueous solution and a biocompatible polymer that is characterized by high swelling capability, high elasticity and low mechanical strength are disclosed, with exemplary hybrid hydrogels being formed of a plurality of aromatic dipeptides and hyaluronic acid. The hybrid hydrogels are characterized by controllable mechanical and biological properties which can be adjusted by controlling the concentration ratio of the peptides and the polymer, and which average the mechanical and biological properties of the peptides and the polymer. Processes of preparing the hydrogels and uses thereof in pharmaceutical, cosmetic or cosmeceutic applications such as tissue engineering and/or regeneration are further disclosed. 157-. (canceled)58. A hydrogel comprising a fibrous network of a plurality of peptides and at least one biocompatible polymer , wherein said peptides are capable of self-assembling in an aqueous solution so as to form a hydrogel and wherein said biocompatible polymer features at least one characteristic selected from the group consisting of:(i) a storage modulus G′ lower than 500 Pa at 10 Hz frequency and at 25° C.;(ii) a swelling ratio (Q) higher than 500;{'sup': '−1', '(iii) a viscosity at 0.1 Secshear rate and at 25° C., lower than 300 Pa·s; and'}(iv) a viscosity recovery after shear of at least 95%.59. The hydrogel of claim 58 , wherein said biocompatible polymer is a polysaccharide.60. The hydrogel of claim 59 , wherein said biocompatible polymer is hyaluronic acid.61. The hydrogel of claim 59 , wherein said biocompatible polymer is a chitosan.62. The hydrogel of claim 58 , wherein each peptide in said plurality of peptides comprises an amino acid sequence not exceeding 6 amino acids in length claim 58 , whereas said amino acid sequence comprises at least one aromatic amino acid residue.63. The hydrogel of claim 62 , wherein at least one peptide in ...

ORAL CARE COMPOSITIONS

The invention provides a non-aerated, foamable oral care composition comprising less than 1.5% anionic surfactant (by total weight anionic surfactant based on the total weight of the composition), abrasive cleaning agent and hydrophobin. The composition is mild to oral mucosa yet exhibits excellent foamability, texture and storage stability. 1. A non-aerated , foamable oral care composition comprising less than 1.5% anionic surfactant (by total weight anionic surfactant based on the total weight of the composition) , abrasive cleaning agent and hydrophobin.2. A non-aerated claim 1 , foamable oral care composition according to claim 1 , where the hydrophobin is a Class II hydrophobin.3. A non-aerated claim 2 , foamable oral care composition according to claim 2 , where the Class II hydrophobin is HFBI claim 2 , HFBII claim 2 , or a mixture thereof.4. An oral care composition according to claim 1 , in which the amount of anionic surfactant ranges from 0.25 to 1.0% by total weight anionic surfactant based on the total weight of the composition.5. An oral care composition according to claim 1 , in which the abrasive cleaning agent is selected from abrasive silicas claim 1 , calcium carbonates and mixtures thereof.6. An oral care composition according to claim 1 , in which the amount of abrasive cleaning agent ranges from 3 to 75% by total weight abrasive cleaning agent based on the total weight of the composition.7. An oral care composition according to claim 1 , in which the amount of hydrophobin ranges from 0.01% to 2% by total weight hydrophobin based on the total weight of the composition.8. An oral care composition according to claim 1 , which is in the form of a dentifrice and which comprises water claim 1 , humectant claim 1 , and binder or thickening agent.9. An oral care composition according to claim 1 , which further comprises a flavouring agent in an amount ranging from 0.1 to 1.0% by total weight flavouring agent based on the total weight of the composition ...

PEPTIDES USED IN THE TREATMENT AND/OR CARE OF THE SKIN, MUCOUS MEMBRANES AND/OR HAIR AND ITS USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS

Peptides of general formula (I): R—W—X-AA-AA-AA-AA-Y—Z—R(I) its stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, a preparation process, cosmetic or pharmaceutical compositions which contain them and their use in the treatment and/or care of the skin, mucous membranes and/or hair and the treatment and/or care of those conditions, disorders and/or diseases which are improved or prevented by Hsp stimulation. 1. A peptide of general formula (I){'br': None, 'sub': 1', 'm', '1', '2', '3', '4', 'p', 'q', '2, 'R—W—X-AA-AA-AA-AA-Y—Z—R\u2003\u2003(I)'}its stereoisomers, mixtures thereof and/or its cosmetically or pharmaceutically acceptable salts, wherein:{'sub': '1', 'AAis -His-;'}{'sub': '2', 'AAis selected from the group consisting of -His-, -Leu- and -Pro-'}{'sub': '3', 'AAis -Leu-;'}{'sub': '4', 'AAis selected from the group consisting of -Arg- and -Asn-;'}W, X, Y and Z are independently selected from amongst themselves from the group consisting of the codified amino acids and uncodified amino acids;n, m, p and q are independently selected from amongst themselves and have a value between 0 and 1;n+m+p+q is less or equal to 2;{'sub': 1', '5', '5, 'Ris selected from the group consisting of H, substituted or unsubstituted non-cyclic aliphatic group, substituted or unsubstituted alicyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and R—CO— wherein Ris selected from the group consisting of H, substituted or unsubstituted non-cyclic aliphatic group, substituted or unsubstituted alicyclyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted heterocyclyl and substituted or unsubstituted heteroarylalkyl;'}{'sub': 2', '3', '4', '3', '3', '3', '4, 'Ris selected from the group consisting of —NRR, —ORand —SR, wherein Rand Rare independently selected from the group ...

TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS

Pharmaceutical compositions and methods for the treatment of subjects, including humans, who have or are at risk for various disease, disorders and conditions, including, mitochondria-associated diseases, disorders, and conditions, including respiratory chain disorders, and diseases, disorders and conditions associated with or characterized at least in part by mitochondria swelling, mitochondria dysfunction, mitochondria leaking, oxidative stress, increased mitochondria number, increased mitochondria and mitochondria-related protein mass, and increased mitochondria and related-related proteins expression. 1. A method for improving age-related physiological deficits and increasing longevity in a mammal comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a pharmaceutically acceptable copper (II) antagonist and a pharmaceutically acceptable carrier.2. The method of wherein said copper antagonist is a linear or branched tetramine capable of binding copper (II).3. The method of wherein said linear or branched tetramine is a copper (II) chelator.4. The method of wherein said linear or branched tetramine is selected from the group consisting of 2 claim 3 ,3 claim 3 ,2 tetramine claim 3 , 2 claim 3 ,2 claim 3 ,2 tetramine claim 3 , and 3 claim 3 ,3 claim 3 ,3 tetramine.5. The method of wherein said copper (II) antagonist is triethylenetetramine.6. The method of wherein said copper (II) antagonist is a triethylenetetramine salt.7. The method of wherein said triethylenetetramine salt is a succinate salt.8. The method of wherein said triethylenetetramine succinate salt is triethylenetetramine disuccinate.9. The method of wherein said composition is a tablet or capsule for oral administration.10. The method of wherein said composition is a long-acting tablet or capsule for oral administration.11. The method of wherein said copper antagonist is selected from the group consisting penicillamine claim 1 , N- ...

Silk fibroin porous material and method for producing same

By a silk fibroin porous material containing silk fibroin and an amino acid and a method for producing a silk fibroin porous material including freezing a fibroin solution having an amino acid added to a fibroin aqueous solution and subsequently thawing the solution to obtain a porous material, a porous material which does not contain a solvent and which is high in safety and a method for producing the same are provided.

COSMETIC COMPOSITION FOR RESTORING LIPIDIC LAYER OF THE STRATUM CORNEUM IN ORTHORHOMBIC

The present invention refers to a cosmetic composition of the oil-in-glycol type comprising (a) at least one sucrose non-ionic surfactant or derivatives thereof, (b) at least one fatty alcohol, (c) at least one glycol and (d) at least one ingredient selected from aminoacid and/or peptide, as well as associated uses, products and methods. The composition of the invention is capable of restoring the cutaneous barrier, reorganizing the lipidic layer of the stratum corneum in orthorhombic, conceding hydration, renewal and cellular energization in the long run. In a particular embodiment, said composition can be used simultaneously as an emulsifying system for preparing cosmetic products, for example, in the preparation of creams, lotions, etc. 1. OIL-IN-GLYCOL COSMETIC COMPOSITION FOR RESTORING CUTANEOUS BARRIER , wherein it comprises (a) at least one sucrose non-ionic surfactant or derivatives thereof , (b) at least one fatty alcohol , (c) at least one glycol and (d) at least one ingredient selected from aminoacid and/or peptide.2. COMPOSITION claim 1 , according to the claim 1 , wherein the non-ionic surfactant (a) is an ester of sucrose.3. COMPOSITION claim 2 , according to claim 2 , wherein the non-ionic surfactant (a) is selected from sucrose stearate claim 2 , sucrose tristearate claim 2 , sucrose hexaerucate claim 2 , sucrose tribehenate or mixtures thereof.4. COMPOSITION claim 1 , according to claim 1 , wherein the non-ionic surfactant (a) is a mixture of sucrose stearate and trisucrose stearate in the ratio of 2:1.5. COMPOSITION claim 1 , according to claim 1 , wherein it contains from 10 to 20% by weight of non-ionic surfactant (a) in relation to the total weight of the composition.6. COMPOSITION claim 1 , according to claim 1 , wherein the fatty alcohol (b) is selected from among those that have a carbon chain of C10 to C22.7. COMPOSITION claim 6 , according to claim 6 , wherein the fatty alcohol (b) is selected from among behenyl alcohol claim 6 , isocetyl ...

Gastric retentive gabapentin dosage forms and methods for using same

Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of immediate release gabapentin, the gastric retentive gabapentin dosage forms provided herein have the advantages of improving patient compliance for gabapentin treatment. In addition to the foregoing, the gastric retentive gabapentin dosages forms also exhibit decreased blood plasma concentrations and increased bioavailability throughout the dosing regimen.

Chinese Medicine Hair-blackening Preparation and Formula and Preparation Method Therefor

A preparation having the effect of blackening hair and a method for the preparation thereof, the preparation containing extracts of fresh ginger, huangqi (), heshouwu (), black sesame, danggui (), goujizi (Chinese wolfberry), chuanqiong (), danshen (), wild chrysanthemum, red dates, black beans, walnuts, white mulberry root-bark, nuzhenzi (), hanliancao (), mulberry fruit, black-bone chicken and duck fat, and also containing 65% ethanol solution and 40% ethanol solution, the whole being variously subjected to techniques of mixing, grinding, maceration and extraction to produce a thick ointment composition. The preparation is suitable for all hair and scalp types, and when used after washing of the hair produces no allergic reactions or toxic side-effects, allowing the medicinal elements swiftly to penetrate and be absorbed by the skin to achieve blackening of the hair with quickly visible results. The hair is blackened and nourished, cost is low and the preparation technique is simple. 1astragalus mongholicus, polygonum multiflorumangelica sinensis, fructus lycii, ligusticum wallichii, salviae miltiorrhizae, chrysanthemum indicum. A formula of Chinese materia medica preparation beneficial for the growth of black hair , thereof characterized in that the invention is a thick paste composition which is prepared by the use of ginger , , black sesame , , red dates , black soya bean , walnuts , cortex mori radicis , fructus ligustri lucidi , eclipta alba , mulberry , fat extract of silkie and duck , in addition , 65% ethanol solution and 40% ethanol solution and wherein the quality of each composition is:Ginger 55-100 g{'i': 'Astragalus mongholicus', '75-100 g'}{'i': 'Polygonum multiflorum', '100-150 g'}Black sesame 80-90 g{'i': 'Angelica sinensis', '60-120 g'}{'i': 'Fructus lycii', '85-125 g'}{'i': 'Ligusticum wallichii', '60-80 g'}{'i': 'Salviae miltiorrhizae', '75-95 g'}{'i': 'Chrysanthemum indicum', '40-50 g'}Red dates 60-100 gBlack soya bean 100-120 gWalnuts 50-80 ...

Chinese Medicine Hair-regrowth Preparation and Formula and Preparation Method Therefor

Disclosed in the present invention are a formula and preparation method for a hair-regrowth preparation, the preparation containing extracts of fresh ginger, huangqi (Radix astragali), heshouwu (Polygonum multiflorum), black ants, danggui (), lianzicao (), chuanqiong (Ligusticum chuanxiong), danshen (), dodder seed, almonds, black beans, walnuts, qingxiangzi (Semen celosiae), digupi (Chinese Wolfberry Root-bark), hanliancao (), mulberry fruit, black-bone chicken and duck fat, and also containing 65% ethanol solution and 40% ethanol solution, the whole being variously subjected to techniques of mixing, grinding, maceration and extraction to produce a thick-ointment composition. The preparation of the present invention is suitable for all hair and scalp types, and when used after washing of the hair produces no allergic reactions or toxic side-effects, allowing the medicinal elements swiftly to penetrate and be absorbed by the skin to achieve regrowth of the hair with quickly visible results. Hair regrowth is effective, cost is low and the preparation technique is simple. 1angelica sinensis, alternanthera sessilis, ligusticum wallichii, salviae miltiorrhizaeeclipta alba. A formula of Chinese materia medica preparation beneficial for hair growth , thereof characterized in that the invention is a thick paste composition which is prepared by the use of ginger , astragalus mongholicus , polygonum multiflorum , black ants , , dodder seed , almonds , black soya bean , walnuts , the seed of feather cockscomb , cortex lycii radicis , , mulberry , fat extract of silkie and duck , in addition , 65% ethanol solution and 40% ethanol solution and wherein the quality of each composition is:Ginger 55-100 gAstragalus mongholicus 75-100 gPolygonum multiforum 100-150 gBlack ants80-90 g{'i': 'Angelica sinensis', '60-120 g'}{'i': 'Alternanthera sessilis', '85-125 g'}{'i': 'Ligusticum wallichii', '60-80 g'}{'i': 'Salviae miltiorrhizae', '75-95 g'}Dodder seed 40-50 gAlmonds 60-100 gBlack ...

TREATMENT OF NEUROPATHIC PAIN WITH N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONISTS

Central neuropathic pain is treated with an analgesic composition that consists essentially of an N-methyl-D-aspartate (NMDA) receptor antagonist. In one embodiment, the invention includes chronic administration of the (NMDA) receptor antagonist. In another embodiment, the invention is use of an NMDA receptor antagonist or component thereof for the manufacture of a medicament than includes an analgesic component that consists essentially of an NMDA receptor antagonist for the chronic treatment of central neuropathic pain. 132-. (canceled)33. A method for treating spinal cord injury in a subject in need thereof , comprising administering to the subject a selected therapy established as preferred by a method comprising steps of:administering to a set of subjects a plurality of distinct therapeutic regimens that all administer the same active ingredient or ingredients;collecting input from subjects in the set regarding the subjects' preference between or among administered therapeutic regimens;determining that one of the therapeutic regimens is statistically selected as preferred by subjects in the set over at least one other of the therapeutic regimens, and therefore is the selected therapy.34. The method of claim 33 , wherein the selected therapy involves administration of two or more active ingredients.35. The method of claim 33 , wherein the subject being administered the selected therapy is a human patient.36. The method of claim 33 , wherein the set of subjects undergo evaluation at least once weekly during the sequence of different treatments.37. The method of claim 36 , wherein the set of subjects undergo evaluation at least twice weekly during the sequence of different treatments.38. The method of claim 33 , wherein the step of collecting input from subjects in the set comprises collecting subjects' assessment of global pain intensity.39. The method of claim 33 , wherein the step of collecting input from subjects in the set comprises collecting subjects' ...

METHODS, COMPOSITIONS AND KITS FOR PROVIDING A THERAPEUTIC TREATMENT

The present invention encompasses a therapeutic method which employs treatment of a disease such as cancer with triiodothyronine (T3) together with an anti-thyroid treatment such as treatment with an anti-thyroid agent, treatment with radioiodine and surgical removal of all or part of the thyroid gland. A pharmaceutical composition comprising T3 and an anti-thyroid agent and a kit comprising the same are also encompassed by the invention. 1. A therapeutic method , comprising administering to a subject in need of a therapeutic treatment:{'sub': '3', 'a triiodothyronine (T) or biochemical analogue thereof; and'}(ii) at least one anti-thyroid treatment selected from the group consisting of treatment with an anti-thyroid agent, treatment with radioiodine and surgical removal of all or part of the thyroid gland.2. A therapeutic method , comprising treating a subject having cancer with:{'sub': '3', '(i) triiodothyronine (T) or biochemical analogue thereof; and'}(ii) at least one anti-thyroid treatment selected from the group consisting of treatment with an anti-thyroid agent, treatment with radioiodine and surgical removal of all or part of the thyroid gland;wherein said method is effective to achieve at least one of the following.(a) sensitization in the subject of cancer to anti-cancer treatment;(b) treating the cancer.3. The therapeutic method of claim 1 , comprising treating a subject having cancer.4. The therapeutic method of claim 3 , wherein the treatment is effective to achieve at least one of the following:(a) sensitization in the subject having cancer to anti-cancer treatment;(b) treating the cancer.5. (canceled)6. The therapeutic method of claim 1 , wherein said biochemical analogue is an L-isomer of T.7. The therapeutic method of claim 6 , wherein said L-isomer of Tis liothyronine sodium.89-. (canceled)10. The therapeutic method of claim 1 , wherein the daily amount of Tor biochemical analogue thereof is between about 5 μg and between about 40 μg.1112-. ( ...

COMPOSITIONS FOR ENHANCING NAIL GROWTH

The present invention is directed to compositions and methods for stimulating the growth of nails and cuticles in a mammal, including humans. The compositions may be administered topically to the nail bed, nail matrix and cuticle in an amount effective to increase nail growth and thicken, strengthen and smooth the nail. The composition is also effective in strengthening and growing nails, including fingernails and toenails. 1. A method of accelerating nail growth , treating brittle nails and strengthening nails in a human or animal , the method comprising:applying an oil-in-water emulsion to the nails, cuticles or nail matrix of the human or animal at least once a day, wherein said emulsion comprises cyclosporine A.2. The method of wherein the oil is castor oil and the emulsion further comprises the surfactant polysorbate 80.3. The method of further comprising glycerine.4. The method of wherein the oil is selected from the group consisting of: Anise oil; Castor oil; Clove oil; Cassia oil; Cinnamon oil; oils having a specific gravity between 0.90 and 0.95; Almond oil; Corn oil; Arachis oil; Cottonseed oil; Safflower oil; Maize oil; Linseed oil; Rapeseed oil; Soybean oil; Olive oil; Caraway oil; Rosemary oil; Peanut oil; Peppermint oil; Sunflower oil; Eucalyptus oil; Sesame oil; an oil having a specific gravity specific gravity below 0.9; Mineral oil; Coriander oil; Lavender oil; Citronella oil; Juniper oil; Lemon oil; Orange oil; Clary sage oil; Nutmeg oil; and Tea tree oil or mixtures thereof.5. The method of wherein the oil-in-water emulsion further contains a surfactant selected from the group consisting of Polysorbate 80 claim 1 , carboxylated and ethoxylated alcohols claim 1 , amine oxides claim 1 , block polymers claim 1 , fatty acids including carboxylic fatty acids claim 1 , ethoxylated alkyl phenols claim 1 , ethoxylated fatty esters claim 1 , glycerol esters claim 1 , lanolin-based derivatives claim 1 , lignin derivatives claim 1 , methyl esters claim 1 , ...

DRYING, ANTI-SMEAR, AND ANTI-ODOR AGENT FOR SPRAY TANNING

In some example embodiments, there is provided a method for sunless tanning. The method may include applying a sunless tanning solution to the skin and applying, during a drying stage of the sunless tanning solution, a powder to at least dry the tanning solution. Related compounds and methods may also be disclosed. 1. A method for sunless tanning comprising:applying a sunless tanning solution to the skin; andapplying, during a drying stage of the sunless tanning solution, a powder to at least dry the tanning solution.2. The method of claim 1 , wherein the powder comprises talc.3. The method of claim 1 , wherein the powder comprises talc claim 1 , aluminum starch octenylsuccinate claim 1 , cornstarch claim 1 , tapioca starch claim 1 , fragrance claim 1 , silica claim 1 , Kaolin claim 1 , and magnesium carbonate.4. The method of claim 1 , wherein the powder talc and fragrance.5. The method of claim 1 , wherein the powder comprises a compound silk powder claim 1 , chlorphenesin claim 1 , sodium benzoate claim 1 , mica claim 1 , titanium dioxide claim 1 , fragrance claim 1 , and iron oxides.6. The method of claim 1 , wherein the powder comprises about 42.55% talc claim 1 , about 20% aluminum starch octenylsuccinate claim 1 , about 10% zea mays starch claim 1 , about 10% tapioca starch claim 1 , about 6% fragrance claim 1 , about 5% silica claim 1 , about 4% kaolin claim 1 , about 0.29% chlorphenesin claim 1 , about 0.15% sodium benzoate claim 1 , and about 2% at least one of mica claim 1 , titanium dioxide claim 1 , and iron oxide.7. A composition of matter for drying a sunless tanning solution applied to the skin claim 1 , the composition of matter comprising a powder and a fragrance.8. The composition of matter of claim 7 , wherein the powder further comprises aluminum starch octenylsuccinate claim 7 , cornstarch claim 7 , tapioca starch claim 7 , fragrance claim 7 , silica claim 7 , Kaolin claim 7 , and magnesium carbonate.9. The composition of matter of claim 7 , ...

CYCLOSPORINE COMPOSITIONS FOR ENHANCING NAIL GROWTH

The present invention is directed to cyclosporine compositions and methods for stimulating the growth of nails and cuticles in a mammal, including humans. The compositions may be administered topically to the nail bed, nail matrix and cuticle in an amount effective to increase nail growth and thicken, strengthen and smooth the nail. The composition is also effective in strengthening and growing nails, including fingernails and toenails. 1. A method of accelerating nail growth , treating brittle nails or strengthening nail growth in a human or animal , the method comprising:topically applying a composition comprising cyclosporine to the nails, cuticles or nail matrix of the human or animal at least once a day, wherein said composition is selected from the group consisting of an emulsion, solution, gel, paste, dispersion and suspension.2. The method of wherein the cyclosporine is cyclosporine A.3. The method of wherein the cyclosporine is a cyclosporine A derivative or segment.4. The method of wherein the composition is an emulsion.5. The method of wherein the cyclosporine is cyclosporine A and is present in the emulsion in the amount of 0.05% w/v.6. The method of claim 5 , further comprising glycerin claim 5 , castor oil claim 5 , polysorbate 80 and carbomer 1342.7. The method of where in the cyclosporine is cyclosporine A and is present in a solution in the amount 0.01% w/v to 0.0125% w/v of the composition.8. The method of wherein the cyclosporine is present in the amount of 0.001% w/v to 50% w/v of the composition. This application is a divisional of U.S. application Ser. No. 12/683,811 filed Jan. 7, 2010, which claims the benefit of U.S. Provisional Application Ser. No. 61/143,317, filed Jan. 8, 2009; U.S. Provisional Application Ser. No. 61/181,353, filed May 27, 2009; U.S. Provisional Application Ser. No. 61/181,165 filed May 26, 2009; and, U.S. Provisional Application Ser. No. 61/160,946 filed Mar. 17, 2009 each of which is hereby incorporated by reference in ...

THERAPEUTIC AND COSMETIC USES AND APPLICATIONS OF CALRETICULIN

Therapeutic and cosmetic uses and applications of calreticulin are provided. In particular, the invention relates to therapeutic and cosmetic uses and applications of calreticulin to a patient in need of such treatment including in tissue repair, wound healing, ulcers, reducing scar formation, and reducing or eliminating wrinkles. 1. A method of treating wrinkles and/or fine lines in a subject in need thereof , which method comprises administering to said wrinkles an effective amount of calreticulin or a functional fragment or derivative thereof.2. The method of claim 1 , wherein said treatment results in at least one effect on wrinkles and/or fine lines selected from the group consisting of reducing the noticeability claim 1 , improving the appearance claim 1 , decreasing the depth claim 1 , decreasing the number claim 1 , and any combination thereof.3. A method of achieving a tissue reconstruction in a patient in need thereof claim 1 , which method comprises administering to the patient a therapeutically effective amount of calreticulin or a functional fragment or derivative thereof.4. A method of repairing damaged bone and/or cartilage in a patient in need thereof claim 1 , which method comprises administering to the damaged bone and/or cartilage of the patient a therapeutically effective amount of calreticulin or a functional fragment or derivative thereof.5. A method of stimulating regeneration of an epidermal appendage in a wound or skin of a patient in need thereof claim 1 , which method comprises administering to the wound or skin of the patient a therapeutically effective amount of calreticulin or a functional fragment or derivative thereof.6. The method of claim 5 , wherein the epidermal appendage is a hair follicle.7. A method for enhancing phagocytosis of bacteria by phagocytes within a wound claim 5 , of a patient in need thereof claim 5 , which method comprises administering to the wound of the patient a therapeutically effective amount of calreticulin ...

Moisturizing Composition Comprising an Aminopeptide Mixture

The invention is directed to skin moisturizing compositions comprising an aminopeptide mixture. The composition replenishes the skins natural moisturization factor and delivers excellent sensory benefits. The composition is not unpleasantly viscous during and after application. 1. A skin composition comprising: i. a water soluble amino acid or functionalized amino acid;', 'ii. water soluble dipeptide having a molecular weight from about 150 to about 410;', 'iii. water soluble tripeptide having a molecular weight from about 225 to about 600 or water soluble vitamins comprising peptide bonds or both; and, 'a) an aminopeptide mixture comprising 'wherein amino acid and water soluble dipeptide together make up from 50 to 99% by weight of the total weight of the aminopeptide mixture.', 'b) cosmetically acceptable carrier'}2. The skin composition according to wherein the amino acid or functionalized amino acid has a partitioning coefficient log kp of −4.5 to 0 in n-octanol-water.3. The skin composition according to wherein the amino acid or functionalized amino acid is selected from the group consisting of glutamine claim 1 , aspargine claim 1 , glycine claim 1 , glutamic acid claim 1 , threonine claim 1 , lysine claim 1 , alanine claim 1 , serine claim 1 , hydroxyproline claim 1 , N-acetyl-L-tyrosine claim 1 , N-acetyl-L-hydroxyproline claim 1 , N-acetyl-L-cysteine claim 1 , L-ornitine monochloride and a mixture thereof.4. The skin composition according to wherein the dipeptide is glycyl-L-glytamine claim 1 , glycyl-L-tyrosine claim 1 , L-alanyl-L-glytamine claim 1 , glycylglycine claim 1 , lysyl lysine claim 1 , glycyl alanine claim 1 , glycyl lysine claim 1 , glycyl hystidine or a mixture thereof.5. The skin composition according to wherein the water soluble vitamin comprising peptide bond comprises D-L-panthenol and the water soluble vitamin derivative comprises calcium pantetheine-S-sulfonate.6. The skin composition according to wherein the tripeptide is L-glytathione ...

METHODS FOR TREATING VASOMOTOR SYMPTOMS USING GABA ANALOGS IN A GASTRIC RETENTIVE DOSAGE FORM

Methods for treating vasomotor symptoms associated with menopause are described. 134.-. (canceled)35. A titration regimen for treating a subject experiencing menopause-related vasomotor symptoms , comprising:administering a first total daily dose of gabapentin in a dosage form for a first time period;administering a second total daily dose of gabapentin in the dosage form for a second time period;wherein the second total daily dose is greater than the first total daily dose; andwherein the dosage form comprises a hydrophilic polymer, wherein after administration the dosage form swells to a size that is retained in the stomach of the subject.36. The regimen of claim 35 , further comprising administering a third total daily dose of gabapentin in the dosage form for a third period of time.37. The regimen of claim 35 , wherein administering the first total daily dose of gabapentin comprises administering the first total daily dose once per day.38. The regimen of claim 37 , wherein the first total daily dose is administered in the evening.39. The regimen of claim 35 , wherein the first total daily dose is between about 600 mg and 1200 mg.40. The regimen of claim 35 , wherein the first total daily dose is about 600 mg.41. The regimen of claim 35 , wherein the first period of time is about 1 to 3 days.42. The regimen of claim 35 , wherein the first period of time is about 3 days.43. The regimen of claim 35 , wherein administering the second total daily dose comprises administering the second total daily dose once per day.44. The regimen of claim 43 , wherein the second total daily dose is administered in the evening.45. The regimen of claim 35 , wherein the second total daily dose is between about 800 mg and 1500 mg.46. The regimen of claim 35 , wherein the second total daily dose is about 1200 mg.47. The regimen of claim 35 , wherein the second period of time is between about 2 to 4 days.48. The regimen of claim 35 , wherein the second period of time is about 3 days.49. ...

COSMETIC COMPOSITION FOR IMPROVING SKIN ELASTICITY

Provided is a cosmetic composition for improving skin elasticity containing extract and a polymersome in which an anti-aging peptide is stabilized as active ingredients. The cosmetic composition of the present disclosure is efficacious in improving skin wrinkles, restoring skin elasticity and increasing skin water content, and thus is effective for improving skin elasticity. 1Phyllanthus urinaria. A cosmetic composition comprising extract and a polymersome in which an anti-aging peptide is stabilized as active ingredients.2. The cosmetic composition according to claim 1 , wherein the anti-aging peptide is palmitoyl tripeptide-5 or diaminopropionoyl tripeptide 33.3. The cosmetic composition according to claim 1 , wherein the polymersome in which an anti-aging peptide is stabilized is ABcell.4. The cosmetic composition according to claim 1 , wherein the composition maintains skin structure by increasing expression of the perlecan gene and thereby promoting regeneration of the epidermis and the dermis and the improvement of adhesion between the epidermis and the dermis.5. The cosmetic composition according to claim 1 , wherein the composition increases production of the perlecan protein.6. The cosmetic composition according to claim 1 , wherein the composition restores production of the perlecan protein decreased by UV.7. The cosmetic composition according to claim 1 , wherein the composition improves skin wrinkles claim 1 , restores skin elasticity and increases skin water content.8Phyllanthus urinaria. A method for improving skin elasticity comprising administering an effective amount of extract and a polymersome in which an anti-aging peptide is stabilized to a subject in such need claim 1 , wherein the method is for improving skin elasticity.9. The method for improving skin elasticity according to claim 8 , wherein the anti-aging peptide is palmitoyl tripeptide-5 or diaminopropionoyl tripeptide 33.10. The method for improving skin elasticity according to claim 8 , ...

METHOD OF USE OF STABILIZED NON-PLANT-DERIVED GROWTH FACTOR IN SKIN CARE

Cosmetic and dermatologic compositions for skin care, containing a non-plant derived growth factor, purified from a host organisms or host cells such as bacterial, yeast, or animal cells, including insect cells, or a mixture of growth factors in purified form, for use in topical therapeutics, dermatology and cosmetics. Importantly this invention provides stabilized, safer growth factors available for use for cosmetic and topical treatment. Preferred composition comprises a non-plant derived growth factor and hyaluronic acid. The skin-care/dermatological compositions with stabilized growth factor do not carry the risk of unwanted breakdown products and the resulting loss of activity of the composition. 1. A skin care/dermatological composition comprising at least one non-plant derived heterologous growth factor and at least one pharmaceutically and/or cosmetically acceptable excipient.2. The skin care/dermatological composition of comprising an excipient formula that stabilizes the non-plant derived heterologous growth factor protein.3. The skin care/dermatological composition of comprising hyaluronic acid.4. The skin care/dermatological composition of wherein the hyaluronic acid is provided in a concentration in the range of about 0.01 to about 2% by weight.5. The skin care/dermatological composition of claim 1 , suitable for treatment of a skin condition selected from one or more of dry skin claim 1 , eczema claim 1 , dermatitis claim 1 , cracked skin claim 1 , rash claim 1 , skin redness claim 1 , scar tissue claim 1 , psoriasis claim 1 , and edema.6. The skin care/dermatological composition of claim 2 , wherein said protein stabilising stabilizing formula comprises glycerol claim 2 , water claim 2 , and calcium chloride.7. The skin care/dermatological composition of claim 6 , wherein said protein stabilizing formula comprises the following ingredients (% by weight): glycerol in the range from 10 to 90% claim 6 , calcium chloride in the range from 0.1 mM to 200 mM ...

Methods Of Treating Autism With mGluR5 Antagonists

mGluR5 antagonists are used for the treatment of autism. The human treated by the methods of the invention can also have fragile X syndrome, epilepsy and anxiety. 1. A method of treating autism in a human , comprising the step of orally administering to the human a composition that includes a mGluR5 antagonist , wherein the mGluR5 antagonist is administered to the human at a dose of about 10 mg/kg body weight.2. The method of claim 2 , wherein the human further has fragile X syndrome.3. The method of claim 2 , wherein the human further has a seizure disorder.4. The method of claim 3 , wherein the seizure disorder includes epilepsy.5. The method of claim 2 , wherein the human further has an anxiety disorder.6. The method of claim 2 , wherein the human further has a deficit in sociability.7. The method of claim 2 , wherein the human further has a deficit in a reciprocal verbal and nonverbal communication.8. The method of claim 2 , wherein the human further has a repetitive behavior disorder.9. The method of claim 2 , wherein the mGluR5 antagonist is administered twice a day to the human. This application is a continuation of U.S. application Ser. No. 12/688,408, filed Jan. 15, 2010, which is a continuation of U.S. application Ser. No. 11/015,328, filed Dec. 17, 2004, now U.S. Pat. No. 7,648,993, which is a continuation of U.S. application Ser. No. 10/408,771, filed Apr. 4, 2003, now U.S. Pat. No. 6,916,821, which is a continuation-in-part of U.S. application Ser. No. 10/114,433, filed Apr. 2, 2002, now U.S. Pat. No. 6,890,931 and a continuation-in-part of International Application No. PCT/US02/10211, which designated the United States and was filed Apr. 2, 2002, published in English, both of which claim the benefit of U.S. Application No. 60/280,915, filed Apr. 2, 2001. The teachings of the above applications are incorporated herein by reference in their entirety.In the mammalian central nervous system (CNS), the transmission of nerve impulses is controlled by the ...

USE OF ADRENERGIC BETA-3-RECEPTOR AGONISTS IN ANTI-AGING

A method for treating an aging-related disease is disclosed comprising administering to a subject a pharmaceutical composition comprising an adrenergic beta-3-receptor agonist. 1. A method for treating an aging-related disease , comprising administering to a subject in need of the treatment a pharmaceutical composition comprising an adrenergic beta-3-receptor agonist.23. The method of claim 1 , wherein the adrenergic beta--receptor agonist is selected from the group consisting of CL316243 claim 1 , N-5984 claim 1 , BMS-194449 claim 1 , BMS-196085 claim 1 , CP114271 claim 1 , CP80625 claim 1 , BRL 37344 claim 1 , SR58611A claim 1 , TAK2677 claim 1 , and N25984.3. The method of claim 1 , wherein the adrenergic beta-3-receptor agonist is selected from the group consisting of BRL 37344 claim 1 , SR58611A claim 1 , TAK2677 claim 1 , and N25984.4. The method of claim 1 , wherein the aging-related disease is selected from a group consisting of Alzheimer's disease claim 1 , myocardial fibrosis claim 1 , renal failure claim 1 , therioma claim 1 , and lipofuscin.5. The method of claim 4 , wherein the aging-related disease is lipofuscin.6. The method of claim 4 , wherein the aging-related disease is myocardial fibrosis. The present invention claims priority from Chinese application number 201210020843.9 filed on Jan. 30, 2012, the disclosure of which is incorporated herein by reference.The present invention relates to a new usage of adrenergic beta-3-receptor (ADRB 3) agonists, and in particular to its usage in anti-aging or preparation of anti-aging medicaments.Adrenergic beta-3-receptor, also known as beta-3 adrenergic receptor or beta-3 adrenoreceptor, a beta-adrenergic receptor, is located mainly in adipose tissue and is involved in the regulation of lipolysis and thermogenesis. ADRB 3 activating drugs could theoretically be used as weight-loss agents, but are limited by the side effect of tremors. Some ADRB 3 agonists have demonstrated antistress effects in animal studies ...

USE OF ADRENERGIC BETA-E-RECEPTOR BLOCKERS IN CANCER TREATMENT

A method for treating an cancer disease is disclosed comprising administering to a subject a pharmaceutical composition comprising an adrenergic beta-3-receptor blocker. 1. A method for treating a cancer disease , comprising administering to a subject in need of the treatment a pharmaceutical composition comprising an adrenergic beta-3-receptor blocker.2. The method of claim 1 , wherein the adrenergic beta-3-receptor agonist is SR59230A or its derivatives.3. The method of claim 1 , wherein the cancer disease is selected from a group consisting of breast carcinomas claim 1 , leukemia claim 1 , pulmonary carcinomas claim 1 , hepatocarcinomas claim 1 , colon cancers claim 1 , pancreatic cancers claim 1 , prostate cancers.4. The method of claim 3 , wherein the cancer disease is breast carcinomas.5. The method of claim 3 , wherein the cancer disease is leukemia. The present invention claims priority from Chinese application number 201210020844.3 filed on Jan. 30, 2012, the disclosure of which is incorporated herein by reference.The present invention relates to a new usage of adrenergic beta-3-receptor (ADRB 3) blockers, and in particular to its usage in treatment of cancers or other diseases.Adrenergic beta-3-receptor, also known as beta-3 adrenergic receptor or beta-3 adrenoreceptor, a beta-adrenergic receptor, is located mainly in adipose tissue and is involved in the regulation of lipolysis and thermogenesis. ADRB 3 activating drugs could theoretically be used as weight-loss agents, but are limited by the side effect of tremors. Some ADRB 3 agonists have demonstrated antistress effects in animal studies, suggesting they also have a role in the CNS. Beta-3 receptors are found in gallbladder, urinary bladder, and in brown adipose tissue. Their role in gallbladder physiology is unknown, but they are thought to play a role in lipolysis and thermogenesis in brown fat. Our search did not reveal any reports about potential effect of beta-3 receptors in genesis and ...

HAIR TREATMENT COMPOSITION

An aerated composition comprising, surfactant aggregates, perfume and a hydrophobin. 1. A stable aerated composition comprising a lamellar phase comprising cationic surfactant , perfume , hydrophobia and at least 5% by volume of air at 20° C.2. (canceled)3. An aerated composition according to in which the surfactant aggregates further comprise a fatty alcohol.4. An aerated composition according to in which the ratio of cationic surfactant to fatty alcohol is from 1:1 to 1:4.5. An aerated composition according to in which at least 50% volume of the product comprises air.6. An aerated composition according to comprising bubbles claim 1 , the bubbles having a initial average diameter size from 5 to 100 microns.7. An aerated treatment composition according to in which the average bubble size after 4 months storage at 45° C. is 300 microns or less.8. An aerated composition according to in which the cationic surfactant is insoluble in water at 20° C.9. An aerated composition according to in which the cationic surfactant comprises a derivative of quaternary ammonium or an amine having at least one long chain alkyl group has had on average around about 16 to about 40 carbon atoms.10. An aerated composition according to in which the cationic surfactant is behenyltrimethylammonium or salt thereof.11. An aerated composition according to in which the hydrophobin is a class II hydrophobin HFBII.12. An aerated composition according to that is a hair treatment composition.13. A method of treating hair comprising the step of applying to the hair the aerated composition described in . This invention relates to aerated perfumed compositions.Perfume is a characteristic of many products that is important to consumers. Many perfumed products do not have the strength of perfume required without using a large quantity of perfume in the product.US2009136433 (BASF) discloses what appear to be prophetic compositions comprising cationic surfactant and hydrophobin. They are not aerated. The ...

Biopolymer Produced By Fermenting the Extract of Soybean with Folic Acid and a Composition Containing Thereof

Provided are a folyl extract of fermented soybean (EFS) produced by fermenting a culture including a folic acid and soybean extract by using a microorganism, and a composition including the folyl EFS. The folyl EFS has an anti-histamine effect, an anti-allergic effect, a calcium-absorption-promotion effect, a bone-growth-promotion effect, a cell growth promotion effect, a collagen biosynthesis promotion effect, a wrinkle improvement effect, and an UV-induced cell damage inhibition effect. Accordingly, the folyl EFS can be used in a skin external application or cosmetic composition, a health supplement food composition, a feed composition, and a pharmaceutical composition. 1. A folyl extract of fermented soybeans (EFS) , comprising folic acid polyglutamate as a major component , wherein the folyl EFS is produced by fermenting a culture comprising a folic acid and soybean extract by using a microorganism.2bacilluscorynebacterium. The folyl EFS of claim 1 , wherein the microorganism is selected from a genus microorganism or a genus microorganism.3Bacillus subtilis.. The folyl EFS of claim 1 , wherein the microorganism is4. The folyl EFS of claim 1 , wherein the folyl EFS has an anti-histamine effect.5. The folyl EFS of claim 1 , wherein the folyl EFS has an anti-allergic effect.6. The folyl EFS of claim 1 , wherein the folyl EFS has a calcium-absorption-promotion effect.7. The folyl EFS of claim 1 , wherein the folyl EFS has a bone-growth-promotion effect.8. The folyl EFS of claim 1 , wherein the folyl EFS has a collagen-biosynthesis-promotion effect.9. The folyl EFS of claim 1 , wherein the folyl EFS has a wrinkle-improvement effect.10. The folyl EFS of claim 1 , wherein the folyl EFS has a cell growth-promotion effect.11. A composition for external skin application or cosmetics claim 1 , comprising the folyl EFS of as an active component.12. The composition for external skin application or cosmetics of claim 11 , wherein the composition is used for anti-allergic or ...

Hair treatment agents having low-dose oligopeptides

A hair treatment agent having advantageous properties is provided. The hair treatment agent contains, based on weight of the agent, 0.00001 to ≦0.05% by weight of at least one oligopeptide having at least one amino acid sequence Glu-Glu-Glu (formula (A)), wherein the amino group may be present in a free or protonated manner, and the carboxy groups may be present in a free or deprotonated manner.

TISSUE REPAIR USING ALLOGENEIC DERMAL FIBROBLASTS

The present invention provides a method for the repair of subcutaneous or dermal tissue in a subject, comprising in one aspect the injection of a suspension of allogeneic dermal fibroblasts into the subject. By injecting a suspension of allogeneic cells, the invention provides, for example, long-term augmentation of the subadjacent tissue without the disadvantages that accompany the preparation and/or use of presently available materials such as autologous fibroblasts cells or collagen. 1. A method for the augmentation of subcutaneous or dermal tissue in a subject , which method comprises the steps of:(i) providing a suspension of allogeneic dermal fibroblasts; and(ii) injecting an effective volume of the suspension into tissue subadjacent to the subcutaneous or dermal tissue so that the tissue is augmented.2. The method of claim 1 , wherein the method is cosmetic.3. The method of or claim 1 , further comprising a step of identifying a defect that is susceptible to amelioration by augmentation of the subadjacent subcutaneous or dermal tissue.3. The method of any preceding claim claim 1 , in which the fibroblasts are passaged.4. The method of any preceding claim claim 1 , wherein the defect is a rhytid claim 1 , stretch mark claim 1 , a depressed scar claim 1 , a cutaneous depression of non-traumatic origin or an under-development of the lip.5. The method of any preceding claim claim 1 , wherein the suspension further comprises fibrin in an amount effective to form an injectable.6. The method of claim 5 , wherein the fibrin is at a final concentration of 0.1 to 20 mg/ml.7. The method of or claim 5 , wherein the fibrin is human.8. The method of any preceding claim claim 5 , wherein the suspension further comprises collagen and/or hyaluronic acid.9. The method of any preceding claim claim 5 , which further comprises the steps of:a) obtaining a dermal biopsy from a source allogeneic to the subject;b) passaging the dermal fibroblasts from the dermal biopsy in a culture ...

SKIN COLLAGEN PRODUCTION-PROMOTING AGENT

A skin collagen production-promoting agent includes a milk protein fraction having following properties (a) to (c) as an active ingredient: (a) being derived from milk, (b) containing proteins having a molecular weight determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of 6000 to 150,000 daltons, and (c) containing 12 to 14 wt % of basic amino acids with respect to the constituent amino acid composition, and having a basic amino acid/acidic amino acid ratio of 0.5 to 0.7. 1. A skin collagen production-promoting agent comprising a milk protein fraction having following properties (a) to (c) as an active ingredient:(a) being derived from milk,(b) containing proteins having a molecular weight determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of 6000 to 150,000 daltons, and(c) containing 12 to 14 wt % of basic amino acids with respect to the constituent amino acid composition, and having a basic amino acid/acidic amino acid ratio of 0.5 to 0.7.2. A skin collagen production-promoting agent comprising a degradation product of a milk protein fraction having following properties (a) to (c) as an active ingredient:(a) being derived from milk,(b) containing proteins having a molecular weight determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of 6000 to 150,000 daltons, and(c) containing 12 to 14 wt % of basic amino acids with respect to the constituent amino acid composition, and having a basic amino acid/acidic amino acid ratio of 0.5 to 0.7.3. A food or beverage product for promoting skin collagen production comprising the milk protein fraction according to .4. A cosmetic for promoting skin collagen production comprising the milk protein fraction according to .5. A method for promoting skin collagen production comprising oral administration of a milk protein fraction having following properties (a) to (c) in an amount of 10 μg/day or more per adult claim 1 , or applying a ...

Methods And Compositions For Regenerating And Repairing Damaged Or Aged Tissue Or Organs Using Nonviable Irradiated Or Lyophilized Pluripotent Stem Cells

Compositions and methods are provided herein for regenerating and repairing damaged or aged tissue or organs using nonviable lethally irradiated or lyophilized pluripotent stem cells. In one aspect, the compositions and methods described herein provide anti-aging benefits to the skin by increasing the hydration reducing fine lines, wrinkles, and pores of the skin. Compositions and methods are also provided for promoting wound healing using lyophilized pluripotent stem cell powder. A method is provided for inducing cardiac muscle regeneration in a primate comprising delivering nonviable lethally irradiated pluripotent stem cells to damaged or aged areas of the heart. The compositions and methods include nonviable lethally irradiated or lyophilized pluripotent stem cells. In one aspect, the compositions and methods utilize nonviable pluripotent stem cells in the form of a powder, such as lyophilized stem cells. 1. A wound healing composition comprising lyophilized pluripotent stem cells dispersed in a pharmaceutically acceptable carrier and the lyophilized pluripotent stem cells included in a therapeutically effective amount.2. The wound healing composition according to claim 1 , wherein the pluripotent stem cells are embryonic stem cells.3. The wound healing composition according to claim 1 , wherein the lyophilized pluripotent stem cells do not include conditioned media.4. The wound healing composition according to claim 1 , wherein the therapeutically effective amount comprises about 5×10to about 1×10lyophilized nonviable pluripotent stem cells or cell contents thereof.5. A method for promoting wound healing in a subject claim 1 , the method comprising administering a wound healing composition comprising lyophilized pluripotent stem cells to a wound of a subject in need of wound healing.6. The method according to claim 5 , further comprising preparing the wound healing composition by mixing lyophilized pluripotent stem cells with liquid media.7. The method ...

USES OF AGONISTS OF DELTA OPIOID RECEPTOR IN COSMETIC AND DERMOCOSMETIC FIELD

The present invention relates to the use of a DOR ligand for stimulating pigmentation in a cosmetic composition and to the use of rubiscolin-6 or its derivatives in a cosmetic composition. 1. A cosmetic method for stimulating pigmentation of skin or hair , comprising applying to human skin and/or hair a composition comprising an agonist of δ opioid receptor.2. The method of claim 1 , wherein the agonist of δ opioid receptor is selective for delta opioid receptor claim 1 , and preferably selected from the group consisting of BU-48 claim 1 , SNC-80 claim 1 , C-8813 claim 1 , DPI-287 claim 1 , DPI-221 claim 1 , TAN-67 claim 1 , BW373U86 claim 1 , SIOM claim 1 , RWJ-394 claim 1 ,674 claim 1 , rubiscolin-6 and its derivatives having an activity of agonist of δ opioid receptor claim 1 , deltorphin and its derivatives having an activity of agonist of δ opioid receptor claim 1 , DPDPE claim 1 , DSLET claim 1 , JOM-13 claim 1 , DSTBULET claim 1 , BUBU claim 1 , and BUBUC.3. The method of claim 2 , wherein the agonist of δ opioid receptor is a peptide selected from rubiscolin-6 and its derivatives having an activity of agonist of δ opioid receptor.5. The method of claim 4 , wherein the agonist of δ opioid receptor is a peptide selected from the group consisting of or a peptide having an activity of agonist of δ opioid receptor and comprising a sequence selected in the group consisting of YPLDLF (SEQ ID No 1) claim 4 , YPIDLF (SEQ ID No 7) claim 4 , YPMDLF (SEQ ID No 8) claim 4 , YPLDIF (SEQ ID No 9) claim 4 , YPLDLL (SEQ ID No 10) claim 4 , YPLDLI (SEQ ID No 11) claim 4 , YPLDLM (SEQ ID No 12) claim 4 , YPLDLV (SEQ ID No 13) claim 4 , YPLDLA (SEQ ID No 14) claim 4 , YPIDLV (SEQ ID No 15) claim 4 , YPMDLV (SEQ ID No 16) claim 4 , YPLDIV (SEQ ID No 17) claim 4 , YPIDIV (SEQ ID No 18) claim 4 , YPMDIV (SEQ ID No 19) claim 4 , YPIDLV (SEQ ID No 20) claim 4 , YPIDMV (SEQ ID No 21) claim 4 , YPIDII (SEQ ID No 22) claim 4 , YPMDII (SEQ ID No 23) claim 4 , YPMDL (SEQ ID No 24) claim ...

SKIN WETTING COMPOSITIONS AND METHODS

Disclosed are skin wetting and penetrating compositions and methods, where the compositions comprise the following, or combinations thereof: a surfactant, yeast exo-proteins, a stabilizer, and optionally an oil, humectant, or dermatological active agent. 1. A method of enhancing wetting , spreading , or uptake of a composition on a surface , the method comprising contacting the surface with the composition , wherein the composition comprises a non-enzymatic , yeast fermentation derived mixture , a surfactant , and a stabilizer.2. The method of claim 1 , wherein the surface is a biological surface.3. The method of claim 1 , wherein the surface is skin or hair.4. The method of claim 1 , wherein the yeast fermentation derived mixture comprises at least one yeast exo-protein.5Saccharomyces cerevisiae.. The method of claim 1 , wherein the yeast is6. The method of claim 1 , wherein the surfactant comprises two or more surfactants.7. The method of claim 1 , wherein the fermentation process is aerobic.8. The method of claim 1 , wherein the surfactant comprises an anionic claim 1 , a non-ionic claim 1 , or an amphoteric surfactant claim 1 , or a combination thereof.9calendula. The method of claim 1 , wherein the composition further comprises one or more ingredients selected from the group consisting of aloe vera extract claim 1 , extract claim 1 , glycerol claim 1 , hyaluronic acid claim 1 , argeriline claim 1 , carbomer claim 1 , plant oil claim 1 , beeswax claim 1 , a vitamin claim 1 , an antioxidant claim 1 , a fragrance claim 1 , inosine claim 1 , and beta glucan.10. The method of claim 1 , wherein the yeast fermentation derived mixture comprises heat shock proteins.11. A composition for treatment of skin and hair with enhanced wetting claim 1 , spreading and uptake claim 1 , the composition comprising (1) a non-enzymatic claim 1 , yeast fermentation derived mixture claim 1 , (2) a surfactant claim 1 , and (3) a stabilizer.12. The composition of claim 11 , wherein the ...

COMPOSITIONS FOR REDUCING OXIDATIVE STRESS AND USES THEREOF

The present invention relates to the use of one or more tripeptides selected from the group consisting of Lys-Pro-Val, Lys-Pro-Thrand pGlu-His-Profor the reduction of oxidative stress. The above tripeptides are particularly useful for the treatment of a disease or damage caused by oxidative stress; such as vitiligo, scleroderma, necrosis, or erythema; furthermore, a disease or damage of the hair, like premature hair loss or premature formation of grey hair. Furthermore the invention relates the cosmetic use of the above tripeptides, in particular against skin aging. Further the invention relates cosmetic compositions containing at least one of said tripeptides. 2. The method of claim 1 , wherein amino acids of compound (a) or (b) have either (L) or (D) configurations.3. The method of claim 1 , wherein the compound is selected from the group consisting of(a) (L)Lys-(D)Pro-(L)Thr and(b) (L)pGlu-(L)His-(L)Pro.4. The method of claim 1 , wherein the compound is chemically modified by alkylation claim 1 , arylation claim 1 , etherification claim 1 , esterification claim 1 , or combinations thereof.5. The method of claim 1 , wherein the compound is acetylated at the N-terminus claim 1 , amidated at the C-terminus claim 1 , esterified at the C-terminus claim 1 , or combinations thereof.6. The method of claim 1 , wherein the compound is (a) Lys-Pro-Thr.7. The method of claim 6 , wherein the compound is (a) (L)Lys-(D)Pro-(L)Thr.8. The method of claim 1 , wherein following the step of applying the skin of the subject is exposed to UV-A-containing sunlight.9. The method of claim 1 , wherein the composition comprises a cosmetically acceptable carrier or excipient.10. The method of wherein the carrier or excipient is selected from the group consisting of moisturizing substances claim 9 , olfactory agents claim 9 , emulsifiers claim 9 , and preservatives.11. The method of wherein the composition comprises one or more UV-filtering substance(s) that can absorb UV radiation in the UV ...

POWDEROUS FORMULATIONS OF FAT-SOLUBLE ACTIVE INGREDIENTS

Stable powderous formulations containing a fat-soluble active ingredient, e.g., vitamin A, in a matrix of a native lupin protein composition are disclosed. 1. Stable powderous formulations comprising a fat-soluble active ingredient in a matrix of a native lupin protein composition wherein the protein is cross-linked.2. Formulations according to claim 1 , wherein the lupin protein composition is a lupin protein isolate having a protein content of more than 90 wt.-%.3. Formulations according to claim 1 , wherein the lupin protein composition is a lupin protein concentrate having a protein content of about 60-90 wt.-%.4. Formulations according to claim 1 , wherein the lupin protein composition is a lupin protein flour having a protein content of about 40-60 wt.-%.5. Formulations according to claim 1 , wherein the native lupin protein composition is selected from the group consisting of a lupin protein isolate having a protein content of more than 90 wt.-% claim 1 , a lupin protein concentrate having a protein content of about 60-90 wt.-% claim 1 , a lupin protein flour having a protein content of about 40-60 wt.-% claim 1 , and mixtures of any of the foregoing.6. Formulations according to claim 1 , wherein the fat-soluble active ingredient is vitamin A claim 1 , D claim 1 , E or K claim 1 , or a carotenoid claim 1 , or a polyunsaturated fatty acid claim 1 , or esters thereof claim 1 , or mixtures thereof.7. Formulations according to claim 1 , wherein the fat-soluble active ingredient is a plant or animal oil or fat claim 1 , particularly sunflower oil claim 1 , palm oil or corn oil.8. Formulations according to claim 1 , comprising additionally a reducing sugar claim 1 , particularly glucose claim 1 , fructose claim 1 , or xylose.9. Formulations according to claim 1 , wherein the protein is cross-linked.10. Food claim 1 , beverages claim 1 , animal feeds claim 1 , cosmetics or drugs comprising a formulation according to .11. A process for the preparation of a ...

DERMATOPONTIN-ACTIVATING PEPTIDES AND COSMETIC COMPOSITIONS INCLUDING SAME

This invention relates to peptides activating dermatopontin in the skin. 2. The peptide of whereinAA represents any amino acid with the exception of arginine, cysteine, leucine, glycine and glutamic acid, and n and p=0 or 1 with n different p; and{'sub': 2', '1', '30', '2', '1', '4, 'Rrepresents the carboxyl function of the C-terminal amino acid having either a hydroxyl group free or substituted by a group chosen from a Cto Calkyl chain or an —NH, —NHY or —NYY′ group with Y and Y′ representing a Cto Calkyl chain.'}4. The peptide of claim 1 , wherein said peptide of general formula (I) is solubilized in one or more physiologically suitable solvents selected from the group consisting of water claim 1 , glycerol claim 1 , ethanol claim 1 , propanediol claim 1 , butylene glycol claim 1 , dipropylene glycol claim 1 , the ethoxylated or propoxylated diglycols claim 1 , the cyclic polyols claim 1 , and mixtures of these solvents.5. (canceled)6. (canceled)8. The composition of claim 7 , wherein said peptide is present in a concentration of between 10M and 10M with respect to the total weight of the composition.9. The composition of wherein the composition is suitable for topical administration.10. The composition of further comprising at least one other active agent.11. The composition of claim 10 , wherein the other active agent is selected from the group consisting of regenerating claim 10 , anti-aging claim 10 , anti-wrinkle claim 10 , thickening claim 10 , anti-free radical claim 10 , anti-glycation claim 10 , hydrating claim 10 , antibacterial claim 10 , antifungal claim 10 , keratolytic claim 10 , muscle relaxing claim 10 , exfoliating claim 10 , and toning agents claim 10 , agents stimulating the synthesis of dermal macromolecules or energy metabolism claim 10 , agents modulating cutaneous differentiation claim 10 , pigmentation or depigmentation claim 10 , agents stimulating nail or hair growth claim 10 , agents stimulating microcirculation claim 10 , sunscreens or ...

NOVEL FORMULATIONS OF FACTOR VIIa INHIBITORS AND UTILITY

A method for treating a subject, such as a human patient, having a vascular disorder. The treatment method administers a therapeutic effective amount of a nanoparticle or a chemical structure to the subject to treat the disorders. The nanoparticle includes a poly L-arginine polymer and a Factor VIIa inhibitor conjugated to, or encapsulated in, the poly L-arginine polymer. The chemical structure includes a Factor VIIa inhibitor that includes at least one nitric oxide (NO) donor. The disorder may be sickle cell disease; stimulated or pathological angiogenesis associated disorders, cancer, ocular angiogenesis-mediated disorders such as diabetic retinopathy and macular degeneration, coagulation and/or platelet activation-associated disorders, pulmonary hypertension, or combinations thereof. 2. The method of claim 1 , wherein the Factor VIIa inhibitor is encapsulated in the poly L-arginine polymer and is not covalently bonded to the poly L-arginine polymer.3. The method of claim 1 , wherein the Factor VIIa inhibitor is conjugated to the poly L-arginine polymer by being covalently bonded to the poly L-arginine polymer.4. The method of claim 1 , wherein the poly L-arginine polymer is cross-linked with at least one substance selected from the group consisting of chitosan claim 1 , poly (lactic-co-glycolic) acid (PLGA) claim 1 , fatty acids claim 1 , bile acids claim 1 , amino acids claim 1 , hyaluronic acid claim 1 , and combinations thereof.5. The method of claim 1 , wherein the poly L-arginine polymer is cross-linked to chitosan.6. The method of claim 1 , wherein the Factor VIIa inhibitor does not include any nitric oxide (NO) donor.7. The method of claim 1 , wherein the Factor VIIa inhibitor includes at least one nitric oxide (NO) donor.8. The method of claim 1 , wherein said administrating comprises administrating the therapeutic effective amount in the range of 0.1-10 mg per kilogram of body weight of the subject.9. The method of claim 1 , wherein the vascular disorder ...

GUANIDINO ACETIC ACID USED AS AN ANIMAL FOOD ADDITIVE

The present invention relates to the use of guanidinoacetic acid and/or salts thereof as feed additive, in predominantly vegetarian diets, in particular use being made of salts with hydrochloric acid, hydrobromic acid and phosphoric acid. The use proceeds especially in individual doses from 0.01 to 100 g/kg of feed in the form of powders, granules, pastilles or capsules, the feed additive also being able to be used in combination with other physiologically active materials of value. The claimed use which is suitable especially for breeding and growing livestock, has recourse to a compound which is in particular stable in aqueous solution, can be converted to creatine under physiological conditions, and, in contrast to other guanidine derivatives, is completely available to physiological sectors of use. 19-. (canceled)10. A method comprising improving feed uptake , increasing growth performance , increasing muscle meat gain , increasing meat quality or increasing reproduction performance in an animal by administering a sufficient amount of feed additive as a part of a diet for the animal , wherein the feed additive comprises guanidinoacetic , acid or a salt thereof , wherein the feed additive is administered to animals in an aquaculture.11. A method comprising administering a therapeutic composition comprising guanidinoacetic acid or a salt thereof for breeding and growing an animal to strengthen the immune system and to improve the reproduction performance of the animal , wherein the therapeutic composition is administered to animals in an aquaculture.12. A method comprising administering a sufficient amount of a composition comprising guanidinoacetic acid or a salt thereof to breeding and growing animals to prevent or mitigate a consequence of heat stress , wherein the composition is administered to animals in an aquaculture.13. The method of claim 10 , wherein the animal is a salmon or a shrimp.14. The method of claim 11 , wherein the animal is a salmon or a ...

Methods for treating dental diseases, disorders and injuries

Methods for preventing, reversing, ameliorating or treating dental diseases, disorders or injuries are provided. In particular, methods for preventing, reversing, ameliorating or treating dental diseases of the gingival (gums) and bone are provided. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and/or other agents. 1. A method for preventing , reversing , ameliorating or treating a dental disease , disorder or injury in a patient in need thereof , the method comprising the step of administering to the patient a therapeutically effective amount of one or more compositions selected from the group consisting of extraembryonic cytokine-secreting (ECS) cells , conditioned medium derived therefrom , cell lysate derived therefrom , cell products derived therefrom , and physiologic cytokine solution (PCS).2. The method of wherein the dental disease is selected from the group consisting of gingivitis and periodontitis.3. The method of wherein the ECS cells are Amnion-derived Multipotent Progenitor (AMP) cells.4. The method of wherein the conditioned medium is Amnion-derived Cellular Cytokine Solution (ACCS) or pooled ACCS.5. The method of wherein the PCS is formulated for sustained-release.6. The method of wherein the ACCS or pooled ACCS is formulated for sustained-release.7. The method of wherein the ECS cells claim 1 , conditioned medium derived therefrom claim 1 , cell lysate derived therefrom claim 1 , or cell products derived therefrom are administered in combination with other agents or treatment modalities.8. The method of wherein the other ...

ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACH

The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum. 1. A method of treating at least one of shock and potential multi-organ failure due to shock in a mammal , comprising:diagnosing the mammal with a shock condition;administering a therapeutically effective amount of a protease inhibitor in a liquid formulation at a dosage of at least 20 mg/kg;wherein the liquid formulation is administered to a location in a gastrointestinal tract, wherein the location is upstream of another location at which pancreatic proteases are released into the gastrointestinal tract; andwherein the liquid formulation is administered under a protocol effective to treat the shock and potential multi-organ failure from the location,2. The method of wherein the location is the stomach and wherein the step of administering is performed via administration via a nasogastric tube or a catheter.3. The method of wherein the location is the stomach and wherein the step of administering is performed via administration via an oral solution or direct injection.4. The method of wherein the protease inhibitor is tranexamic acid and wherein the liquid formulation comprises an isotonic PEG solution.5. The method of wherein the step of administering is performed claim 1 , optionally using divided daily doses claim 1 , over at least two days.6. The method of wherein the dosage is at least 50 mg/kg.7. The method of wherein the dosage is at least 100 mg/kg.8. The method of wherein the liquid formulation ...

COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING MELANOMA

The present disclosure relates to the field of oncology, more particularly to the field of melanoma. Provided are methods of treating melanoma, particularly advanced cutaneous melanoma, with a combination of pharmaceutical agents comprising MDM4-specific antagonists (such as an inhibitor of the MDM4-p53 interaction or a molecule that decreases MDM4 protein stability) or MDM4-MDM2 dual inhibitors (i.e., molecules that disrupt the interactions between p53 and MDM2 and p53 and MDM4) and one or more chemotherapeutic agents such as for example alkylating agents (i.e., Dacarbazine (DITC) or melphalan), alkylating-like agents (i.e., cisplatin or carboplatin) or mitotic inhibitors (taxanes docetaxel or paclitaxel) and PI3K-AKT, B-RAF and MEK inhibitors. Further provided are pharmaceutical formulations of MDM4-specific antagonists (be it an inhibitor of the MDM4-p53 interaction or a molecule that decreases MDM4 protein stability) or MDM4-MDM2 dual inhibitors (i.e., molecules that disrupt the interactions between p53 and MDM2 and p53 and MDM4) and a pharmaceutical formulation of one or more chemotherapeutic agents such as for example alkylating agents (i.e., Dacarbazine (DITC) or melphalan), alkylating-like agents (i.e., cisplatin or carboplatin) or mitotic inhibitors (taxanes docetaxel or paclitaxel) and B-RAF and MEK inhibitors. 2. The method for preventing or treating of melanoma according to claim 1 , wherein said one or more chemotherapeutic agents are selected from camptothecin derivatives claim 1 , paclitaxel claim 1 , docetaxel claim 1 , melphalan claim 1 , dacarbazine claim 1 , temozolomide claim 1 , epothilone B claim 1 , 5-FU claim 1 , gemcitabine claim 1 , oxaliplatin claim 1 , cisplatinum claim 1 , carboplatin claim 1 , doxorubicin claim 1 , imatinib claim 1 , erlotinib claim 1 , bevacizumab claim 1 , cetuximab and a Raf kinase inhibitor.3. The method according to claim 1 , wherein said Raf kinase inhibitor is a B-RAF kinase inhibitor.4. The method according to ...

COSMETIC

A composition is provided that includes a fish spawn protein isolate. A natural product extract is also present that includes unsaturated fatty acids and sterols. An emulsifier is provided to form a mixture of the isolate and the extract. A composition is also provided that includes an egg hatching protein isolate and at least one biocide protective of isolate activity. An emulsifier forms a mixture with the isolate that has an aqueous phase buffered to a pH of between 5.6 and 7.9. A process of producing such a cosmetic has an emulsion or an aqueous phase that is buffered to a pH of between 5.5 and 7.9 prior to the addition of isolate to the emulsion. A process of improving skin appearance is provided that includes the application of the cosmetic to the skin at least three times per week to achieve the improvement of the skin appearance. 1. A cosmetic comprising:a fish spawn protein isolate having an anti-inflammatory effect on mammalian skin;a natural product extract comprising unsaturated fatty acids and sterols, said natural product extract having anti-oxidant activity on the mammalian skin; andan emulsifier or a solubilizer, or a combination thereof forming a mixture of said isolate and said extract.2. The cosmetic of wherein said fish spawn protein isolate is present from 0.00001 to 10 total weight percent.3. The cosmetic of wherein said natural product extract is a plant extract.4. The cosmetic of wherein said unsaturated fatty acids include at least one of an omega-3 claim 1 , omega-6 claim 1 , or omega-9 fatty acid.5. The cosmetic of wherein said sterols include at least one of cholesterol claim 1 , campesterol claim 1 , stigmasterol claim 1 , or sitosterol.6. The cosmetic of further comprising an ascorbic acid or ascorbate salt.7. The cosmetic of wherein said fish spawn protein isolate claim 1 , said natural product extract claim 1 , and said emulsifier are all substantially free of silicone claim 1 , petrolatum claim 1 , synthetic paraben claim 1 , and ...

HEAT-EXTRACTED OMENTUM EXTRACTS, COMPOSITIONS, METHODS OF PREPARING AND USES THEREOF

Disclosed herein are compositions including an extract of mammalian omentum wherein the extract is a liquid portion of the mammalian omentum, such as an oil, extracted when the omentum is heated to a temperature of between 210 and 240 degrees Fahrenheit. Also disclosed are methods of making a composition including an extract of mammalian omentum wherein the method includes heating mammalian omentum to a temperature of between 212 degrees Fahrenheit and 225 degrees Fahrenheit, such as 215 degrees Fahrenheit and 220 degrees Fahrenheit. Methods of use of the disclosed extracts and compositions are provided including methods of inducing or enhancing angiogenesis, methods of improving skin quality and methods of promoting hair growth and/or inhibiting hair loss. 1. A composition comprising: an extract of mammalian omentum wherein the extract is a liquid portion of the mammalian omentum extracted when the omentum is heated to a temperature of between 210 degrees Fahrenheit and 240 degrees Fahrenheit.2. The composition of claim 1 , wherein the extract is a liquid portion of the mammalian omentum extracted when the omentum is heated to a temperature of between 212 degrees Fahrenheit and 225 degrees Fahrenheit.3. The composition of claim 2 , wherein the extract is a liquid portion of the mammalian omentum extracted when the omentum is heated to a temperature of between 215 degrees Fahrenheit and 220 degrees Fahrenheit.4. The composition of claim 1 , wherein an organic solvent is not used to extract the extract.5. The composition of claim 3 , wherein the mammalian omentum is soaked in a 2.5% saline solution for at least 24 hours prior to extraction of the liquid portion.6. The composition of claim 1 , wherein the omentum is porcine omentum.7. A method of making a composition comprising an extract of mammalian omentum claim 1 , comprising:heating the mammalian omentum to a temperature of between 210 degrees Fahrenheit and 240 degrees Fahrenheit and extracting the liquid ...

MINIMIZING INTESTINAL DYSFUNCTION

Techniques are discloded for treating or reducing sumptoms associated with abdominal dysfunction or ileus following surgery or other abdominal episode by treating the area with a combination of one or more protease, antibacterial compound, and inflammatory lipid mediator. 1. A method for treating ilieus , the method comprising:administering to an individual a therapeutic dose of one or more of the following:a protease;an antibacterial compound; andan inflammatory lipid mediator.2. The method of claim 1 , wherein the protease inhibitor is effective for inhibiting the function of one or more of the following: serine protease claim 1 , plasma protease claim 1 , MMP claim 1 , amylase and lipase.3. The method of claim 2 , wherein the protease inhibitor includes cyclokapron.4. The method of claim 3 , wherein the dose of cyclokapron is 10 to 50 mg/100 ml.5. The method of claim 1 , wherein the antibacterial compound is effective against gram-positive and gram-negative bacteria.6. The method of claim 5 , wherein the antibacterial compound includes one or more of ciprofloxacin claim 5 , metronidazole claim 5 , imipenem and cilastatin claim 5 , ticarcillin and clavulanate claim 5 , cefuroxime claim 5 , doxycycline.7. The method of claim 1 , wherein the inflammatory lipid mediator includes albumin.8. The method of claim 7 , wherein the dose of inflammatory lipid mediator is 10 to 50 mg/100 ml.9. The method of claim 1 , wherein the administering step is prophylactically into the abdominal cavity.10. A method for treating abdominal dysfunction claim 1 , the method comprising:administering to an individual a therapeutic dose of one or more of the following:a protease;an antibacterial compound; andan inflammatory lipid mediator.11. The method of claim 10 , wherein the protease inhibitor is effective for inhibiting the function of one or more of the following: serine protease claim 10 , plasma protease claim 10 , MMP claim 10 , amylase and lipase.12. The method of claim 11 , wherein ...

PROCESS FOR PRODUCING A CONDITIONING CLEANING AGENT

A process for producing a conditioning cleaning agent includes the steps of: a) providing a microemulsion, containing (i) at least one alkyl(oligo)glycoside, (ii) at least one ester of glycerin with at least one C-Cfatty acid, (iii) at least one oil which is different from (ii), and (iv) water, and b) mixing the microemulsion with a cosmetic carrier that contains at least one protein hydrolysate. 1. A method for producing a conditioning cleaning agent , comprising the following steps: (i) at least one alkyl(oligo)glycoside,', {'sub': 10', '24, '(ii) at least one ester of glycerol with at least one C-Cfatty acid,'}, '(iii) at least one oil—which is different from (ii), and', '(iv) water, and, 'a) providing a microemulsion comprising'}b) mixing the microemulsion with a cosmetic carrier, which contains at least one protein hydrolyzate.2. The method according to claim 1 , wherein the conditioning cleaning agent comprises—based on its total weight—0.01 to 10 wt. % of at least one protein hydrolyzate of plant claim 1 , animal or marine origin.3. The method according to claim 1 , wherein the protein hydrolyzate is selected from elastin claim 1 , collagen claim 1 , keratin and/or silk protein hydrolyzates having an average molecular weight (weight average) of 100 to 2500 daltons.6. The method according to claim 1 , wherein the conditioning cleaning agent comprises—based on its total weight—0.01 to 50 wt. % of the microemulsion a).7. The method according to claim 1 , wherein the cosmetic cleaning agent comprises—based on its total weight—0.1 to 40 wt. % of at least one anionic surfactant and 0 to 20 wt. % of at least one amphoteric/zwitterionic surfactant and/or 0 to 20 wt. % of at least one nonionic surfactant claim 1 , the quantitative data not comprising the nonionic surfactants in the microemulsion a).8. The method according to claim 1 , wherein the conditioning cleaning agent comprises—based on its total weight—0.01 to 10 wt. % of a cationic polymer.9. A conditioning ...

Continuous Fiber Layer Comprising an Active Substance on the Basis of Bio-polymers, the Use Thereof, and Method for the Production Thereof

The invention relates to continuous fiber layers comprising an active substance on the basis of bio-polymers, comprising a fibrous, bio-polymer active substance carrier, and at least one active substance associated with the carrier and releasable from the continuous fiber layer; to formulations comprising an active substance, the formulations comprising such continuous fiber layers; to the use of continuous fiber layers comprising an active substance for the production of formulations comprising an active substance; and to a method for the production of continuous fiber layers comprising an active substance. The invention further relates to corresponding continuous fiber layers comprising an active substance and to the use thereof for the production of wound treatment and hygiene products, and to the respectively produced wound treatment and hygiene products. 1. An active ingredient-containing fibrous sheetlike structure comprising a fibrous , polymeric , soluble and/or degradable active ingredient carrier and at least one active ingredient which is associated with the carrier and can be released by the fibrous sheetlike structure ,wherein the carrier comprises, as a polymer component, at least one biopolymer which may additionally have been chemically and/or enzymatically modified, andwherein the biopolymer is selected from a C16 spider silk protein comprising the amino acid sequence of SEQ ID NO: 2, an S16 protein comprising the amino acid sequence of SEQ ID NO: 6; or a spinnable protein derived from these proteins having a sequence identity of at least about 60%.2. The fibrous sheetlike structure of claim 1 , wherein the fibrous sheetlike structure is obtained by means of a spinning process.3. The fibrous sheetlike structure of claim 2 , wherein the fibrous sheetlike structure is obtained by means of electrospinning of an electrospinnable solution which comprises at least one biopolymer and at least one active ingredient.4. The fibrous sheetlike structure of ...

NOVEL ANTI-AGING PEPTIDES AND COSMETIC AND/OR PHARMACEUTICAL COMPOSITION CONTAINING SAME

Methods of restoring the circadian rhythm and resynchronizing the biological clock of cells are described. The methods include topically applying a topical composition comprising a cosmetically acceptable medium and an effective quantity of a peptide compound of general formula (I), R-(AA)-X-Ser-Thr-Pro-X-(AA)-R, to skin or skin appendages to be treated. 1. A method of restoring the circadian rhythm and resynchronizing the biological clock of cells , the method comprising: {'br': None, 'sub': 1', 'n', '1', '2', 'p', '2, 'R-(AA)-X-Ser-Thr-Pro-X-(AA)-R'}, 'topically applying, to skin or skin appendages to be treated, a topical composition comprising a cosmetically acceptable medium and an effective quantity of a peptide compound of general formula (I) belowwherein{'sub': '1', 'Xis a threonine, a serine or is equal to zero,'}{'sub': '2', 'Xis an isoleucine, a leucine, a valine, an alanine, a glycine or is equal to zero,'}AA is any amino acid except for proline, and n and p are integers between 0 and 4,{'sub': '1', 'Ris the primary amine function of the N-terminal amino acid, either free or substituted by a protective group which can be selected from an acetyl group, a benzoyl group, a tosyl group or a benzyloxycarbonyl group,'}{'sub': 2', '1', '20', '2', '1', '4, 'Ris the hydroxyl group of the carboxyl function of the C-terminal amino acid, substituted by a protective group which can be selected from a Cto Calkyl chain or a NH, NHY or NYY group where Y is a Cto Calkyl chain,'}said sequence of general formula (I) being formed of 3 to 13 amino acid residues,wherein the peptide compound restores the circadian rhythm and resynchronizes the biological clock of skin cells.2. The method of claim 1 , wherein topically applying includes applying the composition before going to sleep.3. The method of claim 1 , wherein the composition activates cellular renewal claim 1 , stimulates cellular metabolism claim 1 , reduces the dysfunctions caused by jet lag or nightshift work claim 1 ...

Topical Palmitoyl Glutathione Formulations

A topical composition for application to aging skin, including an effective amount of S-acyl glutathione derivative of formula (I) 2. The topical composition of claim 1 , wherein the S-palmitoyl glutathione is present from about 0.01% to about 20% by weight.3. The topical composition of claim 2 , wherein the S-palmitoyl glutathione is present from about 0.1% to about 5% by weight.4. The topical composition of claim 3 , wherein the S-palmitoyl glutathione is present from about 1.0% to about 3.0% by weight.5. The topical composition of claim 1 , wherein the composition comprises an oil in water emulsion.6. A topical composition for application to aging skin comprising:about 0.01% to about 20% by weight of S-palmitoyl glutathione;a mixture of magnesium aspartate, zinc gluconate and copper gluconate;a dermatologically acceptable water-based carrier having about 0.01% to about 15% by weight of at least one emulsifier, and water.7. The topical composition of claim 6 , wherein the S-palmitoyl glutathione is present from about 0.1% to about 5% by weight.8. The topical composition of claim 7 , wherein the S-palmitoyl glutathione is present from about 1.0% to about 3.0% by weight.10. The composition of claim 9 , wherein the S-acyl glutathione derivative is present from about 0.01% to about 20% by weight.11. The composition of claim 10 , wherein the S-acyl glutathione derivative is present from about 0.1% to about 5% by weight.12. The composition of claim 11 , wherein the S-acyl glutathione derivative is present from about 1.0% to about 3.0% by weight.13. The composition of claim 9 , wherein the composition comprises an oil in water emulsion.14. The composition of claim 1 , wherein the composition comprises a cream. The present invention relates to topical compositions comprising S-acyl glutathiones to prevent and to treat skin aging. More specifically, the present invention relates to formulations comprising S-palmitoyl derivatives of glutathione useful for improving the ...

PEPTIDE FOR USE IN THE TREATMENT OF SKIN CONDITIONS

The present invention relates to a peptide of the following formula (I) X(X)-X-Xor a salt or solvate thereof, wherein is an amino acid comprising two or more NH-functionalities, and X, X, and Xare, independently from one another, an amino acid residue, and wherein the salt or solvate is preferably a physiologically acceptable salt or solvate. 1. A peptide of the following formula (I):{'br': None, 'sub': 1', '2', '3', '4, 'X(X)-X-X\u2003\u2003(I)'}or a salt or solvate thereof, wherein{'sub': '1', 'Xis an amino acid comprising two or more NH-functionalities, and'}{'sub': 2', '3', '4, 'X, X, and Xare, independently from one another, an amino acid residue, and'}wherein the salt or solvate is preferably a physiologically acceptable salt or solvate.2. The peptide of claim 1 , wherein{'sub': '1', 'Xis an amino acid residue selected from the group consisting of Arg, His, Lys, 3,6-Diaminohexanoic acid (Bly), N5-Aminocarbonylornithine (Cit), 2,4-Diaminobutanoic acid (Dab), 2,3-Diaminopropanoic acid (Dpr), 2,7-Diaminosuberic acid (Dsu), Homoarginine (Har), Homohistidine (Hhs), 5-Hydroxylysine (Hyl), Ornithine (Orn), Pyrrolysine (Pyl), and derivatives thereof,'}and/or, preferably and{'sub': 2', '4, 'wherein Xand Xare, independently from one another, an amino acid residue selected from the group consisting of Asn, Asp, Gln, Glu, 2-Aminoadipic acid (Aad), alpha-Asparagine (Aan), 2-Aminocapric acid (Aca), alpha-Glutamine (Agn), 2-Aminopimelic acid (Apm), gamma-Amino-β-hydroxybenzenepentanoic acid (App), 2-Aminosuberic acid (Asu), beta-Aspartic acid (Bas), N5-Aminocarbonylornithine (Cit), Diaminopimelic acid (Dpm), 2,7-Diaminosuberic acid (Dsu), gamma-Glutamic acid (Ggu), gamma-Carboxyglutamic acid (Gla), and derivatives thereof,'}and/or, preferably and{'sub': '3', 'wherein Xis an amino acid residue selected from the group consisting of Ala, Cys, Gly, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val, Scy, 2-Aminobutanoic acid (Abu), 2-Aminoheptanoic acid (Ahe), alpha- ...

COSMETIC

A composition is provided that includes a fish spawn protein isolate. A natural product extract is also present that includes unsaturated fatty acids and sterols. An emulsifier is provided to form a mixture of the isolate and the extract. A composition is also provided that includes an egg hatching protein isolate and at least one biocide protective of isolate activity. An emulsifier forms a mixture with the isolate that has an aqueous phase buffered to a pH of between 5.6 and 7.9. A process of producing such a cosmetic has an emulsion or an aqueous phase that is buffered to a pH of between 5.5 and 7.9 prior to the addition of isolate to the emulsion. A process of improving skin appearance is provided that includes the application of the cosmetic to the skin at least three times per week to achieve the improvement of the skin appearance. 1. A cosmetic comprising:a fish spawn protein isolate present from 0.00001 to 10 total weight percent;a natural product extract present from 0.001 to 10 total weight percent and comprising unsaturated fatty acids and sterols, said natural product extract having anti-oxidant activity on the mammalian skin; andan emulsifier or a solubilizer, or a combination thereof forming a mixture of said isolate and said extract.2. (canceled)3. The cosmetic of wherein said natural product extract is a plant extract.4. The cosmetic of wherein said unsaturated fatty acids include at least one of an omega-3 claim 1 , omega-6 claim 1 , or omega-9 fatty acid.5. The cosmetic of wherein said sterols include at least one of cholesterol claim 1 , campesterol claim 1 , stigmasterol claim 1 , or sitosterol.6. The cosmetic of further comprising an ascorbic acid or ascorbate salt.7. The cosmetic of wherein said fish spawn protein isolate claim 1 , said natural product extract claim 1 , and said emulsifier are all substantially free of silicone claim 1 , petrolatum claim 1 , synthetic paraben claim 1 , and mineral oil.8. The cosmetic of wherein said fish spawn ...

Modified Release Tranexamic Acid Formulation

A modified release dosage form for the oral administration of tranexamic acid. 124-. (canceled)25. A modified release dosage form comprising: (i) tranexamic acid;', '(ii) a release controlling material;', '(iii) a binder;', '(iv) a filler;', '(v) a glidant;', '(vi) a disintegrant; and', '(vii) optionally, one or more lubricants; and, '(A) a compressed matrix core which comprises (i) a coating agent which is insoluble in water but soluble in aqueous media with a pH below 4;', '(ii) a film former;', '(iii) a plasticizer; and', '(iv) an anti-sticking agent, '(B) a functional coating on said compressed matrix core which comprises'}wherein the dosage form, exhibits the following dissolution profile when tested in a USP Type 2 (paddle) apparatus at 50 RPM in 900 ml of 0.1 N HCl at 37° C.: after 15 minutes 10-50% of the tranexamic acid is released; after 30 minutes 40-95% of the tranexamic acid is released; after 45 minutes 50-99% of the tranexamic acid is released; and after 60 minutes, not less than 70% of the tranexamic acid is released.26. The modified release dosage form as defined in where the filler is selected from the group consisting of sugars claim 25 , lactose monohydrate claim 25 , calcium phosphate claim 25 , dextrin claim 25 , dextrose claim 25 , maltitol claim 25 , maltose claim 25 , starch claim 25 , sucrose claim 25 , or microcrystalline cellulose.27. The modified release dosage form as defined in wherein said filler comprises lactose monohydrate and microcrystalline cellulose.28. The modified release dosage form as defined in wherein the binder in the core is water soluble.29. The modified release dosage form as defined in where the binder in the core is selected from the group consisting of methyl cellulose claim 25 , hydroxymethyl cellulose claim 25 , polyvinyl pyrrolidone claim 25 , hydroxyethyl cellulose claim 25 , hydroxypropyl cellulose claim 25 , hydroxypropyl methylcellulose claim 25 , polyethylene oxides claim 25 , gums claim 25 , acrylate ...

PROTEOGLYCAN-CONTAINING MATERIAL

The present invention was made in view of an object to produce a novel proteoglycan-containing material, and find a novel use and/or a superior effect of the proteoglycan-containing material. The present invention provides a proteoglycan-containing material obtained from fish cartilage, wherein the proteoglycan-containing material comprises an acidic saccharide component having a molecular weight of not less than 2000 kDa. The proteoglycan-containing material provides advantageous effects for skin-moisturizing and skin anti-aging, including a superior skin fibroblast proliferation effect, an effect of enhancing and improving the skin barrier function, an effect of enhancing and improving the skin's capability to produce collagen, a dermis-thickening inhibition effect, and the like. 18-. (canceled)9. A method for suppressing skin-aging , comprising orally administering a composition comprising a proteoglycan-containing material comprising proteoglycan and acidic saccharide as acidic saccharide components obtained from fish cartilage by extraction , the proteoglycan-containing material comprising , on a dry mass basis , 15 to 70 mass % of acidic saccharide components , 55 mass % or more of the acidic saccharide components having a molecular weight of not less than 2000 kDa.10. The method according to claim 9 , wherein the proteoglycan-containing material comprises an acidic saccharide component having a molecular weight of not less than 5000 kDa.11. The method according to claim 9 , wherein 20 mass % or more of the acidic saccharide components have a molecular weight of not less than 10000 kDa.12. The method according to claim 9 , wherein 20 mass % or more of the acidic saccharide components is proteoglycan.13. The method according to claim 9 , wherein the proteoglycan-containing material comprises 60 mass % or more of acidic saccharide components having a molecular weight of not less than 2000 kDa.14. The method according to claim 9 , wherein the composition ...

DELIVERY OF FUNCTIONAL INGREDIENTS

A primary composition comprising all essential nutrients of a fruit or a plant material, which has an increased stability, bio-availability and miscibility, and a process of forming same are provided. An oral composition containing the primary composition in a foodstuff, food supplement, cosmetic preparation or a pharmaceutical preparation is also provided. 1. A miscible primary composition comprising at least essential lipophilic and hydrophilic bioactive components of a material selected from the group consisting of whole fruit , vegetable material , plant material , and combinations thereof , excluding insoluble fibers , in a carrier selected from the group consisting of milk , milk protein-containing carriers and combinations thereof , wherein the essential lipophilic and hydrophilic bioactive components are extracted from the material by milling the material in the milk or milk protein-containing carrier and the insoluble fibers are removed by centrifuging the carrier after milling and wherein the miscible primary composition is stable , miscible and dispersible in an aqueous system.2. The miscible primary composition according to claim 1 , wherein the material is in a form selected from the group consisting of vegetables claim 1 , leaves claim 1 , flowers claim 1 , fruits claim 1 , seeds and other parts of the plant claim 1 , and combinations thereof.3. The miscible primary composition according to claim 1 , wherein the material is selected from the group consisting of a berry claim 1 , vegetables claim 1 , seeds claim 1 , flowers claim 1 , citrus fruits claim 1 , tomato claim 1 , spinach claim 1 , celery claim 1 , carrots claim 1 , pea claim 1 , kale claim 1 , parsley claim 1 , watercress claim 1 , cabbage claim 1 , broccoli claim 1 , lettuce claim 1 , brussels sprouts claim 1 , collard greens claim 1 , turnip greens claim 1 , fennel claim 1 , onions claim 1 , tea claim 1 , corn claim 1 , cocoa claim 1 , coffee claim 1 , thyme claim 1 , sweet red pepper claim ...

Methods of Improving the Appearance of Aging Skin

A method of improving the appearance of aging skin includes applying to skin tissue having dullness or lack of radiance, or eleven lines, marionette lines, or horizontal forehead lines, or sagging skin, a composition containing S-acyl glutathione derivative having unsaturated or saturated Cacyl group. 2. The method of claim 1 , wherein the composition comprises about 0.01% to about 20% by weight of S-acyl glutathione derivative of formula (I).3. The method of claim 2 , wherein the composition comprises about 0.1% to about 5% by weight of S-acyl glutathione derivative of formula (I).4. The method of claim 3 , wherein the composition comprises about 1.0% to about 3% by weight of S-acyl glutathione derivative of formula (I).5. The method of claim 1 , wherein the skin tissue also has sagging skin and the method improves the appearance thereof.6. The method of claim 1 , wherein the skin tissue also has wrinkles and lines claim 1 , and the method improves the appearance of the wrinkles and lines.7. The method of claim 1 , wherein the skin tissue also has dryness and the method improves the appearance thereof.8. The method of claim 1 , wherein the skin tissue also has discoloration and the method improves the appearance thereof.9. The method of claim 1 , wherein the skin tissue also has redness or blotchiness and the method improves the appearance thereof.10. The method of claim 1 , wherein the skin tissue also has enlarged pores and the method improves the appearance thereof.11. The method of claim 1 , wherein the skin is peri-menopausal claim 1 , menopausal claim 1 , or post-menopausal skin.13. The method of claim 12 , wherein the composition comprises about 0.01% to 20% by weight of S-acyl glutathione derivative.14. The method of claim 13 , wherein the compositions comprises about 0.1% to 5% by weight of S-acyl glutathione derivative.15. The method of claim 14 , wherein the composition comprises about 1.0% to 3% by weight of S-palmitoyl glutathione.16. The method of ...

CAPABILITY OF SMALL-SIZED STEM CELLS TO STIMULATE HAIR GROWTH AND USE THEREOF

Provided are a composition for preventing hair loss and stimulating hair growth, which includes small-sized stem cells, particularly, small-sized stem cells having a diameter of 8 μm or less, or a culture thereof as an active ingredient, a method of preparing the same, and a use of the same. Provided is a use of the composition utilizing a hair growth stimulating function of the small-sized stem cells having a diameter of 8 μm or less to considerably increase activity of hair follicle stem cells in a telogen phase. 1. A composition for preventing hair loss and stimulating hair growth , comprising:small-sized stem cells having a diameter of 8 μm or less or a culture thereof as an active ingredient.2. The composition according to claim 1 , wherein the small-sized stem cells having a diameter of 8 μm or less include at least one selected from the group consisting of bone marrow- claim 1 , umbilical cord blood- claim 1 , adipocyte- claim 1 , blood- claim 1 , liver and intestine- claim 1 , skin- claim 1 , gastrointestinal tract- claim 1 , placenta- claim 1 , nerve- claim 1 , adrenal- claim 1 , epithelium- and uterus-derived human adult stem cells claim 1 , and embryonic stem cells.3. The composition according to claim 2 , wherein the small-sized stem cells having a diameter of 8 μm or less are derived from bone marrow claim 2 , umbilical cord blood or adipocyte.4. The composition according to claim 3 , wherein the small-sized stem cells having a diameter of 8 μm or less are derived from the umbilical cord blood.5. The composition according to claim 4 , wherein the small-sized stem cells having a diameter of 8 μm or less are umbilical cord blood-derived mesenchymal stem cells.6. The composition according to claim 4 , wherein the umbilical cord blood is derived from human.7. The composition according to claim 1 , wherein the culture includes a keratinocyte-serum free medium (K-SFM).8. The composition according to claim 1 , wherein the small-sized stem cells having a ...

HAIR GROWTH PROMOTING CAPACITY OF CONDITIONED MEDIA OF STIMULATED STEM CELLS AND USE THEREOF

Provided is an a composition for preventing hair-loss and promoting hair growth containing as an active ingredient conditioned media of stem cells stimulated by particular hair catagen inducers including TGF-β, a method of manufacturing the same, and a use thereof. In particular, the present invention relates to a use of the function of very effective hair growth by secreting Wnt3a, Bcl-2, CyclinD-1 and the like, which are known as signal transduction proteins. 1. A composition for preventing hair-loss and promoting hair growth comprising , as an active ingredient , a conditioned medium of stem cells stimulated by at least one hair catagen inducer selected from the group consisting of TGF-β , IFN-γ , FGF-5 , IL-1β , TNF-α , K17 , NT-3 , NT-4 , BDNF , and BMP2/4.2. The composition of claim 1 , wherein the hair catagen inducer is at least one factor including TGF-β.3. The composition of claim 1 , wherein the stem cell is at least one selected from the group consisting of human tissue adult stem cells and embryonic stem cells derived from bone marrow claim 1 , umbilical cord blood claim 1 , adipose claim 1 , blood claim 1 , liver and intestines claim 1 , skin claim 1 , gastrointestinal tract claim 1 , placenta claim 1 , nerves claim 1 , adrenal gland claim 1 , epithelium claim 1 , and uterus.4. The composition of claim 3 , wherein the stem cell is derived from umbilical cord blood claim 3 , bone marrow or adipose.5. The composition of claim 3 , wherein the stem cell is derived from umbilical cord blood.6. The composition of claim 1 , wherein the conditioned media stimulated by the hair catagen inducer is obtained by stimulating the stem cells for 22 to 26 hours after adding the hair catagen inducer to the stem cells claim 1 , followed by culturing for a selected period of time of from 1 to 3 days.7. The composition of claim 1 , wherein the conditioned media stimulated by the hair catagen inducer comprises at least one protein selected from the group consisting of Wnt3a ...

METHODS OF INHIBITING CATARACTS AND PRESBYOPIA

Described herein are methods of inhibiting or reversing the progression of cataract formation or presbyopia in an eye by administering a γ-crystallin charge masking agent. Both presbyopia and cataracts are caused by aggregation of the soluble crystalline lens proteins called the crystallins. 1. A method of inhibiting or reversing the progression of cataract formation , presbyopia , or age related degeneration of a crystalline lens in an eye comprisingcontacting the eye with an effective cataract-inhibiting amount of an ophthalmic composition comprising at least one γ-crystallin charge masking agent, [{'sub': '2', 'wherein the reactive group is NH, a succinimide, a carboxylic acid, isocyanate, isothiocyanate, sulfonyl chloride, aldehyde, carbodiimide, acyl azide, anhydride, fluorobenzene, carbonate, N-hydroxysuccinimide ester, imidoester, epoxide and fluorophenyl ester, and'}, 'wherein the molecular bristle is a polyethylene glycol, an alkoxy-polyethylene glycol, or an alkoxypolyethylene glycol having 4 to 200 oxyethylene, alkoxyethylene or aryloxyethylene groups; poly(2-hydroxypropyl)methacrylamide (HPMA); poly(2-hydroxyethyl)methacrylate (HEMA); a ply(2-oxaziline), poly(m-phosphocholine, poly lysine, or poly glutamic acid, the molecular bristle having a molecular weight of 150 to 8000., 'wherein the γ-crystallin charge masking agent is a bifunctional molecule containing a reactive group covalently linked to a molecular bristle,'}25-. (canceled)6. The method of claim 1 , wherein the reactive group is NH claim 1 , N-hydroxysuccinimide or COOH.78-. (canceled)10. The method of claim 1 , wherein the ophthalmic composition is an eye drop or an ophthalmic device.11. The method of claim 10 , wherein the ophthalmic device is a contact lens or a punctal plug.12. The method of claim 1 , wherein the ophthalmic composition is administered by injection claim 1 , iontophoresis or ultrasound enhancement.1314-. (canceled)15. An ophthalmic composition comprising a bifunctional ...

METHOD OF MANUFACTURING COMPOSITION MATERIAL FOR SKIN MOISTURIZING CONTAINING VEHICLE HAVING MULTI-LAYER GLOBULE

Disclosed is a method of manufacturing a composition material for skin moisturizing containing a vehicle having a multi-layer globule. The method includes manufacturing a hydrogenated lecithin dispersion solution by adding hydrogenated lecithin to purified water at 70 to 90° C. with agitation to thus perform dispersion, manufacturing a pre-emulsion base by adding a saturated fatty alcohol having 12 to 22 carbon atoms to the hydrogenated lecithin dispersion solution at 70 to 90° C. with agitation to thus perform dispersion, manufacturing a composition material base for skin moisturizing by adding the pre-emulsion base and water-soluble polypeptide to the purified water at 70 to 90° C. with agitation to thus perform dispersion, and manufacturing a multi-layer globule for skin moisturizing including phospholipid bilayers by adding oil to the composition material base for skin moisturizing at 70 to 90° C. with agitation to thus perform dispersion. 1. A method of manufacturing a composition material for skin moisturizing containing a vehicle having a multi-layer globule , the method comprising:manufacturing a hydrogenated lecithin dispersion solution by adding hydrogenated lecithin to purified water at 70 to 90° C. with agitation to thus perform dispersion;manufacturing a pre-emulsion base by adding saturated fatty alcohol having 12 to 22 carbon atoms to the hydrogenated lecithin dispersion solution at 70 to 90° C. with agitation to thus perform dispersion;manufacturing a composition material base for skin moisturizing by adding the pre-emulsion base and water-soluble polypeptide to the purified water at 70 to 90° C. with agitation to thus perform dispersion; andmanufacturing a multi-layer globule for skin moisturizing including phospholipid bilayers by adding oil to the composition material base for skin moisturizing at 70 to 90° C. with agitation to thus perform dispersion.2. The method of claim 1 , wherein the water-soluble polypeptide is RH-polypeptide-64 (aquaporin ...

Lipofilling with ex-vivo expanded adipose tissue-derived stem cells for cosmetic breast filling or for facial filling and/or rejuvenation

The present invention relates to a composition comprising ex-vivo expanded adipose tissue derived stem cell (ASC) or ex-vivo expanded adipose tissue-derived stem cells (ASC) mixed with harvested fat tissue at a ratio of 5,0×10−2,0×10ASCs/mL fat; for example 1,0×10−2,0×10and the use of ex-vivo expanded adipose tissue-derived stem cells or ex-vivo expanded adipose tissue-derived stem cell enriched fat grafts as an agent for cosmetic breast filling/augmentation or for facial filling/rejuvenation. 1. A composition comprising ex-vivo expanded adipose tissue-derived stem cell (ASC) enriched fat grafts or ex-vivo expanded adipose tissue-derived stem cells (ASC) mixed with harvested fat tissue at a ratio of 5 ,0×10−2 ,0×10ASCs/mL fat.2. Use of ex-vivo expanded adipose tissue-derived stem cell enriched fat grafts as a breast filling agent.3. Use of ex-vivo expanded adipose tissue-derived stem cell enriched fat grafts or ex-vivo expanded adipose tissue-derived stem cells as a facial filling agent.4. Use of ex-vivo expanded adipose tissue-derived stem cell enriched fat grafts or ex-vivo expanded adipose tissue-derived stem cells for cosmetic breast filling.5. Use of ex-vivo expanded adipose tissue-derived stem cell enriched fat grafts or ex-vivo expanded adipose tissue-derived stem cells for cosmetic facial filling.6. Cosmetic method of breast filling wherein adipose tissue-derived stem cell (ASC) enriched fat grafts is mixed with harvested fat tissue at a ratio of 5 ,0×10−2 ,0×10ASCs/mL fat , and wherein the fat is injected as aliquots or as strings with a long needle horizontally (parallel to the body) by inserting the needle from several points around the areola margin and at several points at the inframammary fold in variable directions and planes to achieve an even and natural appearing distribution of the graft.7. Cosmetic method of facial filling wherein expanded adipose tissue-derived stem cell (ASC) enriched fat grafts or ex-vivo expanded adipose tissue-derived stem ...

MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR-DERIVED PEPTIDE AND COMPOSITION CONTAINING SAME

The present invention provides small peptide fragments derived from microphthalmia-associated transcription factor (MITF) and a pharmaceutical composition for preventing or treating melanoma comprising the same as an active ingredient. And also, the present invention provides a cosmetic composition for skin-whitening and/or for inhibiting skin pigmentation, comprising the peptide fragments as an active ingredient. 1. A peptide selected from the group consisting of the peptide of SEQ ID NO: 1 , the peptide of SEQ ID NO: 2 , the peptide of SEQ ID NO: 3 and the peptide of SEQ ID NO: 4.2. A pharmaceutical composition for preventing or treating melanoma , comprising a peptide selected from the group consisting of the peptide of SEQ ID NO: 1 , the peptide of SEQ ID NO: 2 , the peptide of SEQ ID NO: 3 and the peptide of SEQ ID NO: 4 as an active ingredient.3. A cosmetic composition for skin-whitening , comprising a peptide selected from the group consisting of the peptide of SEQ ID NO: 1 , the peptide of SEQ ID NO: 2 , the peptide of SEQ ID NO: 3 and the peptide of SEQ ID NO: 4 as an active ingredient.4. A cosmetic composition for inhibiting skin pigmentation , comprising a peptide selected from the group consisting of the peptide of SEQ ID NO: 1 , the peptide of SEQ ID NO: 2 , the peptide of SEQ ID NO: 3 and the peptide of SEQ ID NO: 4 as an active ingredient.5. The cosmetic composition according to claim 4 , wherein the skin pigmentation is a skin pigmentation induced by exposure to ultraviolet radiation. The present invention relates to small peptide fragments derived from microphthalmia-associated transcription factor (MITF) and a pharmaceutical composition for preventing or treating melanoma comprising the same as an active ingredient. And also, the present invention relates to a cosmetic composition for skin-whitening and/or for inhibiting skin pigmentation, comprising the peptide fragments as an active ingredient.Melanin is dark brown pigments found in the eyes or ...

COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES

A compound has a formula (I) R-W-X-AA-AA-AA-AA-AA-AA-(AA)-(AA)-Y-Z-R, its stereoisomers and/or its cosmetically or pharmaceutically acceptable salts, wherein: AAis Glu or replaced by Asp, Gln or Asn, AAis Glu or replaced by Asp or Gln; AAis Met or replaced by Leu or Ile; AAis Gln or replaced by Glu, Asn or Asp; AAis Arg or replaced by Lys; AAis Arg or replaced by Lys or His; AAis Ala, Ser, Gly, Thr, Pro, Glu, Lys, or Val; AAis Asp, Glu, Asn, or Gln. In the compound, no more than two of AA, AA, AA, AA, AAand AAare replaced, a and b are 0 or 1; W, X, Y and Z are amino acids; m, n, p and q are each 0 or 1; and Rand Rare not amino acids. A method of skin treatment with the compound is also described. 117-. (canceled)18. A compound according to formula (I):{'br': None, 'sub': 1', 'm', 'n', '1', '2', '3', '4', '5', '6', '7', 'a', '8', 'p', 'q', '2, 'R-W-X-AA-AA-AA-AA-AA-AA-(AA)-(AA)Y-Z-R\u2003\u2003(I),'}its stereoisomers and/or its cosmetically or pharmaceutically acceptable salts, wherein:{'sub': 1', '2', '3', '4', '5', '6', '7', '8, 'AAis Glu; AAis Glu; AAis Met; AAis Gln; AAis Arg; AAis Arg; AAis selected from the group consisting of Ala, Ser, Gly, Thr, Pro, Glu, Lys and Val; AAis selected from the group consisting of Asp, Glu, Asn and Gln; and'}{'sub': 1', '2', '3', '4', '5', '6, 'claim-text': [{'sub': '1', 'when AAis replaced, it is replaced by an amino acid selected from the group consisting of Asp, Gln and Asn;'}, {'sub': '2', 'when AAis replaced, it is replaced by an amino acid selected from the group consisting of Asp and Gln;'}, {'sub': '3', 'when AAis replaced, it is replaced by an amino acid selected from the group consisting of Leu and Ile;'}, {'sub': '4', 'when AAis replaced, it is replaced by an amino acid selected from the group consisting of Glu, Asn and Asp;'}, {'sub': '5', 'when AAis replaced, it is replaced by Lys; and'}, {'sub': '6', 'when AAis replaced, it is replaced by an amino acid selected from the group consisting of Lys and His;'}], '0, 1 or 2 ...

NOVEL PEPTIDE AND USE THEREOF

The invention provides a peptide and an immunostimulant or hair grower containing the peptide as an active ingredient, as well as a method for hair growth or regrowth promotion by administering an effective amount of the peptide to a mammal. The peptide has 23 or less amino acids and includes the amino acid sequence LHRLKRLRKRL (SEQ ID NO: 1), preferably the amino acid sequence LHRLKRLRKRLK (SEQ ID NO: 9). 1. A method for hair growth or regrowth promotion , comprising administering an effective amount of a peptide of 23 or less amino acids comprising the amino acid sequence LHRLKRLRKRLK (SEQ ID NO: 9) to a mammal.2. The method of claim 1 , wherein the peptide comprises the amino acid sequence ELKLIFLHRLKRLRKRLKRK (SEQ ID NO: 2) or an amino acid sequence having 90% or more identity with the amino acid sequence ELKLIFLHRLKRLRKRLKRK.3. The method of claim 2 , wherein the peptide is amidated at the C-terminus.4. The method of claim 3 , wherein the peptide is acetylated at the N-terminus5. The method of claim 2 , wherein the peptide is acetylated at the N-terminus.6. The method of claim 1 , wherein the peptide is amidated at the C-terminus.7. The method of claim 6 , wherein the peptide is acetylated at the N-terminus.8. The method of claim 1 , wherein the peptide is acetylated at the N-terminus. This patent application is a divisional of copending U.S. patent application Ser. No. 15/514,310, filed on Mar. 24, 2017, which is the U.S. national phase of International Patent Application No. PCT/JP2015/077139, filed Sep. 25, 2015, which claims the benefit of Japanese Patent Application No. 2014-197386, filed on Sep. 26, 2014, which are incorporated by reference in their entireties herein.Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: 3,902 bytes ASCII (Text) file named “740543SequenceListing.txt,” created Sep. 14, 2018.The present invention relates to a ...

ULTRAMARINE FLUORESCENT PROTEIN, CONSTRUCTION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF PROTEIN SUNSCREEN AGENT

An ultramarine fluorescent protein, is a protein selected from (a) and (b) protein: (a) a protein consisting of an amino acid sequence set forth in SEQ ID:NO. 2; (b) a protein derived from (a) by substitution, deletion or addition with one or more amino acids in the amino acid sequence of (a) and having activity of the ultramarine fluorescent protein. The ultramarine fluorescent protein (UFP) has the characteristics of pH-insensitivity and light stability, and its chromophore can absorb long-wavelength ultraviolet (UVA) and release fluorescence at wavelength longer than 400 nm. And the aromatic amino acids residue (with content of 9.2%) can absorb medium wavelength ultraviolet (UVB) and release UVA. 1. An ultramarine fluorescent protein (UFP) , wherein the ultramarine fluorescent protein is a protein selected from the (a) or (b) protein:(a) a protein consisting of an amino acid sequence set forth in SEQ ID:NO. 2;(b) a protein derived from (a) by substitution, deletion or addition with one or more amino acids in the amino acid sequence of (a), and having activity of the ultramarine fluorescent protein.2. The ultramarine fluorescent protein according to claim 1 , wherein the nucleotide sequence of a gene encoding the ultramarine fluorescent protein is set forth in SEQ ID:NO. 1.3. The ultramarine fluorescent protein according to claim 1 , wherein the ultramarine fluorescent protein is able to use in preparation of protein for sunscreen.4. A method for constructing an ultramarine fluorescent protein comprising:1) obtaining DNA molecules by using PCR site-directed mutagenesis: carrying out PCR site-directed mutagenesis by using mutation primers based on F46L, T65Q, W66F, Q69L, Y145G, H148S and T203V sites, with pETCFP-Cl as a template;{'i': 'E. coli', '2) transforming the obtained DNA molecules into DH5α, and obtaining the gene-mutated UFP after bacteria selection and sequencing;'}3) double enzyme digesting pETUFP-Cl, and expression vectors pET-24a and pHND by ...

IMPROVEMENTS RELATING TO ENCAPSULATED BENEFIT AGENTS

A particle comprising:—(a) a spacer which is a polyethylene glycol (PEG) chain with molecular weight Mw (and therefore the required length) of the spacer extending from the particle from 3000 to 400,000; (b) a deposition aid; and (c) a benefit agent, wherein the spacer is attached directly to the particle and the deposition aid is attached to the end of the spacer. 1. A particle comprising:a. a spacer which is a polyethylene glycol (PEG) chain with molecular weight Mw (and therefore the required length) of the spacer extending from the particle from 3000 to 400,000;b. a deposition aid; andc. a benefit agent,wherein the spacer is attached directly to the particle and the deposition aid is attached to the end of the spacer.2. (canceled)3. A particle as claimed in claim 1 , wherein the deposition aid comprises a peptide claim 1 , protein or mixture thereof.4. A particle as claimed in claim 3 , wherein the deposition aid is a peptide claim 3 , comprising from 10 to 250 amino acids.5. A particle as claimed in claim 4 , wherein the peptide comprises from 17 to 20 amino acids.6. A particle as claimed in claim 1 , wherein the peptide is a linear peptide.7. A particle as claimed in claim 1 , wherein the peptide is a linear peptide and has an amino acid composition of EKFILPRY claim 1 , or of SFEHP claim 1 , where the amino acids can occur in any order along the peptide backbone claim 1 , and the amine end of the peptide is acetylated.8. A particle as claimed in claim 7 , wherein the peptide has an amino acid sequence selected from ACE FYIEFEREIRKLLEPPRYKK OH (SEQ ID NO: 1) claim 7 , and FESSSPEHSFSSFFPFSFSH (SEQ ID NO: 2)where ACE is an acetyl protecting group on the NHterminus and OH indicates a free carboxylate at the end of the peptide.9. A particle as claimed in claim 1 , which comprises a core which comprises the benefit agent claim 1 , and at least one shell.10. A particle as claimed in claim 1 , wherein the benefit agent is selected from a perfume claim 1 , an anti- ...

TREATMENT OF A DIASTOLIC CARDIAC DYSFUNCTION WITH A TRPV2 RECEPTOR AGONIST

Described herein are inventions directed to methods of treating a diastolic cardiac dysfunction and the symptoms thereof in a subject that includes administering an amount of a TRPV2 receptor agonist effective to treat the diastolic cardiac dysfunction. The TRPV2 receptor agonist may be administered in at least one of an injection, orally, or transdermally. The amount of TRPV2 receptor agonist is sufficient to result in an improved performance on quantitative diagnostic criteria. In an embodiment, the TRPV2 receptor agonist is administered over a period of about 8 hours to about 24 hours. The TRPV2 receptor agonist may be used for short term treatments, i.e., less than a week, or it may be administered in a long term manner, i.e., over a period of weeks, months, or even years. Exemplary TRPV2 receptor agonists include probenecid, 2-aminoethoxydiphenyl borate, cannabinol, cannabidiol, and combinations thereof. 1. A method of treating a diastolic cardiac dysfunction in a subject comprising administering an amount of a Transient Receptor Potential Vanilloid 2 (“TRPV2”) receptor agonist effective to stimulate TRPV2 receptors on cardiomyocytes in the subject to increase the rate of cardiac relaxation to a level sufficient to treat the diastolic cardiac dysfunction wherein the amount of TRPV2 receptor agonist is administered via at least one of an injection , oral administration , or a transdermal administration.2. The method of wherein the TRPV2 receptor agonist is selected from the group consisting of probenecid claim 1 , 2-aminoethoxydiphenyl borate (2APB) claim 1 , cannabinol claim 1 , cannabidiol claim 1 , and combinations thereof.3. The method of wherein the diastolic cardiac dysfunction is selected from the group consisting of heart failure with preserved ejection fraction (HFpEF) or a precursor of HFpEF.4. The method of wherein the precursor of HFpEF is selected from the group consisting of diastolic dysfunction claim 3 , left ventricular hypertrophy with impaired ...

CAPABILITY OF SMALL-SIZED STEM CELLS TO STIMULATE HAIR GROWTH AND USE THEREOF

Provided are a composition for preventing hair loss and stimulating hair growth, which includes small-sized stem cells, particularly, small-sized stem cells having a diameter of 8 μm or less, or a culture thereof as an active ingredient, a method of preparing the same, and a use of the same. Provided is a use of the composition utilizing a hair growth stimulating function of the small-sized stem cells having a diameter of 8 μm or less to considerably increase activity of hair follicle stem cells in a telogen phase. 1. A method of treating the Alopecia or hair-loss; or stimulating hair growth , comprising administering an effective amount of isolated population of small-sized stem cells having a diameter of 8 um or less , as an active ingredient.2. The method according to claim 1 , wherein the small-sized stem cells having a diameter of 8 um or less include at least one selected from the group consisting of bone marrow- claim 1 , umbilical cord blood- claim 1 , adipocyte- claim 1 , blood- claim 1 , liver and intestine- claim 1 , skin- claim 1 , gastrointestinal tract- claim 1 , placenta- claim 1 , nerve- claim 1 , adrenal- claim 1 , epithelium- and uterus-derived human adult stem cells claim 1 , and embryonic stem cells.3. The method according to claim 2 , wherein the small-sized stem cells having a diameter of 8 um or less are derived from bone marrow claim 2 , umbilical cord blood or adipocyte.4. The method according to claim 3 , wherein the small-sized stem cells having a diameter of 8 um or less are derived from the umbilical cord blood.5. The method according to claim 4 , wherein the small-sized stem cells having a diameter of 8 um or less are umbilical cord blood-derived mesenchymal stem cells.6. The method according to claim 4 , wherein the umbilical cord blood is derived from human.7. The method according to claim 1 , wherein the small-sized stem cells having a diameter of 8 um or less activates hair follicle stem cells.8. The method according to claim 7 , ...

WOUND HEALING

The invention relates to methods and compositions for improving wound healing and in particular for preventing scar formation and thus loss of function that can occur in injured tissues during the natural wound healing process. Particularly, although by no means exclusively, the invention relates to the healing of chronic wounds such as diabetic ulcers. 1. A therapeutic composition comprising isolated or purified choroid plexus (CP) secreted proteins , wherein the CP secreted proteins are isolated or purified from CP conditioned media.2. The therapeutic composition as claimed in claim 1 , wherein the CP secreted proteins comprise a mixture of at least 2 of the following factors VEGF claim 1 , CTGF claim 1 , PDGF claim 1 , BMP-7 claim 1 , FGF-2 claim 1 , TGFβ claim 1 , TGF-α claim 1 , IL-6 claim 1 , IL-8/CXC chemokines claim 1 , IGF-1 claim 1 , Cystatin claim 1 , α-2microglobulin claim 1 , Pleiotrophic factor β claim 1 , NGF claim 1 , NT claim 1 , transthyretin claim 1 , retinoic acid claim 1 , PTHLH claim 1 , haptocorrin claim 1 , tropomodulin 3 claim 1 , PEDF claim 1 , β-2-microglobulin claim 1 , somatostatin claim 1 , fibronectin claim 1 , laminin β1 and secreted extracellular matrix factors.3. The therapeutic composition as claimed in further comprising one or more immunostimulatory compounds selected from the group consisting of glucocorticosteroids claim 1 , non-steroidal anti-inflammatory drugs (NSAIDS) claim 1 , PDGF claim 1 , EGF claim 1 , IGF and TNF-α antagonists.4. The therapeutic composition as claimed in claim 1 , formulated for systemic or local administration.5. A therapeutic composition as claimed in claim 4 , formulated for oral claim 4 , intravenous claim 4 , cutaneous claim 4 , intradermal claim 4 , topical claim 4 , nasal claim 4 , intramuscular or intraperitoneal administration.6. The cosmetic composition comprising isolated or purified CP secreted proteins as claimed in .7. The cosmetic composition as claimed in claim 6 , formulated for topical ...

PROTEIN CAGE-STABILIZED PICKERING EMULSIONS AND THE USE THEREOF

The present invention relates to a Pickering emulsion comprising an aqueous phase, an oil phase and a nanoparticle, wherein the nanoparticle is a protein cage. The protein cage is preferably a E2 protein of pyruvate hydrogenase multi-enzyme complex or an E2LC2 protein. Preferably the aqueous or oil phase of the Pickering emulsion comprises an agent, or the protein cage is coupled to or loaded with an agent, wherein the agent is a therapeutic, nutritional, nutraceutical or cosmetic agent. The invention further includes use of the Pickering emulsions disclosed herein in pharmaceutical, cosmetic, or food applications, or as a controlled release delivery system, and use of protein cages as emulsifiers in Pickering emulsions. 1. Pickering emulsion comprising an aqueous phase , an oil phase immiscible with said aqueous phase , and a nanoparticle dispersed in said aqueous phase and adsorbed to the liquid-liquid interface between said aqueous phase and said oil phase , wherein said nanoparticle is a protein cage.2. The Pickering emulsion according to claim 1 , wherein the protein cage is composed of protein units selected from the group consisting of E2 protein of pyruvate dehydrogenase multi-enzyme complex (E2) claim 1 , Ferritin (Ftn) claim 1 , heat shock proteins (Hsp) claim 1 , DNA-binding protein from starved cells (Dps) claim 1 , lumazine synthase claim 1 , viral capsids claim 1 , and Vault.3. The Pickering emulsion according to claim 1 , wherein the protein cage is composed of E2 protein of pyruvate dehydrogenase multi-enzyme complex and/or ferritin units and/or fragments claim 1 , single chains or domains of said proteins.4Bacillus stearothermophilusArchaeoglobus fulgidusHomo sapiens. The Pickering emulsion according to claim 1 , wherein the protein cage is composed of protein units selected from the group consisting of E2 protein of pyruvate dehydrogenase multi-enzyme complex (E2) having the amino acid sequence of SEQ ID NO:1 claim 1 , E2LC2 protein having the ...

COSMETIC FORMULATIONS FOR TOPICAL APPLICATIONS CONTAINING ERYTHROPOIETIN-DERIVED MOLECULES

The invention relates to cosmetic formulations and new peptide related entities designed for the cosmetic treatment of the human skin. In more detail, the invention is related to peptides that target CD90 positive tissue cells and correspond to or derive from the partial sequence of erythropoietin (EPO) but do not substantially elicit a hematopoietic but a tissue regenerative and protective effect. In particular, the invention discloses EPO-derived tissue-protective peptides in functional relation to lipid structures and agents that trigger vasculature relaxation and promote transdermal transport of the polypeptide entities to the targeted skin cells. 122-. (canceled)24. The cosmetic formulation or composition according to claim 23 , wherein the lipid compound or lipid structure is based on a sphingolipid claim 23 , such as a ceramide claim 23 , or phospholipid such as a phosphatidylcholine.25. The cosmetic formulation or composition according to claim 23 , wherein the triggering agent comprises one or more amino acids or amino acid derivatives claim 23 , selected from the group consisting of arginine claim 23 , phenylalanine claim 23 , lysine claim 23 , glutamine claim 23 , tyrosine claim 23 , tryptophan claim 23 , valine claim 23 , proline claim 23 , citrulline claim 23 , creatine claim 23 , taurine claim 23 , and a polypeptide comprising or consisting of two or more identical or different amino acids as specified.26. The cosmetic formulation or composition according to comprising vitamin B5 claim 25 , and/or vitamin E claim 25 , and/or choline.27. The cosmetic formulation or composition according to claim 23 , wherein the triggering agent is N-terminally and/or C-terminally linked to the tissue-protective polypeptide (tpP) by covalent bonding.28. A cosmetic formulation according to claim 23 , composed of (i) a cream or lotion base composition and (ii) a composition comprising said tissue protective polypeptide claim 23 , a sphingolipid and/or a phospholipid claim ...

COMPOSITIONS AND METHODS OF TREATING CANCER HARBORING PIKC3A MUTATIONS

A method of treating cancer cells having mutated PIK3CA gene or protein of a subject in need thereof includes administering to the subject a therapeutically effective amount of an inhibitor of one or more enzymes of the glutamine metabolism pathway. 1. A method of determining the susceptibility and/or responsiveness of a cancer cancer cells , precancerous cells , and/or benign tumor cells of a subject to treatment with an inhibitor of one or more enzymes of a glutamine metabolism pathway of the cancer cells , the precancerous cells , and/or the benign tumor cells , comprising:obtaining a sample of the cancer cells, the precancerous cells, and/or the benign tumor cells from the subject;assaying the cancer cells, the precancerous cells, and/or the benign tumor cells for the presence a mutated PIK3CA gene or a mutant form of PIK3CA protein or a biologically active fragment thereof; anddetermining that the subject should be treated with the inhibitor if the cancer cells have the mutated PIK3CA gene or the mutant form of PIK3CA protein or a biologically active fragment thereof.2. The method of claim 1 , wherein cancer cells and the precancerous cells are obtained from a tumor or biological sample of the subject.3. The method of claim 1 , wherein the mutation is detected using an amplification assay or by molecular cloning or sequencing or microarray analysis.4. The method of claim 1 , wherein the PIK3CA gene in the sample is amplified by polymerase chain reaction or ligase chain reaction.5. The method of claim 1 , wherein a DNA hybridization assay is used to detect the PIK3CA gene in the sample.6. The method of claim 1 , wherein the cancer cells are selected from the group consisting of lung cancer claim 1 , digestive and gastrointestinal cancers claim 1 , gastrointestinal stromal tumors claim 1 , gastrointestinal carcinoid tumors claim 1 , colon cancer claim 1 , rectal cancer claim 1 , anal cancer claim 1 , bile duct cancer claim 1 , small intestine cancer claim 1 , and ...

NOVEL COMPOSITIONS AND USES THEREOF

The present invention provides a composition for stimulating hair growth in a mammal comprising a modified osteopontin polypeptide in which an RGD domain is inactivated; and a pharmaceutically acceptable and/or cosmetically acceptable excipient, carrier or diluent. The invention further provides methods of stimulating hair growth in a mammal. 1. A composition for stimulating hair growth in a mammal comprising:(a) a modified osteopontin polypeptide in which an RGD domain is inactivated; and(b) a pharmaceutically acceptable and/or cosmetically acceptable excipient, carrier or diluent.24-. (canceled)5. A composition according to wherein the polypeptide is capable of inducing the formation of new hair follicles claim 1 , or stem cells for producing the same.6. A composition according to wherein the polypeptide is fewer than 500 amino acids in length claim 1 , for example fewer than 40 claim 1 , 30 claim 1 , 20 claim 1 , 15 claim 1 , or 10 amino acids in length.711-. (canceled)1315-. (canceled)16. A composition according to wherein the fragment comprises or consists of an amino acid sequence according to any one SEQ ID NOs: 5 to 62.17. A composition according to wherein the fragment comprises or consists of an amino acid sequence of SEQ ID NO: 5.1826-. (canceled)28. (canceled)2927. A composition according to claim wherein the fragment comprises or consists of an amino acid sequence according to any one SEQ ID NOs: 63 to 120.30. A composition according to wherein the fragment comprises or consists of an amino acid sequence of SEQ ID NO: 63.3142-. (canceled)43. A composition according to for topical claim 1 , transdermal claim 1 , parenteral or oral administration.4446-. (canceled)47. A polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 63 or a fragment claim 1 , variant claim 1 , derivative or fusion thereof (or a fusion of said fragment claim 1 , variant or derivative) which retains a hair growth stimulatory activity of the amino acid sequence ...

TRANEXAMIC ACID FORMULATIONS

Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith. 1. A tranexamic acid formulation comprising:tranexamic acid or a pharmaceutically acceptable salt thereof; anda modified release material;wherein the tranexamic acid or pharmaceutically acceptable salt thereof is present in an amount from about 50% to about 95% by weight of the formulation;wherein the modified release material is present in an amount from about 5% to about 50% by weight of the formulation; andwherein said formulation provides an in-vitro dissolution release rate of the tranexamic acid or pharmaceutically acceptable salt thereof, when measured by a USP 27 Apparatus Type II Paddle Method @50 RPM in 900 ml water at 37±0.5° C., of less than about 40% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 15 minutes, less than about 70% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 45 minutes and not less than about 50% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 90 minutes.2. The formulation of claim 1 , wherein said formulation provides an in-vitro dissolution release rate of the tranexamic acid or pharmaceutically acceptable salt thereof claim 1 , when measured by the USP 27 Apparatus Type II Paddle Method @50 RPM in 900 ml water at 37±0.5° C. claim 1 , of about 0% to about 40% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 15 minutes claim 1 , from about 20% to about 60% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 30 minutes claim 1 , from about 40% to about 65% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 45 minutes claim 1 , from about 50% to about 95% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 60 minutes claim 1 , ...

Hair Treatment Products and Methods for Straightening Hair

Methods and hair treatment products for smoothing or straightening hair having a formulation including at least one reducing agent, at least one protein fraction, at least one emollient, at least one emulsifier; and an aqueous diluent. The hair treatment product having a viscosity of from about 1 to about 1000 cps and a pH of about 1.5 to about 3. 1. A hair treatment product including:from about 1.0 to about 15.0 percent by weight of at least one reducing agent;from about 0.5 to about 20.0 percent by weight of at least one protein fraction;from about 1.0 to about 10.0 percent by weight of at least one emollient;from about 0.1 to about 5.0 percent by weight of at least one emulsifier;from about 0.1 to about 10.0 percent by weight of a masking fragrance;greater than 1.0 percent by weight of an aqueous diluent; such that the hair treatment product has a viscosity of about 1 to about 1000 cps;wherein the hair treatment product has a pH of about 1.5 to about 3.2. The hair treatment product of claim 1 , wherein the reducing agents are selected from the group consisting of glyoxylic acid claim 1 , cysteine HCL claim 1 , citric acid claim 1 , glycolic acid claim 1 , lactic acid claim 1 , ascorbic acid and combinations thereof.3. The hair treatment product of claim 1 , wherein the protein fractions are selected from the group consisting of hydrolyzed wheat protein claim 1 , silk protein claim 1 , sericin claim 1 , keratin protein and combinations thereof.4. The hair treatment product of claim 1 , wherein the emollients are selected from the group consisting of glycerin claim 1 , sorbitol claim 1 , propylene glycol claim 1 , caprylyl glycol claim 1 , propanediol and combinations thereof.5. The hair treatment product of claim 1 , wherein the emulsifiers are selected from the group consisting of PEG-40 Hydrogenated Castor Oil claim 1 , PPG-5 Ceteth 20 claim 1 , PEG-60 Almond Glycerides claim 1 , PPG-2 Hydroxyethyl Cocamide claim 1 , Polysorbate 20 claim 1 , Polysorbate 80 claim ...

COMBINATION OF CANAGLIFLOZIN AND PROBENECID FOR THE TREAMENT OF HYPERURICEMIA

The present invention is directed to methods for treating hyperuricemia and related disorders, comprising co-therapy with canagliflozin and probenecid. 1. A method for treating hyperuricemia or a related disorder comprising administering to a subject in need thereof , a therapeutically effective amount of co-therapy comprising canagliflozin and probenecid.2. A method as in claim 1 , wherein the treatment of hyperuricemia or related disorder prevents symptoms of gout.3. A method as in claim 1 , wherein the hyperuricemia or related disorder is selected from the group consisting of gout claim 1 , urate nephropathy claim 1 , chronic kidney disease claim 1 , hypertension due to hyperurecemia claim 1 , and kidney stones.4. A method as in claim 1 , wherein the canagliflozin is present as a crystalline hemihydrate.5. A method as in claim 1 , wherein the canagliflozin is administered in an amount in the range of from about 50 to about 500 mg.6. A method as in claim 5 , wherein the canagliflozin is administered in an amount in the range of from about 100 to about 300 mg.7. A method as in claim 1 , wherein the probenecid is administered in an amount in the range of from about 250 to about 1000 mg.8. A method as in claim 1 , wherein the canagliflozin is administered in an amount in the range of from about 100 mg to about 300 mg per day; andwherein the probenecid is administered in an amount in the range of from about 250 mg to about 1000 mg per day.9. A method for treating gout comprising administering to a subject in need thereof claim 1 , a therapeutically effective amount of co-therapy comprising canagliflozin and probenecid.10. A pharmaceutical composition comprising a therapeutically effective amount co-therapy of canagliflozin and probenecid; and a pharmaceutically acceptable carrier.11. A pharmaceutical composition as in claim 10 , wherein the canagliflozin is present as a crystalline hemihydrate.12. A pharmaceutical composition as in claim 10 , wherein the canagliflozin ...

METHODS FOR PROMOTING WOUND HEALING AND HAIR GROWTH

The present invention generally relates to uses of glial cell line-derived growth factor (GDNF) in cutaneous wound healing and hair growth. Methods of effecting hair growth and/or wound healing which feature administration of GDNF, or a biologically active fragment thereof, to subjects, e.g., human subject, are disclosed herein. The invention relates also to formulations and kits for achieving the indicated pharmaceutical advantages. 1. A method of promoting cutaneous wound healing in a subject , the method comprising the step of administering at a wound site on said subject a composition comprising a therapeutically effective dose of isolated glial cell derived growth factor (GDNF) , or a biologically active fragment thereof , and repeating said administration for a time period sufficient to promote said cutaneous wound healing.2. A method for promoting hair growth on a subject , the method comprising the step of administering at site of desired hair growth on said subject a composition comprising a pharmaceutically effective dose of isolated glial cell derived growth factor (GDNF) , or a biologically active fragment thereof , and repeating said administration for a time period sufficient to promote said hair growth on said subject.3. The method of claim 2 , wherein said pharmaceutically effective dose is a dose sufficient to promote a 25% increase in hair follicle number or a 25% decrease in hair loss over a period of 3-4 months.4. The method of claim 1 , wherein said GDNF comprises the amino acid sequence having at least 90% identity to the amino acid sequence of residues 78-211 of SEQ ID NO:2 or residues 118-211 of SEQ ID NO:2.5. (canceled)6. (canceled)7. The method of claim 1 , wherein the GDNF claim 1 , or biologically active fragment thereof is glycosylated at the glycosylation site occurring at amino acid residues 126-128 of SEQ ID NO:2 or at the glycosylation site occurring at amino acid residues 162-164 of SEQ ID NO:4.8. The method of claim 1 , wherein ...

Targeted Polymeric Inflammation-Resolving Nanoparticles

Sub-100 micron multimodal nanoparticles have four main components: 1) a target element (peptides, lipids, antibodies, small molecules, etc.) that can selectively bind to cells, tissues, or organs of the body; 2) a diagnostic agent such as a fluorophore or NMR contrast agent that allows visualization of nanoparticles at the site of delivery and/or a therapeutic or prophylactic agent; 3) an outside “stealth” layer that allows the particles to evade recognition by immune system components and increase particle circulation half-life; and 4) a biodegradable polymeric material, forming an inner core which can carry therapeutics and release the payloads at a sustained rate after systemic, intraperitoneal, or mucosal administration. These particles possess excellent stability, high loading efficiency, multiple agent encapsulation, targeting and imaging. They are targeted to sites of, or associated with, inflammation caused by a disease, disorder; trauma, chemotherapy or radiation. 1. A method of modulating inflammation and promoting inflammation resolution by administering to the site of inflammation , or promoting targeting to those sites , polymeric nanoparticles comprisingtargeting moieties that selectively bind to cells, tissues, or organs of the body at a site of, or associated with, inflammation and/or failed resolution associated with or resulting from a disease, disorder; trauma, chemotherapy or radiation;therapeutic, prophylactic or diagnostic agents on the surface of and optionally, encapsulated within the nanoparticles, that alleviate one or more symptoms of inflammation, directly or by treating the disease or disorder causing the inflammation;an outside hydrophilic polymer layer that allows the particles to evade recognition by immune system components and increase particle circulation half-life; anda biodegradable polymeric material, forming an inner core which can carry therapeutic or diagnostic agents and release the therapeutic or diagnostic agents at a ...

TRANSDERMALLY ABSORBABLE BASE MATERIAL CONTAINING LIPID PEPTIDE COMPOUND

A transdermally absorbable base material including: a lipid peptide compound including at least one of compound of Formula (1) below and the similar compounds or pharmaceutically usable salts thereof; a surfactant; a specific polyhydric alcohol; a fatty acid; and water, 2. The transdermally absorbable base material according to claim 1 , wherein the lipid peptide compound is a compound of Formula (1) claim 1 , wherein Ris a linear aliphatic group having a carbon atom number of 15; Ris a hydrogen atom; and Ris 4-imidazole methyl group.3. The transdermally absorbable base material according to claim 1 , being stick-shaped.4. The transdermally absorbable base material according to claim 1 , further comprising at least one oleaginous base material.5. The transdermally absorbable base material according to an one of claim 1 , further comprising at least one organic acid.6. The transdermally absorbable base material according to claim 1 , comprising claim 1 , as the surfactant claim 1 , at least one compound selected from the group consisting of ethylene glycol alkyl ethers claim 1 , phospholipid claim 1 , and polyglycerin fatty acid esters.7. The transdermally absorbable base material according to claim 1 , further comprising polyoxyethylene (20) sorbitan monolaurate (CAS registry number 9005-64-5) as the surfactant.8. The transdermally absorbable base material according to claim 1 , wherein the fatty acid is stearic acid.9. The transdermally absorbable base material according to claim 5 , wherein the organic acid is at least one selected from the group consisting of oxalic acid claim 5 , citric acid claim 5 , and ascorbic acid.10. The transdermally absorbable base material according to claim 1 , being used for cosmetics or pharmaceutical products. The present invention relates to a transdermally absorbable base material that contains a lipid peptide compound and is useful as a base material for transdermally absorbable formulation, and preferably relates to a stick- ...

COMPOSITIONS AND METHODS FOR NANOPARTICLE-BASED DRUG DELIVERY AND IMAGING

Methods and compositions described herein use polysaccharide nanoparticles (or polysaccharide-coated nanoparticles) to retain and deliver unaltered therapeutic agents to sites of disease. The polysaccharide nanoparticles are non-covalently associated with the unaltered therapeutic agent. The polysaccharide is able to retain cargo (drugs, diagnostics, etc.) without chemical modification of the agent. The nanoparticle maintains its association with the agent through non-covalent interactions but releases its agent in response to changes in the microenvironment, e.g., at the site of cancer cells or cancer tissue. 1. A method of delivering one or more agents to a site in a subject , the method comprising:administering a nanoparticle composition comprising:one or more unaltered agents associated with nanoparticles comprising a polysaccharide wherein an intensity-weighted average diameter of the nanoparticles as determined by dynamic light scattering is from 1 nm to 500 nm.2. (canceled)3. The method of claim 1 , wherein the nanoparticles are at least 50 wt. % polysaccharide (e.g. claim 1 , at least 60 wt. % claim 1 , at least 70 wt. % claim 1 , at least 80 wt. % claim 1 , at least 90 wt. %).4. The method of claim 1 , wherein each of the nanoparticles have a surface comprising the polysaccharide.56-. (canceled)7. The method of claim 1 , wherein the polysaccharide comprises a member selected from the group consisting of dextran claim 1 , amylose claim 1 , amylopectin claim 1 , glycogen claim 1 , cellulose claim 1 , arabonixylan claim 1 , and pectin.8. The method of claim 1 , wherein the disease claim 1 , disorder claim 1 , or condition is a member selected from the group consisting of cancer claim 1 , rheumatoid arthritis claim 1 , atherosclerosis claim 1 , cystic fibrosis claim 1 , diabetic ketoacidosis claim 1 , cardiac arrest claim 1 , stroke claim 1 , renal failure claim 1 , malaria claim 1 , lactic acid acidosis claim 1 , and inflammation.922-. (canceled)23. A ...

Hypoallergenic composition for skin regeneration or skin soothing, containing culture product or extract of aureobasidium pullulans strain

Disclosed in the present specification is a hypoallergenic composition for skin regeneration or skin soothing, containing, as an active ingredient, an Aureobasidium pullulans strain, a lysate thereof, a culture product thereof, or an extract of the strain, lysate or culture product. Unlike conventional functional ingredients, the composition is non-irritating to the skin, and thus is safe, while having a skin regeneration effect, and has a skin soothing effect by relieving irritation.

COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY

Compositions comprising an active agent and a decoy molecule and methods for treating pain by topically administering such compositions are described herein. The compositions may be powdered. Compositions include a decoy molecule with a specified average molecular weight and no high molecular weight decoy molecule. The extracellular components include hyaluronic acid, collagen, fibronectin, elastin, lectin, and fragments thereof and combinations thereof. 1. A composition comprising:a powdered active agent; anda powdered penetration enhancer.2. The composition of claim 1 , wherein the penetration enhancer is selected from the group consisting of alcohols claim 1 , glycols claim 1 , fatty acids claim 1 , fatty esters claim 1 , fatty ethers claim 1 , occlusive agents claim 1 , surface active agents claim 1 , dimethyl amino propionic acid derivatives claim 1 , terpenes claim 1 , decoy molecules claim 1 , sulfoxides claim 1 , cyclic ethers claim 1 , amides claim 1 , amines claim 1 , and the like and combinations thereof3. The composition of claim 1 , wherein the penetration enhancer is selected from the group consisting of hyaluronic acid claim 1 , collagen claim 1 , fibronectin claim 1 , elastin claim 1 , lectin claim 1 , fragments thereof claim 1 , and combinations thereof.4. The compositions of claim 1 , wherein the penetration enhancer is dehydrated or lyophilized.5. The composition of claim 1 , wherein the penetration enhancers has an average molecular weight of about 2 claim 1 ,000 Da to about 100 claim 1 ,000 Da.6. The composition of claim 1 , wherein the powdered active agent and powdered penetration enhancer each individually have an average particle size of about 0.01 μm to about 100 μm.7. The composition of claim 1 , wherein the active agent is selected from the group consisting of baclofen claim 1 , vigabatrin claim 1 , gabapentin claim 1 , pregabalin claim 1 , y-amino-phosphinic acid derivatives claim 1 , and combinations thereof.8. The composition of claim ...

FORMULATIONS OF TRIPHENYL CALCILYTIC COMPOUNDS

The present disclosure provides tablet formulations including a triphenyl calcilytic compound for the treatment of autosomal dominant hypocalcemia (ADH), where the compound is represented by formula (I): 2. The tablet formulation of claim 1 , in two or more dosage strengths.3. The tablet formulation of claim 1 , wherein a ratio of the compound by weight to a total weight of one or more pharmaceutically acceptable excipients is constant across the two or more dosage strengths.5. The tablet formulation of claim 4 , wherein CLTX-305 is in an amount of about 10 milligrams (mg) claim 4 , about 30 mg claim 4 , about 60 mg claim 4 , about 120 mg claim 4 , about 240 mg claim 4 , about 360 mg claim 4 , or about 720 mg in each tablet.6. The tablet formulation of claim 5 , wherein the ratio of CLTX-305 to a total weight of one or more pharmaceutically acceptable excipients is from about 1:6.5 to about 1:2 by weight.7. The tablet formulation of claim 6 , wherein the ratio is about 1:6 by weight.8. The tablet formulation of claim 4 , wherein CLTX-305 is present in an amount of from about 13% to about 35% by weight of the tablet formulation.9. The tablet formulation of claim 8 , wherein CLTX-305 is present in an amount of about 14.3% by weight of the tablet formulation.10. (canceled)11. The tablet formulation of claim 1 , wherein the one or more fillers are mannitol claim 1 , sorbitol claim 1 , xylitol claim 1 , lactitol claim 1 , microcrystalline cellulose claim 1 , silicified microcrystalline cellulose claim 1 , cellulose claim 1 , or a combination thereof.12. The tablet formulation of claim 11 , wherein the one or more fillers comprise mannitol and microcrystalline cellulose.13. The tablet formulation of claim 12 , wherein a ratio of mannitol to microcrystalline cellulose is no more than 5.14. (canceled)15. The tablet formulation of claim 12 , wherein mannitol is present in an amount of about 39.5% by weight of the tablet formulation; and/or microcrystalline cellulose is ...

SKIN CREAM

The present invention relates to skin care compositions, including cosmeceuticals, for topical application, and more particularly, a skin cream, comprising exosomes and cell culture medium conditioned by cells grown in two-dimensional culture. Also included are methods of making and using such compositions and kits comprising the skin cream therein. 1. A skin cream for treating a skin defect , comprising exosome enriched conditioned medium from cultured substantially homogenous foreskin derived fibroblast cells , wherein said exosomes are isolated from cultures of cells grown under conditions to promote secretion of at least one growth factor into nutrient medium.2. The skin cream of claim 1 , wherein the exosomes are isolated from conditioned medium that is the same as or is different from the exosome enriched conditioned medium.3. The skin cream of claim 2 , wherein the conditioned media are different.4. The skin cream of claim 3 , wherein:(i) the exosome enriched conditioned medium is generated from transformed cells and the exosomes are isolated from conditioned medium generated from non-transformed cells or(ii) the exosome enriched conditioned medium is generated from non-transformed cells and the exosomes are isolated from conditioned medium generated from transformed cells.5. The skin cream of claim 4 , wherein said transformed cells are from a cell line designated as ATCC Accession No. PTA-11680 and said non-transformed cells are from a cell line designated as ATCC Accession No. PTA-11681.6. The skin cream of claim 1 , wherein the skin cream further comprises one or more solvents claim 1 , a base solvent claim 1 , one or more botanicals claim 1 , and one or more emollients.7. The skin cream of claim 1 , wherein the exosomes comprise at least one molecule selected from the group consisting of a protein claim 1 , DNA claim 1 , RNA claim 1 , and combinations thereof.8. The skin cream of claim 7 , wherein the skin cream comprises TGF Beta-1 claim 7 , TGF Beta-2 ...

Methods for Modulating Hair Growth Using Truncated Laminin-511

Disclosed are methods for the use of a truncated, recombinant laminin-511 for modifying hair growth as well as delivery devices, kits and methods for topically administering truncated, recombinant laminin-511. Furthermore disclosed are delivery devices, kits and methods using modulators of full-length laminin-511 expression or function to decrease hair growth in areas of unwanted hair growth. 1. A biodegradable or biocompatible microneedle device for topical application of a laminin-511 peptide to a subject , the device comprising an array of microneedles comprising a composition comprising a laminin-511 peptide and a pharmaceutically acceptable carrier in a therapeutically effective amount to increase scalp hair growth and to decrease scalp hair loss in a subject ,2. The microneedle device of claim 1 , wherein the laminin-511 peptide is a truncated claim 1 , recombinant laminin-511 peptide trimer comprising an alpha-5 chain comprising a sequence substantially identical to SEQ ID NO:1; a beta-1 chain comprising a sequence substantially identical to SEQ ID NO:2; and a gamma-1 chain comprising a sequence substantially identical to SEQ ID NO:3.3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. A method for delivering a laminin-511 peptide to dermal layers of a subject's scalp claim 1 , the method comprising providing an array of biocompatible or biodegradable microneedles comprising a composition comprising a laminin-511 peptide and a pharmaceutically acceptable carrier in a therapeutically effective amount to increase scalp hair growth and to decrease scalp hair loss in a subject; whereby said array is suited to be inserted into said subject's scalp with a pressure sufficient to deliver said composition to the dermal layers of said subject's scalp.9. The method of claim 8 , wherein the laminin-511 peptide is a truncated claim 8 , recombinant laminin-511 peptide trimer comprising an alpha-5 chain comprising a sequence substantially identical to SEQ ID ...

COSMETIC USE OF ARTHROFACTIN

The present invention relates to the non-therapeutic cosmetic use of a mixture of arthrofactins as a moisturizer particularly for the skin, mucosa and particularly dry skin. 2. The composition according to claim 1 , wherein R′ is a saturated alkyl chain with 7 carbon atoms.5. The composition according to claim 1 , wherein said at least one derivative of arthrofactin A is a mixture of said compounds of formulas (IIA) claim 1 , (IIB) and (IIC).6. The composition according to claim 1 , wherein said mixture of arthrofactins mostly comprises arthrofactin A.7Pseudomonas. The composition according to claim 1 , wherein said mixture of arthrofactins is likely to be obtained by fermentation with the sp. strain MIS38.8. The composition according to claim 1 , said composition being in the form of a care composition.9. A method for non-therapeutic cosmetic treatment which comprises applying a mixture of arthrofactins as defined in claim 1 , on the skin.10. The method according to claim 9 , wherein the mixture of arthrofactins is applied on the skin and particularly dry skin.11. A non-therapeutic cosmetic treatment for moisturizing keratinic material which comprises applying to said keratinic material a mixture of arthrofactins as defined in .14. The composition according to claim 1 , wherein said at least one derivative of arthrofactin A is a mixture of said compounds of formulas (IIA) claim 1 , (IIB) and (IIC).15. The composition according to claim 1 , wherein said mixture of arthrofactins mostly comprises arthrofactin A.16. A method for non-therapeutic cosmetic treatment which comprises applying a mixture of arthrofactins as defined in claim 2 , on the skin.17. A method for non-therapeutic cosmetic treatment which comprises applying a mixture of arthrofactins as defined in claim 3 , on the skin.18. A method for non-therapeutic cosmetic treatment which comprises applying a mixture of arthrofactins as defined in claim 4 , on the skin.19. A method for non-therapeutic cosmetic ...

GASTRORETENTIVE DOSAGE FORMS FOR SUSTAINED DRUG DELIVERY

The present disclosure is directed to floating gastroretentive dosage forms with prolonged gastric residence time. The disclosure also provides rapidly expanding sustained release or combined immediate release and sustained release formulations comprising drugs that require targeted release in the proximal gastrointestinal tract for maximum therapeutic benefit. The rapidly expanding floating gastroretentive dosage forms comprise a permeable elastic membrane providing desired characteristics for drug release and mechanical strength to maintain tablet integrity. 1. A floating gastroretentive dosage form comprising:a) a matrix core that is a sustained release swellable matrix core comprising an active agent, a swellable water-soluble polymer, an acid, and a gas-generating agent; and wherein the water-insoluble permeable elastic membrane surrounds the matrix core,', 'wherein the swellable water-soluble polymer is present in an amount of from about 1% to about 30% w/w of the matrix core weight,', 'wherein the water-insoluble permeable elastic membrane comprises a plasticizer, and a copolymer of ethyl acrylate, methyl methacrylate, and trimethylammonioethyl methacrylate chloride,', 'wherein the plasticizer is present in an amount of from about 5% to about 30% w/w of the total plasticizer and copolymer weight, and the copolymer is present in an amount of from about 70% to about 95% w/w of the total plasticizer and copolymer weight,', 'wherein the dosage form provides gastric retention and sustained release of the active agent for at least about 8 hours., 'b) a water-insoluble permeable elastic membrane containing an orifice;'}2. The dosage form of claim 1 , wherein the active agent is a highly soluble drug or a moderately soluble drug.3. The dosage form of claim 1 , wherein the dosage form on contact with GI fluids claim 1 , expands in about 30 minutes or less to a size that prevents its passage through pyloric sphincter.4. The dosage form of claim 1 , wherein the dosage ...

RECOMBINANT FILAGGRIN POLYPEPTIDES FOR CELL IMPORTATION

Disclosed are recombinant polypeptides that include (a) a filaggrin amino acid sequence and (b) a cell importation signal sequence that includes a motif of two to fifteen amino acids, wherein the motif includes at least one arginine residue and at least one methionine residue. Also disclosed are nucleic acids encoding the recombinant polypeptides of the present invention, and compositions that include the recombinant polypeptides and nucleic acids of the present invention. Methods of treating or preventing a skin disease or skin disorder using the compositions of the present invention are also included, as well as kits that include a sealed containing that includes a recombinant polypeptide of the present invention. 1. A recombinant polypeptide comprising a human filaggrin sequence and a cell importation sequence positioned on the N-terminus side or the C-terminus side of the filaggrin sequence.2. The recombinant polypeptide of claim 1 , further comprising a linker region positioned between the human filaggrin sequence and the cell importation sequence.3. The recombinant polypeptide of claim 1 , wherein the cell importation sequence comprises an RMR tag.4. The recombinant polypeptide of claim 3 , wherein the RMR tag comprises SEQ ID NO:23.5. The recombinant polypeptide of claim 3 , wherein the RMR tag consists of SEQ ID NO:23.6. The recombinant polypeptide of claim 3 , wherein the cell importation sequence is positioned on the C-terminus side of the filaggrin sequence.7. The recombinant polypeptide of claim 1 , comprised in a topical formulation.8. The recombinant polypeptide of claim 7 , wherein the topical formulation is an emulsion claim 7 , a cream claim 7 , a lotion claim 7 , a gel claim 7 , or an ointment.9. A recombinant polypeptide comprising a human filaggrin sequence and an RMR sequence motif positioned on the N terminus side or the C-terminus side of the filaggrin sequence.10. The recombinant polypeptide of claim 9 , wherein the motif comprises repeating ...

Applications of Surfactin in Cosmetic Products

Surfactin is a biosurfactant produced by and is a natural cycloaliphatic peptide having a ring structure made of 7 amino acids. The surfactin has various functions including anti-aging, anti-wrinkle, increasing skin penetration of cosmetic products (skin penetration agent), foaming agent, and emulsifier. 1. A method for an anti-aging treatment comprising:administering a cosmetic composition to a subject in need thereof, wherein the cosmetic composition comprises surfactin in a concentration between 25-100 μm, and pharmaceutically acceptable vehicles, excipients, diluents or adjuvants,wherein the cosmetic composition performs an antiaging effect via enhancement of sirtuin.2. The method as recited in claim 1 , wherein the surfactin is a cycloaliphatic peptide comprising a hepapeptide (L)Glu-(L)Leu-(D)Leu-(L)Val-(L)Asp-(D)Leu-(L)Leu linked to a β-hydroxy fatty acid claim 1 , and the distribution of the fatty acids at the fatty acid end of the surfactin are as follows:(1) iso-C13>3%;(2) C13>0.65%;(3) iso-C14>17%;(4) C14<41%; and(5) iso-C15<11%.3. The method as recited in claim 2 , wherein the distribution of the fatty acids at the fatty acid end of the surfactin are as follows:(1) iso-C13>10%;(2) C13>25%;(3) iso-C14>35%;(4) C14<25%; and(5) iso-C15<3%.4. The method as recited in claim 3 , wherein the distribution of the fatty acids at the fatty acid end of the surfactin are as follows: (1) iso-C13=11%; (2) C13=26%; (3) iso-C14=37%; (4) C14=24%; and (5) iso-C15=2%.5. The method as recited in claim 1 , wherein the molecular weight of the surfactin is 1022 or 1036 Da.6. The method as recited in claim 1 , wherein the surfactin comprises its isomers.7. The method as recited in claim 1 , wherein the anti-aging cosmetic composition further comprises at least one of the following ingredients: alcohols claim 1 , esters claim 1 , complex polysaccharides claim 1 , nut oils claim 1 , and vitamins.8. The method as recited in claim 7 , wherein the alcohol comprises at least one of the ...

NEUROTOXINS EXHIBITING SHORTENED BIOLOGICAL ACTIVITY

The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a Neurotoxin polypeptide exhibiting a reduced duration of biological effect in a subject, wherein the polypeptide comprises at least one degradation signal in the light chain as well as vectors and host cells comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising the polynucleotides and polypeptides as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments. 1. A pharmaceutical composition comprising a modified neurotoxin polypeptide exhibiting a reduced duration of muscle paralysis in a subject , wherein the neurotoxin polypeptide comprises at least one degradation signal in a light chain of the neurotoxin polypeptide , wherein the degradation signal in the light chain of the neurotoxin polypeptide is selected from:a) at least one internally or terminally introduced PEST motif;b) at least one internally or terminally introduced E3 ligase recognition motif;c) an N-terminal oligo-lysine residue;d) an N-terminally linked ubiquitin;e) a substitution of the N-terminal proline with a basic amino acid;f) substitutions of surface displayed amino acid residues with lysine; andg) a substitution of the N-terminal proline with a basic amino acid in combination with substitutions of surface displayed amino acid residues with lysine; andone or more pharmaceutically acceptable carriers.2. The pharmaceutical composition of claim 1 , wherein the duration of the muscle paralysis in a subject persists less than 4 claim 1 , 3 or 2 weeks.3. The pharmaceutical composition of claim 1 , wherein the light chain of the neurotoxin polypeptide exhibiting a reduced duration of muscle paralysis in a subject is a modified form of a neurotoxin light chain ...

USE OF COMPOSITION CONTAINING P-113 PEPTIDE IN PREPARING COSMETICS HAVING MOISTURIZING FUNCTION

The present invention provides a use of a composition in preparing a cosmetic having moisturizing effect, wherein the composition comprises a P-113 peptide, wherein the P-113 peptide comprises the sequence of SEQ ID NO: 1. It is hypoallergenic and non-cytotoxic, which means it does not cause harms or allergies to the skin and can be used as an ingredient of cosmetic products. The P-113 peptide fragment has moisture absorption and moisture retention effects, therefore it can be formulated with other ingredients of moisturizing cosmetic products, enhancing the moisturizing effect of other moisturizing ingredients. In addition, the P-113 peptide fragment is capable of inhibiting the production of MMP-9 and thus decreases collagen degradation, thereby achieving the anti-wrinkle and anti-aging effects. The cosmetic of the present invention comprises not only the peptide, but also active ingredients of cosmetic products and essence liquid formulations. Accordingly, it not only provides major effects such as moisturizing and anti-wrinkle, but also enhances other composite functions, such as astringent effect, whitening, anti-aging, anti-oxidation or skin tissue activation. 1. A method for moisturizing the skin of a subject , comprising administering to the skin of the subject a composition comprises a P-113 peptide , wherein the P-113 peptide comprises the sequence of SEQ ID NO: 1.2. The method of claim 1 , wherein the P-113 peptide is selected from a histatin-5.3. The method of claim 1 , wherein the moisture absorption rate of the P-113 peptide is from 30% to 80%.4. The method of claim 1 , wherein the moisture retention rate of the P-113 peptide is from 70% to 100%.5. The method of claim 1 , wherein the P-113 peptide has an anti-wrinkle function claim 1 , which decreases degradation of collagen on the skin by inhibiting matrix metallopoateinase-9 (MMP-9).6. The method of claim 1 , wherein the composition is a cosmetic.7. (canceled)8. The method of claim 6 , wherein the ...

Production method of cosmetic, preparation method of gel for cosmetics, and method of reducing use amount of polymer thickener blended in cosmetic raw materials

A production method of a cosmetic that includes blending at least one lipid peptide-type gelator that contains a low-molecular lipid peptide or a pharmaceutically usable salt thereof at a ratio of 0.1% by weight to 0.5% by weight based on a mass of the polymer thickener to form a thickening gel; a preparation method of a gel for cosmetics that includes blending, into an aqueous medium for cosmetics, a polymer thickener and at least one lipid peptide-type gelator that contains a low-molecular lipid peptide or a pharmaceutically usable salt thereof at the above-mentioned ratio to form a gel; and a method of reducing the use amount of a polymer thickener in production of a cosmetic that includes blending at least one lipid peptide-type gelator that contains a low-molecular lipid peptide or a pharmaceutically usable salt thereof at the above-mentioned ratio.

SELF-ASSEMBLING ULTRASHORT ALIPHATIC CYCLIC PEPTIDES FOR BIOMEDICAL APPLICATIONS

The invention relates to cyclic peptides of 3-9 amino acids comprising 2-7 aliphatic and 0-2 polar amino acids that are capable of self-assembling, wherein said aliphatic amino acids are arranged in decreasing hydrophobicity from N- to C-terminus and at least a portion of the cyclic peptide has to have its amino acids in alternating D- and L-configuration, as well as their use in hydrogels as well as co-gels or co-hydrogels. The hydrogels of the invention may be used in nanomedicine or drug delivery, cell culture or alternatively in electronic devices. 2. (canceled)3. The cyclic peptide according to claim 1 , wherein said aliphatic amino acids are selected from the group consisting of alanine (Ala claim 1 , A) claim 1 , homoallylglycine claim 1 , homopropargylglycine claim 1 , isoleucine (Ile claim 1 , I) claim 1 , norleucine claim 1 , leucine (Leu claim 1 , L) claim 1 , valine (Val claim 1 , V) and glycine (Gly claim 1 , G) claim 1 , preferably from the group consisting of alanine (Ala claim 1 , A) claim 1 , isoleucine (Ile claim 1 , I) claim 1 , leucine (Leu claim 1 , L) claim 1 , valine (Val claim 1 , V) and glycine (Gly claim 1 , G).4. The cyclic peptide according to claim 1 , wherein all or a portion of said aliphatic amino acids are arranged in an order of decreasing amino acid size claim 1 , wherein the size of the aliphatic amino acids is defined as I=L>V>A>G.6. The cyclic peptide according to claim 1 , wherein a is an integer from 3 to 7.7. The cyclic peptide according to claim 1 , wherein said polar amino acids are selected from the group consisting of aspartic acid (Asp claim 1 , D) claim 1 , asparagine (Asn claim 1 , N) claim 1 , glutamic acid (Glu claim 1 , E) claim 1 , glutamine (Gln claim 1 , Q) claim 1 , 5-N-ethyl-glutamine (theanine) claim 1 , citrulline claim 1 , thio-citrulline claim 1 , cysteine (Cys claim 1 , C) claim 1 , homocysteine claim 1 , methionine (Met claim 1 , M) claim 1 , ethionine claim 1 , selenomethionine claim 1 , ...

NICOTINIC ACETYLCHOLINE RECEPTOR PEPTIDE ANTAGONIST CONOTOXIN COMPOSITIONS AND RELATED METHODS

The present invention relates to novel peptide antagonists that inhibit binding of acetylcholine to the active site of the muscle-type nicotinic acetylcholine receptor. The peptide antagonists of the invention are useful in cosmetic compositions that prevent or improve the appearance of skin wrinkles and related skin conditions. The invention further relates to cosmetic and pharmaceutical compositions comprising a peptide antagonist of the invention, and methods for their use. 121.-. (canceled)23. The muscle-type nicotinic acetylcholine receptor peptide antagonist of claim 22 , wherein:Xaa1 is absent;Xaa2 is absent;the Xaa3-Xaa8 linkage is selected from: a Cys-Cys linkage, a Sec-Sec linkage, a cystathionine linkage, a lactam bridge, a thioether linkage, and a dicarba linkage;the Xaa4-Xaa14 linkage is selected from: a Cys-Cys linkage, a Sec-Sec linkage, a cystathionine linkage, a lactam bridge, a thioether linkage, and a dicarba linkage;Xaa5 is selected from: Asn, Asp, Gln, Glu, and His;Xaa6 is selected from: Pro and hydroxyproline;Xaa7 is selected from: Ala, Gly, Val, Leu, and Ile;Xaa9 is selected from: Ala, Gly, Val, Leu, and Ile;Xaa10 is selected from: His and Lys;Xaa11 is selected from: Asp, Gln, Glu, Arg, His, and Lys;Xaa12 is selected from: Trp and Tyr; andXaa13 is selected from: Cys, Met, Sec, Ser, and Thr.24. The muscle-type nicotinic acetylcholine receptor peptide antagonist of claim 22 , wherein:Xaa1 is absent;Xaa2 is absent;the Xaa3-Xaa8 linkage is selected from: a Cys-Cys linkage, a Sec-Sec linkage, a cystathionine linkage, a lactam bridge, a thioether linkage, and a dicarba linkage;the Xaa4-Xaa14 linkage is selected from: a Cys-Cys linkage, a Sec-Sec linkage, a cystathionine linkage, a lactam bridge, a thioether linkage, and a dicarba linkage;Xaa5 is selected from: Asn, Asp, Gln, Glu, Arg, His and Lys;Xaa6 is selected from: Pro and hydroxyproline;Xaa7 is selected from: Ala, Gly, Val, Leu, and Ile;Xaa9 is selected from: Ala, Gly, Val, Leu, and Ile;Xaa10 ...

PEPTIDES AND COMPOSITIONS FOR USE IN COSMETICS AND MEDICINE

The present invention relates to a family of peptides which are able to interfere in the formation of complex Munc18-Syntaxin-1 and, hence, are useful in the prevention and/or treatment of neuronal exocytosis and/or muscle contractility disorders; and to prevent, reduce and/or eliminate skin aging and/or expression signs. 118-. (canceled)19. A peptide or composition comprising said peptide for use as a medicament wherein the peptide is capable of interfering in the Munc18-Syntaxin-1 complex interaction and competing with SEQ ID NO: 3 and/or SEQ ID NO: 4 , acceptable isomers , salts , solvates and/or derivatives and/or mixtures thereof.20. The peptide or composition for use in accordance with claim 19 , wherein the sequence of the peptide is SEQ ID NO: 3 and/or SEQ ID NO: 4.25. A method of reducing or treating neuronal exocytosis disorders selected from senile dementia claim 19 , Alzheimer's related dementia claim 19 , AIDS-related dementia claim 19 , epilepsy claim 19 , amiotrophic sclerosis claim 19 , multiple/lateral sclerosis claim 19 , mastocytosis claim 19 , chronic migraine or anxiety disorders or reducing or treating muscle contractility disorders selected from myotonia claim 19 , myotonic dystrophy claim 19 , myotonia congenita claim 19 , Parkinson disease claim 19 , Secondary Parkinsonism claim 19 , Huntington disease claim 19 , spasticity claim 19 , Tardive Dysinesia (TD) or dystonia comprising applying the peptide or composition according to .26. A method of reducing and/or eliminating skin aging and/or expression signs in a subject comprising applying a cosmetic comprising the peptide or composition according to claim 19 , wherein the peptide capable of interfering in the Munc18-Syntaxin-1 complex interaction and competing with SEQ ID NO: 3 and/or SEQ ID NO: 4 claim 19 , acceptable isomers claim 19 , salts claim 19 , solvates and/or derivatives and/or mixtures thereof.27. The method in accordance with claim 26 , wherein the sequence of the peptide is SEQ ...

NIACIN-PEPTIDE HAVING SKIN WHITENING ACTIVITY AND USE FOR SAME

Provided is niacin-peptide which has skin whitening activity. The peptide of the present invention has skin whitening activity by inhibiting melanogenesis, that is, by inhibiting the expression of a gene related to melanogenesis (for example, TRP-1, TRP2, or MIFT). The peptide of the present invention has high stability and skin permeability. Also provided is a cosmetic composition for skin whitening which contains the niacin-peptide. 1. A peptide having skin whitening effect , characterized in that the peptide is selected from the group consisting of Nicotinoyl-PS , Nicotinoyl-EQ , Nicotinoyl-ET , Nicotinoyl-FP , Nicotinoyl-NI , Nicotinoyl-NL , Nicotinoyl-NP , Nicotinoyl-NY , Nicotinoyl-PG , Nicotinoyl-QI , Nicotinoyl-VA , Nicotinoyl-VF , Nicotinoyl-VS , Nicotinoyl-VT , Nicotinoyl-WM , Nicotinoyl-YR , Nicotinoyl-YT , Nicotinoyl-AHK , Nicotinoyl-FWY , Nicotinoyl-GHR , Nicotinoyl-GPHyp , Nicotinoyl-TYR , Nicotinoyl-YGY , Nicotinoyl-PLG , Nicotinoyl-PLG-NH , Nicotinoyl-beta-AHSH , Nicotinoyl-DKYV , Nicotinoyl-GEPG , Nicotinoyl-GQPR , Nicotinoyl-GRKG , Nicotinoyl-KAKA , Nicotinoyl-SSNA , Nicotinoyl-VPAA , Nicotinoyl-YPFF , Nicotinoyl-YPFF-NH , Nicotinoyl-GPRPA , Nicotinoyl-GPRPA-NH , Nicotinoyl-ISELGW , Nicotinoyl-KLAKK , Nicotinoyl-KRGDR , Nicotinoyl-KRGKP , Nicotinoyl-KTTKS , Nicotinoyl-KVARP , Nicotinoyl-RKDVY , Nicotinoyl-YGGFL , Nicotinoyl-YGGFM , Nicotinoyl-SIKVAV , Nicotinoyl-VEPIPY , Nicotinoyl-VGVAPG , Nicotinoyl-EEMQRR , Nicotinoyl-EEMQRR-NH , Nicotinoyl-GPQGPQ and Nicotinoyl-YGYTGA.2. The peptide according to claim 1 , wherein the peptide inhibits melanogenesis.3. The peptide according to claim 1 , wherein the peptide inhibits the activity of tyrosinase.4. The peptide according to claim 1 , wherein the peptide inhibits the expression of TRP-1 (tyrosinase-related protein-1).5. The peptide according to claim 1 , wherein the peptide inhibits the expression of TRP-2 (tyrosinase-related protein-2).6. The peptide according to claim 1 , wherein the peptide inhibits ...

MICROSPHERE SKIN TREATMENT

This application provides a microsphere suitable for tissue engineering that comprises connective tissue growth factor (CTGF). Also provided is a matrix, material or scaffold suitable for tissue engineering that comprises connective tissue growth factor (CTGF) and basic fibroblast growth factor (bFGF). Additionally, methods of treating skin of a human are provided. The methods comprise administering to the skin microspheres comprising a growth factor that increases fibroblast proliferation or collagen, elastin, or glycosaminoglycan synthesis. Further provided are the use of the above microspheres for the treatment of the skin of a human. Additionally, this application proves the use of the above microsphere for the manufacture of a medicament for the treatment of the skin of a human. 1. A method of treating skin of a subject comprising:administering to skin of a subject (i) a first microsphere comprising connective tissue growth factor (CTGF) and basic fibroblast growth factor (bFGF) or (ii) a second microsphere comprising CTGF and a third microsphere comprising bFGF;wherein the CTGF and the bFGF in combination increases fibroblast proliferation; collagen synthesis; elastin synthesis; or glycosaminoglycan synthesis.2. The method of claim 1 , comprising administering the second microsphere comprising CTGF.3. The method of claim 1 , comprising administering the third microsphere comprising bFGF.4. The method of claim 1 , comprising administering the first microsphere comprising CTGF and bFGF.5. The method of claim 1 , wherein administering to skin of a subject comprises:administering the third microsphere comprising basic fibroblast growth factor (bFGF); andadministering the second microsphere comprising connective tissue growth factor (CTGF).6. The method of claim 1 , wherein the microsphere comprises:(i) between about 0.0001 and about 10,000,000 ng CTGF/ml microspheres and between about 0.0001 and about 10,000,000 ng bFGF/ml microspheres;(ii) between about 0.001 and ...

CULTURE MEDIUM OF ADIPOSE-DERIVED STEM CELL, METHOD FOR PREPARING THE SAME, AND COMPOSITION INCLUDING THE SAME FOR PROMOTING HAIR GROWTH

Provided are a culture medium of an adipose-derived stem cell, a method for preparing the same, and a composition for promoting hair growth, in which the composition includes the culture medium. The adipose-derived stem cell (ADSC-T) according to the present invention exhibits long lifespan, improved cell proliferation rate, and extended proliferation period, as compared with a primary adipose-derived stem cell (ADSC), and thus, the adipose-derived stem cell (ADSC-T) can be usefully used for the study about the adipose-derived stem cell and the mass production of the culture medium of the adipose-derived stem cell. In addition, according to the present invention, the culture medium of the adipose-derived stem cell (ADSC-T) that expresses a T antigen of SV40 exhibits excellent hair growth effectiveness and can be usefully used as a raw material for the hair loss prevention and hair growing agents. 1. A method for preparing a culture medium of an adipose-derived stem cell (ADSC-T) , the method comprising:(a) culturing the adipose-derived stem cell after isolating the adipose-derived stem cell through a centrifuge after treating an enzyme, collagenase, to a suctioned adipose tissue;(b) preparing the adipose-derived stem cell (ADSC-T) expressing a T antigen of SV40 by transfecting a plasmid expression vector (pEF321β-T) into the adipose-derived stem cell cultured in the above step (a); and(c) obtaining a culture medium by culturing the adipose-derived stem cell (ADSC-T) prepared as described above.2. The method according to claim 1 , wherein in the above step (a) claim 1 , the collagenase and the suctioned adipose tissue are mixed in a weight ratio of 1:1 to react them at 30 to 40° C. for 40 to 50 minutes.3. The method according to claim 1 , wherein in the above step (a) claim 1 , the centrifugation is carried out at 500 to 1000 G for 2 to 5 minutes.4. The method according to claim 1 , wherein in the above step (a) claim 1 , the isolated adipose-derived stem cell is ...

Oral Dosage forms having a High Loading of a Gabapentin Prodrug

Sustained release oral dosage forms with a high loading of a gabapentin prodrug are disclosed. 130.-. (canceled)31. A method for treating alcohol dependency comprising orally administering to a patient in need of treatment a therapeutically effective amount of a sustained release tablet dosage form comprising 1-([α-isobutanoyloxyethoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.32. The method of claim 31 , wherein the dosage form comprises from about 300 mg to about 1300 mg of 1-([α-isobutanoyloxyethoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid or a pharmaceutically acceptable salt thereof.33. The method of claim 32 , wherein the dosage form comprises about 600 mg of 1-([α-isobutanoyloxyethoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid or a pharmaceutically acceptable salt thereof.34. The method of claim 31 , wherein the 1-([α-isobutanoyloxyethoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid is in the free acid form.35. The method of claim 31 , wherein the 1-([α-isobutanoyloxyethoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid or pharmaceutically acceptable salt thereof is crystalline.36. The method of claim 35 , wherein the crystalline 1-([α-isobutanoyloxyethoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid has a melting point range of between about 63° C. and about 64° C. as determined by differential scanning calorimetry.37. The method of claim 31 , wherein the pharmaceutically acceptable excipient is a lubricant.38. The method of claim 37 , wherein the lubricant is selected from the group consisting of magnesium stearate claim 37 , sodium stearyl fumarate claim 37 , and stearic acid.39. The method of claim 38 , wherein the lubricant is magnesium stearate.40. The method of claim 37 , wherein the lubricant is present in dosage form from about 0.5 wt % to about 4 wt %.41. The method of claim 31 , wherein the tablet dosage form further ...